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ABSTRACT 
 
This study describes the optimization of expression of the bacterial luciferase 
enzyme in mammalian cells.  Previous attempts to express this heterodimeric enzyme 
complex in mammalian cells have been met with only modest success.  In this research 
effort, several vector formats were evaluated to fully determine the optimal format for 
the expression of these genes.  It was determined that the bacterial luciferase enzyme 
produced optimal bioluminescence in mammalian cells when the genes were cloned and 
expressed as a bicistronic transcript fused with an internal ribosomal entry site (IRES).   
To optimize the enzyme expression further, a novel approach to codon optimize 
the genes was performed.  To accomplish this task, completely synthetic versions of the 
codon optimized sequences were generated.  This codon optimization, led to an increase 
in bioluminescence levels greater than two orders of magnitude versus the wild type 
genes.   
Additionally, the availability of the FMNH2 substrate was evaluated and 
determined to be a limiting substrate for the reaction.  In an attempt to alleviate this 
limitation, a flavin oxidoreductase gene (frp) from Vibrio harveyi was cloned and 
expressed along with the codon optimized luxA and luxB genes.  Although the 
expression of this enzyme enhanced the bioluminescence significantly, FMNH2 remains 
the limiting substrate for optimal bioluminescence.   
To produce a usable reporter cell line, the reporter must remain stable within the 
cells for long periods of time.  The overall stability of the engineered cells was assessed 
to determine the persistence of the reporter for long-term monitoring applications.  
These data revealed that the luciferase genes were stable in HEK293 cells for more than 
 vi
forty passages (five months) in culture in the absence of antibiotic, indicating that these 
cell lines would be stable enough for relatively long term monitoring projects and 
applications.  
 vii
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CHAPTER 1 
 
INTRODUCTION 
 
 
Background and Research Objectives 
 Bacterial luciferase is a powerful reporter protein system since it allows for the 
development of real-time autonomous sensors that the invasive manipulations required 
by other reporter proteins do not permit.  Mammalian cell lines expressing reporter 
proteins have been widely used in both basic and applied research for the investigation 
of a variety of cellular functions.  These applications include, but are not limited to, 
promoter analysis (Guignard et al., 1998; Zhang et al., 1997), identification of 
transcription factors (Ichiki et al., 1998; Schwechheimer et al., 1998), discovery of 
genes that are potential targets for disease (Watson et al., 1998) evaluation of cross talk 
mechanisms (Naylor, 1999), and in vivo sensing of tumor and/or disease progression 
(Contag et al., 1998).  However, current mammalian bioreporter technology is limited 
due to its inability to function as a stand-alone, real-time reporter in vivo.  Current 
methodologies that use firefly luciferase (Luc) and green fluorescent protein (GFP) 
reporter systems in mammalian cells require lysis and substrate addition or exogenous 
excitation, respectively, to produce a measurable response.  Consequently, these cells 
cannot serve as continuous on-line monitoring devices.  Bacterial luciferase is unique in 
that it is the only bioreporter system available that generates its own substrate, thus 
eliminating the need for cell destruction or exogenous substrate addition.   
 Extensive work has been published using the bacterial lux system in prokaryotic 
organisms for the development of whole cell biosensors (Simpson et al., 1998; Sayler et 
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al., 2001; Ripp et al., 2000; Corbiser et al., 1999; Kohler et al., 2000; King et al., 1990, 
and VanDyk et al., 2001), advancements in biocomputing applications (Simpson et al., 
2001) and in vivo imaging models (Contag et al., 1998 and Francis et al., 2001).  
Recently, a lux-based yeast reporter cell line has been developed for the detection of 
estrogenic compounds (Gupta et al., 2003).  This research was the first successful 
attempt to express the complete lux operon required for autonomous bioluminescence in 
a eukaryotic organism.  Unfortunately, this technology has yet to be successfully 
implemented into mammalian cells. Several attempts by various groups have been made 
to express bacterial luciferase enzyme in mammalian cells.  These efforts have been met 
with only modest success as numerous obstacles have been encountered preventing 
efficient expression of the lux proteins.  A major effort and the first step required to 
realize the ultimate potential of this technology is to achieve efficient expression of the 
heterodimeric luciferase (luxA and luxB) protein.   
The bacterial luciferase enzyme is a heterodimeric protein complex made up of 
an α and β subunit encoded by the genes luxA and luxB, respectively.  Because it is not 
possible to express multiple genes as a polycistronic operon in eukaryotes, alternate 
expression platforms are needed to obtain optimal thermostability and proper folding 
which should aid in obtaining an adequate bioluminescent signal from mammalian cells.  
Furthermore, the availability of the co-factors required for the lux reaction including 
FMNH2 and O2 in mammalian cells has been suspected to be inadequate and levels need 
to be evaluated.  Other strategies for bioluminescence optimization and possible gene 
amplification have not been previously pursued and the potential is unknown.  This 
avenue of research may result in a mammalian cell line able to produce the 
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bioluminescent levels required for sensitive monitoring of target analytes.  Also, for an 
autonomously driven bioluminescent mammalian cell line to realize its full 
technological potential, the expression system must remain stable for long periods of 
time without the need for selective pressure.  The stability of mammalian cell lines 
harboring the luciferase protein remains a question and needs to be evaluated.  In 
response to these questions, the following hypotheses are tested in this research: 
 
• Hypothesis 1:  Expression of the bacterial luciferase (lux) subunits as individual 
proteins rather than as a monomeric translational fusion results in efficient 
folding and thermostability resulting in a higher bioluminescent signal in 
mammalian cells.  
 
• Hypothesis 2:  Codon optimization of the bacterial luciferase (lux) genes is 
required to significantly enhance translation of the message and ultimately result 
in greater bioluminescence levels from mammalian cells harboring these 
optimized genes. 
 
• Hypothesis 3:  Stably integrated constructs will be persistent in the absence of 
selective pressure for long periods of time. 
 
• Hypothesis 4:  Mammalian cells possess or can be engineered to express 
adequate available concentrations of the required co-factor FMNH2 for efficient 
bioluminescence 
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Literature Review 
Reporter Gene Technology 
 Reporter genes are defined as genes that produce a measurable phenotype that 
can be distinguished from other proteins within a cell (Alam and Cook, 1990).  The use 
of reporter genes for applied technologies requires that the signal be easily detected and 
respond rapidly, possess a linear response to the target analyte for quantification and 
produce a reproducible signal (Naylor, 1999 and Wood, 1995).  Several reporter 
proteins have been shown to be valuable tools for advancing both basic and applied 
research. Examples of such basic applications include the development of reporter 
fusions for the identification and analysis of promoter regions (Guignard et al., 1998; 
Zhang et al., 1997), identification of transcription factors and induction/repression 
schemes (Ichiki et al., 1998; Schwechheimer et al., 1998), as well as the discovery of 
genes as potential targets for disease (Watson et al., 1998) and evaluation of cross talk 
and signal transduction mechanisms (Naylor, 1999).  Furthermore, reporter gene fusions 
have been utilized for the creation of whole cell biosensors for environmental 
monitoring (King et al., 1990; Ripp et al., 2000 and Kohler et al., 2000), advancement 
of biocomputing applications (Simpson et al., 2001) and in vivo imaging of disease 
onset and progression (Francis et al., 2001) as well as drug efficacy screening (Contag 
et al., 1998).    
 Reporter genes can be used to study any pathway that is controlled on a 
transcriptional level.  The signals produced are responses to alterations in either gene 
regulation or expression within the cell (Wood, 1995).  Eukaryotic reporter systems 
require receptor proteins for sensing and shuttling of analyte compounds.  These 
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analytes can be extracellular signals that are either detected on the cell surface and 
trigger intracellular signal transduction pathways or bind an intracellular receptor which 
can subsequently bind to specific response elements resulting in transcriptional 
activation (Naylor, 1999).  In either case, by fusing reporter proteins to promoter 
elements within the target pathway, when promoter induction occurs, the reporter 
protein is generated and a detectible phenotypic change occurs within the cell (Figure 
1).  This reporter signal is then measured and provides a simple way to determine if and 
when a particular analyte affects gene expression (Levitzki, 1996).  In prokaryotic 
reporter cell schemes, generally the target analyte can bind directly to the promoter or 
repressor element and induce transcription directly (Figure 2) (Kohler et al., 2000).  
Nevertheless, in either case the ultimate outcome is the same and a detectable and often 
times quantifiable signal is produced.   
 
Reporter Genes and Proteins 
 Several reporter proteins have been shown to be valuable tools in various areas 
of research.  In order for a reporter protein to be useful, the generated signal must have 
a low endogenous background level in the host cell and produce an easily detectable 
response.  Choice of the optimal reporter protein for individual applications is essential 
for success.  There are several criteria that should be considered in the selection process 
of a reporter gene.  (1) The reporter protein should be absent from the host to prevent 
complications in distinguishing signal from background noise. (2) The assay for signal 
detection should either be established or easily measured in a rapid, simple, and cost- 
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Figure 1.  Schematic representation of a generalized eukaryotic bioreporter cell.  
Response elements (RE) are specific for the target analyte. 
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Figure 2.  Schematic diagram of a generalized prokaryotic bioreporter cell.  The 
promoter region is specific for the target analyte.   
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 effective manor.  (3) In order to analyze induction of both small and large changes in 
transcriptional activation, the reporter should have a large linear dynamic range for its 
response  (4) The expression of the reporter gene must not effect the overall physiology 
of the cell (Ausubel et al., 1997).  Each reporter protein identified to date has distinct 
advantages and disadvantages for application.  Table 1 summarizes some of these 
differences between a few of the more commonly used reporter proteins available.   
 There are two main classes of reporter assays available, in vitro and whole-cell 
bioassays.  In vitro reporter applications refer to the protocols in which the 
transcriptional activation is quantified in cell lysates or in the media from excreted 
proteins.  The measurement can be a direct quantification of the protein or an indirect 
response to enzymatic or immunological stimulation (Alam and Cook, 1990).  Although 
these methodologies may be useful under certain circumstances, in vivo or whole cell 
assays provide more reliable data for studies comparing promoter strengths, enhancer 
regions and determining other cell requirements.  Of all of the known reporter proteins, 
the bacterial luciferase (lux) has the distinct advantage in that it is the only bioreporter 
system available able to make its own substrate and generate an autonomous signal.  
This property has made the bacterial bioluminescence reporter system an invaluable 
tool for the creation of whole cell biosensors for remote sensing in prokaryotic 
organisms (Sayler et al., 2001).  Unfortunately, the one caveat in this technology to date 
is that it has not been efficiently expressed in mammalian cells limiting its full potential 
(Meighen, 1991 and Naylor, 1999).   
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Table 1.  Comparison of commonly used reporter proteins used for sensing     
applications. 
Reporter Advantage Disadvantage 
 
Chloramphenicol 
acetyltransferase (CAT) 
No endogenous activity.  
Automated detection 
(ELISA) 
Requires the addition of 
substrate and separation of 
substrate and product. 
 
β-galactosidase 
Stable, Simple colorimetric 
and chemiluminescent 
assay available. 
Endogenous activity 
(mammalian cell). Requires 
the addition of substrate. 
 
Firefly luciferase (LUC) 
High specific activity, no 
endogenous activity, easily 
detectable 
Requires addition of 
substrate (luciferin), O2 and 
ATP. 
 
Green Fluorescent Protein 
(GFP) 
Autofluorescent 
Mutants with altered 
spectral qualities available. 
Moderate sensitivity.  
Background fluorescence 
may interfere. Requires 
exogenous excitation 
 
Bacterial luciferase (lux) 
Broad dynamic range, 
easily measured, no 
exogenous substrate 
addition required. 
 
Requires O2 only 
expressed in prokaryotes 
 
 10
Bacterial Bioluminescence 
 Organisms able to generate light have intrigued researchers for centuries.  
Species able to produce bioluminescence are diverse, ranging from fireflies and 
mushrooms to dinoflagellates and bacteria (Harvey, 1952).  The luciferase enzymes 
involved in the catalysis of the bioluminescence reaction are also evolutionarily very 
diverse with the only one true commonality being that they all require O2 as a co-factor 
(Fisher et al., 1996).   
Bioluminescent bacteria are the most abundant of the light emitting organisms 
(Meighen, 1991).  They can be found in a high abundance in marine, freshwater and 
terrestrial environments (Hastings et al., 1985).  Most bioluminescent bacteria have 
been classified into three genera:  Vibrio, Photobacterium and Photorhabdus (formerly 
Xenorhabdus).  Organisms belonging to the first two genera generally can be found in 
marine environments.  These organisms have been identified as free-living planktonic 
bacteria and symbionts with a variety of fish and squid species (Wilson and Hastings, 
1998).   The Photorhabdus genus contains strains that can colonize terrestrial organisms 
and tend to be found acting in symbiosis with worms and caterpillars (Farmer et al., 
1989 and Colepicolo et al., 1989).  
 
Biochemistry of Bacterial Bioluminescence 
 In all bioluminescent organisms, the enzymes that catalyze the luminescent 
reaction are referred to as luciferases, while the required substrates are luciferins 
(Wilson and Hastings, 1998). Further, this light producing reaction requires molecular 
O2, the reducing power of FMNH2 and the energy of ATP as co-factors and substrates.   
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 The bacterial luciferase enzyme is a heterodimeric protein encoded by the luxA 
and luxB genes.  The heterodimeric complex forms a 77 kDa enzyme comprised of α 
(40 kDa) and β (37 kDa) subunit polypeptides.  Because the subunits are related (>30% 
amino acid homology) they are thought to be products of a gene duplication event 
(Baldwin et al., 1979).  The complete luciferase enzyme is a flavin monooxygenase that 
binds a reduced flavin molecule as a specific substrate.  However, only the α subunit 
carries the active center (Fisher et al., 1995).  A specific role of for the β subunit has not 
become clear, but its presence is essential for a high quantum yield reaction (Baldwin et 
al., 1995).  Nevertheless, the β subunit has been shown to have some impact on the 
enzyme’s thermostability (Meighen et al., 1971; Cline and Hastings, 1972 and Szittner 
and Meighen, 1990), binding of FMNH2 (Cline, 1973; Meighen and Bartlett, 1980; 
Welch and Baldwin, 1981 and Watanabe et al., 1982) as well as efficient binding of 
aldehyde (Tu and Henkin, 1983).   
 All bacterial luciferases studied to date catalyze the same overall reaction: 
 FMNH2 + O2 + RCHO ? FMN + RCOOH + H2O + hv (λmax = 490nm)  
 
The natural aldehyde for the reaction is thought to be tetradecanal in most 
species of luminescent bacteria, however, the more thermostable forms of luciferase 
(Vibrio harveyi and Photorhabdus luminescens) tend to produce higher 
bioluminescence in the presence of dodecanal and decanal (Schmidt et al., 1989). The 
general 1:1 stoichiometry of the luciferase subunits is conserved throughout all species 
of bioluminescent bacteria known (Meighen, 1991).  However, the amino acid sequence 
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of each polypeptide is somewhat diverse.   Certain motifs within the luciferase enzyme 
are conserved throughout.  There is a 60-85% identity between amino acid sequences of 
the α subunit of reported various Vibrio, Photobacterium and Photorhabdus species 
while the β subunit is less conserved with a 50-65% identity (Szittner and Meighen, 
1990).  The higher conservation of the α subunit sequence may be a direct reflection for 
the need to conserve the active center and catalytic properties of luciferase (Meighen et 
al., 1971).   
Although the aldehyde substrate is not necessary for the luciferase reaction 
itself, its presence significantly increases the light output kinetics (Volkova et al., 1999).  
The genes required for synthesis of aldehydes are catalyzed by a multienzyme fatty acid 
reductase and synthase (Rodriduez et al., 1983).  These genes are all located within the 
lux operon of all bioluminescent bacteria.  Generally, the reductase (luxC) and 
transferase (luxD) are located upstream of the luxA and luxB luciferase genes while the 
synthase (luxE) gene is located immediately downstream.  The primary reaction 
catalyzed by this system is the reduction of fatty acids by the reductase and synthase 
enzymes.  The synthase acts to activate the fatty acid, which results in a fatty acyl-AMP 
intermediate that remains bound to the enzyme.  The acyl group is then transferred to 
the synthase and then further transferred to the reductase, where it becomes reduced by 
NAD(P)H to the corresponding aldehyde.  The transferase subunit is responsible for the 
transfer of activated fatty acyl groups.  The fatty acid is then recycled.  Each 
multienzyme complex responsible for this reaction has been found to consist of a 
central tetramer of reductase subunits bound to one synthase and one weakly associated 
transferase subunit (Li et al., 2000). 
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  To produce light, the bioluminescence reaction appears to go through several 
intermediate steps.  With a stoichiometry of 1:1:1, the α and β subunits bind with a 
reduced flavin molecule (FMNH2) to form a C4a hydroxyflavin.  As this hydroxyflavin 
becomes dehydrated to FMN, a blue-green light is emitted (Baldwin et al., 1979).  A 
schematic diagram of the overall reaction is shown in Figure 3.  This enzymatic reaction 
has a relatively slow turnover rate.   
The luciferase subunits have been shown to fold independently and interact 
during the folding process.  They then form an active heterodimeric complex following 
isomerization (Ziegler et al., 1991).  However, because of the relatedness of the two 
subunits, if they are present individually (in the absence of the other subunit) they tend 
to form inactive homodimers that cannot refold into the active heterodimeric form         
(Waddle et al, 1987 and Ziegler et al., 1991).  Because of this complex stoichiometric 
requirement for folding, there is a lag time of at least three to four minutes to complete 
an active enzyme after translation of the subunit polypeptides (Ziegler et al., 1993).  A 
schematic diagram of the folding pattern of the luciferase subunits is shown in Figure 4.   
 
Thermostability of Bacterial Luciferase 
  Bacterial luciferase (lux) genes cloned from various species of luminescent 
bacteria have been used to create a myriad of reporter constructs.  Given that the lux 
operons from V. fischeri and V. harveyi were the first to be cloned (Engebrecht et al., 
1983 and Cohn et al., 1983), the vast majority of these clones are derived from these 
sequences.  However, just as selection of the appropriate reporter for individual 
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Figure 3.  Biochemistry of the bacterial bioluminescence reaction. (Figure Courtesy of A. Heitzer.) 
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Figure 4.  Schematic representation of the folding of an active luciferase (αβ).  luxA 
and luxB represent the individual genes, u denotes the unfolded form of 
the polypeptides, i denotes the inactive form before dimerization, and x 
denotes the homodimeric form that can no longer form an active 
luciferase. Figure adapted from Zeigler et al., 1993. 
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applications is important, the selection of the appropriate luciferase is equally critical.  
A key difference between luciferase enzymes from different species is their overall 
thermostability in vivo.  The luciferase from V. fischeri has been shown to be heat 
labile at temperatures above 30°C losing almost all catalytic properties at 37°C 
(Meighen, 1991).  The V. harveyi luciferase remains relatively stable at 37°C and 
luciferase enzymes from P. luminescens are quite stable at 42°C (Szittner and 
Meighen, 1990).  Furthermore, the luciferase enzyme from P. luminescens is 
optimally bioluminescent at 37°C.  For selection of the application appropriate 
enzyme, the optimal growth temperature for the host should be considered.  For the 
ultimate expression of the bacterial luciferase in mammalian cells, P. luminescens 
would appear to be the appropriate choice and therefore, is the enzyme that was 
chosen in this research.   
 
Use of the Bacterial Luciferase (luxCDABE) Reporter System 
 Various lux-based reporter systems have been constructed mostly by the 
insertion of a specific promoter in front of the lux cassette on either a plasmid or 
transposon and then mobilizing the plasmid into the appropriate strain of bacteria.  
The various constructs that have been designed are too numerous to completely 
review in this document.  Briefly, whole cell bioreporters have been generated to 
monitor the catabolic genes involved in degradation pathways including but not 
limited to; naphthalene (Burlage et al., 1990), toluene (Applegate et al., 1997), and m-
toluate (deLorenzo et al., 1993).  Van Dyk et al. (1995) used lux fusions to monitor 
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heat shock gene expression and then later expanded this technology to monitor 
genome wide expression patterns in E. coli (Van Dyk et al., 2001).  Lux-based 
reporters have also been used to monitor DNA damage (Vollmer et al., 1997), 
oxidative stressors (Wallace et al., 1994) and in the creation of countless whole-cell 
biosensors for monitoring compounds like nitrate (Prest et al., 1997), arsenic (Cai et 
al., 1997), nickel (Tibazarwa et al., 2000), lead (Corbiser et al., 1996), 2,4-D (Hay et 
al, 2000) and iron (Khang et al., 1997). Lux fusions have been further used for the in 
vivo monitoring of pathogenic infection in whole mouse models (Contag et al., 1995; 
Francis et al., 2000 and Francis et al., 2001). 
 
Advantages and Disadvantages of Using Bacterial Luciferase as a Reporter  
 Use of the bacterial luciferase gene system has several advantages over other 
bioreporter systems available.  First, the absence of background luminescence in a 
nonluminescent host makes this a very attractive system because the lower end of the 
signal detection is only limited by the noise within the detector itself.  With the 
development of new, more sensitive detectors and noise reduction schemes, very low 
concentrations of luciferase activity can be detected and quantified.  Secondly, the 
light intensity has been shown to be a direct measurement of the amount of luciferase 
present (Meighen, 1991).  This linear detection range is very wide relative to other 
reporter proteins available (Meighen, 1991).    Furthermore, the luminescent signal 
can be detected within a matter of seconds making the assay relatively quick and easy 
for the user.  
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 The ability to directly measure in vivo gene function without the disruption of 
the cell or loss of cell viability is perhaps the most obvious advantage of the bacterial 
luciferase enzyme system.  This property has made the lux system sought out by 
many for various research applications.   As a result, numerous prokaryotic 
biosensors have been developed.  These sensors have been employed in a variety of 
applications ranging from environmental pollutant monitoring (Sayler et al., 2001; 
Ripp et al., 2000; Corbiser et al., 1999; Kohler et al., 2000; King et al., 1990) to 
visualizing infections in vivo (Francis et al., 2001).  The biggest limitation to date is 
the inability to efficiently express the lux system in eukaryotic organisms.  Recently, 
it was shown that the complete lux operon from P. luminescens can be expressed in 
the yeast S. cerevisiae as proof in principle for the further application into mammalian 
cells (Gupta et al., 2003). 
 However, the exact interpretation of light levels from intact cells is 
complicated because the intensity depends not only on luciferase concentrations 
within the cell, but also the availability of the aldehyde and FMNH2 substrates.  As 
this system is moved into higher eukaryotes this measurement may become more 
complicated (Meighen, 1991). 
 
Expression of Bacterial Luciferase in Mammalian Cells 
 Unlike polycistronic expression of multiple genes often found in bacterial 
systems, eukaryotic gene expression requires that each individual gene be preceded 
by its own promoter.  This has limited the expression of the lux genes in eukaryotes to 
this point.  To overcome this, several researchers have generated a monocistronic 
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version of the V. harveyi luciferase protein by creating a translational fusion of the 
individual subunits.  This fusion protein allows for the expression of both genes from 
a single promoter element.   Unfortunately, these fusion proteins have not produced 
adequate bioluminescence in vivo to generate a reliable mammalian sensor for gene 
expression analysis.  This loss of activity has been attributed to improper folding and 
low thermostability of the fusion (Kirchner et al., 1989; Olsson et al., 1989; 
Almashanu et al., 1990; Escher et al., 1989; Costa, 1991; Pazzagli et al., 1992; 
Gelmini et al., 1993).   Bioluminescence levels were significantly increased if the host 
cells were grown at lower temperatures (Escher et al., 1989; Costa et al., 1991 and 
Almashanu et al., 1990).  Based on these data, it was determined that the fusion was 
unable to properly fold into its active heterodimeric form at 37°C.  This was thought 
to be caused, in part, by the short polylinker region that separates the two subunits.  It 
was hypothesized that a short linker between the two genes may impose an unnatural 
strain on the dimerization process and limit the amount of active heterodimer able to 
form.  To overcome this limitation, several attempts have been made to alter this 
polylinker region and allow for a more natural folding of the two subunits. The 
number of linker codons tested has ranged from one to twenty-two.  The relative 
activities (expressed in E. coli) of the enzyme are lowest with a short (one amino 
acid) linker ranging from 0.04% (Boylan et al., 1989) to 19% (Almashanu et al., 
1990).  The highest activities were obtained with a ten amino acid polylinker, which 
produced 90% activity when grown at 23°C but only 8% at 37°C.  None of the Vibrio 
harveyi fusion proteins reported to date have shown the ability to remain stable at the 
optimal mammalian growth temperature, 37°C. 
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Interestingly, if cells, prokaryotic or eukaryotic, harboring the lux fusion 
genes were grown at 37°C and then cooled to 23°C, a significant increase in 
bioluminescence levels were shown to occur (Costa, 1991 and Escher et al., 1989).  
On the other hand if chloramphenicol was added to the cells prior to the cooling step, 
the bioluminescence remained low (Esther et al., 1989).  These data indicated that the 
light levels produced in the absence of the antibiotic were a result of de novo 
synthesis and suggest a problem in folding of the protein at higher temperatures that 
can not be recovered after folding is complete (Esther et al., 1989).  These data 
further support the model of luxA and luxB folding proposed earlier by Ziegler et al. 
(1991).     
Koncz et al. (1987) reported the expression of the heterodimeric bacterial 
luciferase protein from V. harveyi as individual proteins expressed in a dual promoter 
vector format.  The expression levels, although difficult to compare were said to be 
adequate for monitoring chimeric genes in plant extracts (Koncz et al., 1987).  These 
data also showed for the first time that individual subunits of the protein could be 
transcribed and translated separately and subsequently assemble to form a functional 
luciferase enzyme in a eukaryotic cell. 
 
Internal Ribosomal Entry Sites (IRES) 
 In prokaryotes, translation of multiple adjacent genes within a single operon is 
common.  In these cases, the entire operon is transcribed as a single mRNA regulated 
by the upstream promoter region.  The translation of the mRNA is then initiated by 
direct complementary base pairing between the 16S rRNA and mRNA Shine-
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Dalgarno sequence.  Upon binding, the 30S subunit is brought into an internal 
position around the start codon (AUG) where translation of the protein begins.  
Translation of several proteins from one mRNA is possible (Jackson, 2000).  This 
type of translation scheme is referred to as polycistronic translation.   
 Until recently, it was believed that eukaryotic translation was limited to cap 
dependent initiation.  This mechanism involves a methyl-7-G(5′)pppN structure (cap) 
at the 5′ end of the mRNA that is recognized by a protein complex initiation factor to 
begin translation (Hershey and Merrick, 2000).  This initiation complex scans the 
mRNA for the first AUG triplet downstream of the terminal 5′ cap usually within 50 
to 100 bases where translation begins (Hennecke, 2001).  In this type of initiation, the 
simultaneous translation of multiple proteins from one mRNA is not possible and 
monocistronic translation is the only option.  Typically, each open reading frame is 
transcribed and translated independently from its own promoter. 
 More recently, alternative translation mechanisms have been identified that 
have been shown to initiate translation in a cap-independent manor in eukaryotic 
organisms and their viral pathogens.  These alternative initiation schemes were first 
identified within the genomes of poliovirus and encephalomyocarditis virus (EMCV) 
(Jackson, 1988 and Jang et al., 1988).  These viral sequences are naturally uncapped 
at their 5′ ends.  They possess several complex features that would be predicted to 
impair efficient ribosome binding (Vagner, 2001).  Nevertheless, protein translation 
was shown to be initiated at these sites, both in vitro and in vivo after viral infection 
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(Martinez-Salas et al., 2001).  Furthermore, these sequences, termed internal 
ribosomal entry sites (IRES) were found in all genera of picnovirus (Vagner, 2001). 
 IRES elements can be defined as specific nucleotide sequences that allow for 
ribosomal entry and translation initiation directly at the start codon (AUG) rather than 
requiring scanning from the 5′ end, cap structure, of the mRNA (Pestova et al., 2001 
and Kozac, 2001). IRES activity is based on the secondary structure of the mRNA 
and has been shown to be extremely sensitive to even point mutations that may alter 
the integrity of this structure (Haller and Semler, 1992).  IRES elements from various 
sources, however, have been shown to lack conservation of primary sequences 
(Pestova et al., 1991).  Known IRES elements also vary greatly in their overall length, 
ranging from 200nt in insect RNA viruses (Wilson et al., 2000) to as large as 600nt in 
picnovirus IRES elements (Nicholson et al., 1991).  Along with these variations in 
nucleotide sequence and size, IRES elements have been shown to have varying 
mechanisms from translation initiation (Martinez-Salas, 1999).  However, certain 
secondary structures remain constant and have been shown to be important for the 
initial physical contact with the 40S ribosomal subunit for translation initiation.  
Examples of these specific regions include, double stranded mRNA segments and 
hairpin loop structures (Honda et al., 1996 and Honda et al., 1999).   
 The IRES element isolated from EMCV has been shown to initiate translation 
by ribosomal binding at codons close to the 3′ border of the IRES sequence (Kalinski 
et al., 1990).  Unlike binding to the ribosomes to a Shine-Dalgarno (linear) sequence, 
IRES binding to the 40S subunit is determined by several noncontiguous sequences 
(Pestova et al., 2001).   Whether the IRES and 18S rRNA physically bind is still yet 
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to be determined.  Once the ribosome binds an elF (elongation) initiation factor 
stimulates the formation of the 48S complex and forms internal loops on the IRES 
sequence (Jubin, 2000 and Pestova et al., 1996).  Then, in an ATP dependent manor, 
translation begins directly at the AUG start codon. 
 Most IRES elements identified to date, represent an evolutionary survival 
scheme for viruses upon infection.  Once the virus infects the host cell, the cap 
dependent translation machinery is shut down and only the viral proteins are made 
(Vagner, 2001).  Interestingly, several eukaryotic cellular IRES elements have also 
been identified.  The first cellular IRES was a 220nt 5′ untranslated region (UTR) of 
the immunoglobulin heavy chain binding protein (BiP).  This protein was shown to be 
highly translated after viral infection and thus in a cap-independent manor (Macejak 
and Scarnow, 1991).  Other cellular IRES elements have since been identified and 
shown to be related to various stress responses.  For example, anti-apoptotic genes 
have been shown to use IRES elements for translation initiation of proteins, like 
Apaf-1 (Coldwell et al., 2000).  Furthermore, translation initiation factors have been 
shown to become translated in this fashion, as well including DAP5 (Henis-Korenblit 
et al., 2000) and ELF4G (Johannes and Sarnow, 1998).  It has been hypothesized that 
translation from IRES elements may have been selected for as a last stitch effort to 
survive harsh conditions by providing a failsafe method to ensure synthesis of certain 
proteins under specific physiological conditions (Pestova et al., 2001).  A list of viral 
and cellular IRES elements that have been identified to date are listed in Table 2. 
Several IRES elements have been used to create bicistronic expression vectors 
for the co-expression of multiple genes from the same promoter (Wong et al., 2002  
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Virus/gene Type Virus/gene Reference 
Viral RNAs   
Picnoviruses Poliovirus (PV) Pelletier and Sonenberg, 
1988 
 Encephalomyocarditis 
virus (EMCV) 
Jang et al., 1988 
 Foot and mouth disease 
virus (FMDV) 
Kuhn et al., 1990 
Flavivirus Hepatitis C virus (HCV) Reynolds et al., 1995 
Pestivirus Classical Swine fever virus Pestova et al., 1998 
Retrovirus Murine leukemia virus Berlioz and Darlix, 1995 
Lentivirus Simian immunodeficiency 
virus 
Ohlmann et al., 2000 
Insect RNA virus Cricket paralysis virus Wilson et al, 2000 
   
Cellular mRNAs   
Translation initiation 
factors 
ElF4G Johannes and Sarnow, 
1998 
 DAP5 Henis-Korenblit et al., 
2000 
 Initiation factor G4 Wong et al., 2002 
Transcription factors c-Myc Stoneley et al., 2000 
 NF-kB-repressing factor  Oumard et al., 2000 
Growth Factors Vascular endothelial 
growth factor 
Huez et al., 1998 
 Fibroblast growth factor Creancier et al., 2000 
 Platelet-derived growth 
factor B 
Bernstein et al., 1997 
Homeotic genes Antennapedia Oh et al., 1992 
Survival Proteins X-linked inhibitor of 
apoptosis 
Holick and Korneluk, 
2000 
 Apaf-1 Coldwell et al., 2000 
Miscellaneous BiP Macejak and Sarnow, 
1991 
Yeast p150 Zhou et al., 2001 
Table 2.  Examples of viral and cellular IRES elements identified to date. 
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and deFelipe, 2002).  These new expression vectors have gained much attention due 
to their potential impact as valuable tools for drug and gene delivery vectors for 
multi-drug combined therapies for treating diseases such as cancer and AIDS 
(deFelipe, 2002).  Consequently, for the expression of multigene enzyme systems like 
bacterial luciferase in eukaryotes, IRES based bicistronic vectors may prove to be an 
invaluable tool.   
Several IRES elements have been tested for implementation into this format 
and improved vector development.  Some IRES elements, like the IRES isolated from 
poliovirus, are vulnerable to adjacent gene placement (Mosser et al., 2000).  The 
EMCV IRES element has been shown to be immune to these types of effects and 
upstream genes have little effect on the downstream gene expression (Gorski and 
Jones, 1999).  This property has made the EMCV IRES the most frequent choice for 
creating reliable, high expression bicistronic vectors (Meilke et al., 2000 and Harries 
et al., 2000).  However, by expressing two genes in a promoter-gene1-IRES-gene2 
format, the expression of the second gene has been shown to possess lower overall 
expression levels ranging from 6-100% activity when compared to the first gene 
(Mizuguchi et al., 2000).  This has been regarded as typical expression levels from 
these vectors and therefore, to determine optimal expression, several clones must be 
tested (Clontech Corporation, personal communication).       
New IRES elements are being frequently discovered and better options for optimal 
expression of multiple genes will become available.  Wong et al., 2002 report that a 
newly isolated IRES element from eukaryotic initiation factor G4 produces more than 
100 fold higher overall expression of the genes that follow it compared to 
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 other IRES elements.  This element possesses enhancer abilities as well as acting as a 
ribosomal entry site.  By using this IRES element or others identified in the future, it 
will be possible to create bicistronic and possibly polycistronic eukaryotic expression 
vectors with enhanced expression of each gene from a single promoter. 
 
 
Codon Usage 
The standard term “universal genetic code” comes from the fact that there are 
64 possible codons coding for only 20 amino acids. Although the genetic code is 
degenerate, the alternate synonymous codons are not used with equal frequency 
(Sharp et al., 1988).  In fact, it has been shown that in multivariate analysis, that each 
species has a major trend in codon usage among genes (Schultz and Yarus, 1996).  
This trend has also been shown to differ from highly expressed versus lower 
expressed genes within the same species (Aota and Ikemura, 1986 and Sharp et al., 
1986).  Several more distinct patterns in codon usage become apparent when genes 
are sorted into the top and bottom 10% of protein activity within the cell (Sharp et al., 
1988).  Within these general trends, it has been shown that there is not only a 
selective difference but also a preference for certain codons in highly expressed 
proteins (Sharp et al., 1993).   The genes that encode for these proteins have a highly 
biased codon usage pattern with a higher frequency of optimal codons used and a 
lower frequency or absence all together of the other possible codons (Grantham et al., 
1981; Ikemura, 1985 and Sharp et al., 1993).  Lowly expressed genes have been 
shown to possess a more random pattern of codon usage (Hoekema et al., 1987).  In 
fact, Gouy and Gauter (1982) showed that the frequency of optimal codons in a 
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particular gene was highly correlated with its expression in E. coli.  The same 
scenario was seen with genes expressed from S. cerevisiae  (Sharp and Cowe, 1991).  
 However, it should be noted that a gene is not necessarily expressed at a low 
level simply because it is made up of low frequency codons (Kurland, 1991).  Codon 
usage is not the only factor involved in gene expression.  Several other factors have 
profound impacts on the expression levels of genes in all organisms.  Non-inhibitory 
flanking sequences that surround the gene and optimal ribosomal binding sites are 
critical (Nassal et al., 1987).  Nevertheless, codon bias does play a key role in the 
expression efficiency in all species tested to date (Amicis and Marchetti, 2000).   
 The question has arisen, to whether or not this increase in gene expression is 
due to a more efficient translation of the protein or some other factor.  The answer to 
this questions still remains unclear, however, evidence is building that it may be a 
combination of factors.  It has been shown, that optimal codons are codons to which 
the species in question possesses an overabundance of that particular tRNA molecule.  
Furthermore, these optimal codons are translated faster than their lower frequency 
counterparts (Sorensen et al., 1989), which is thought to lead to a more efficient 
translation (Anderson and Kurland, 1990). However, the speed of overall protein 
translation has not been shown to be significantly affected (Kurland, 1991).   
Other hypotheses for codon optimization having a direct impact on protein 
expression have been set forth including a reduction of cis acting inhibitory elements 
(AU rich regions) (Kofman et al., 2003a) and an overall increase in mRNA stability 
(Kofman et al., 2003b).   Kofman et al. (2003b) also proposes that there may be an 
inefficient processing and transport from the nucleus of mRNAs possessing lower 
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frequency codons in eukaryotes.  This idea was supported by the fact that if the genes 
were expressed on a plasmid (in the cytoplasm) the activity of the protein was 
somewhat recovered. 
  It is unclear to this point if codon usage has a specific regulatory function in 
cells.  Rare codons are present more frequently in the 5′ end of lowly expressed genes 
in E. coli (Goldman et al., 1995).   It is not known, however, if the optimization of 
only 5′ sequences would be enough to significantly enhance expression to reach 
maximal protein activity (Vervoort et al., 2000).   
Codon optimization is the term given to a synthetic creation of a gene 
sequence to possess the optimal codon usage patterns for the host organism.  Several 
examples of codon optimization have been recently published.  These optimized 
proteins have been primarily designed for expression in mammalian hosts, as 
mammalian expression of foreign genes is often times limited (Narum et al., 2001).  
Some codon optimization schemes have also been designed to optimize human genes 
for expression in yeast or bacteria to provide for a simpler protocol for investigation 
or to generate large quantities of individual proteins (Baev et al., 2001). 
Disbrow et al. (2003) and Arregui et al. (2003) have used codon optimization  to 
optimize the expression of the poorly expressed E5 and E7 proteins from human 
papillomaviruses (HPV) that have been shown to have early transformation activity 
on infected cells.  They have shown that codon optimization was able to increase 
expression as much as 100 fold versus the wild type.  This overexpression of the 
protein resulted in cell death to much of the population expressing the codon 
optimized protein.  Based on this increase in cell mortality, they further hypothesized 
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that the virus may have selectively evolved to use a different coding pattern from the 
host as a way to survive in vivo for longer periods of time (Arregui et al., 2003).  
Other groups have used codon optimization to increase expression of viral or bacterial 
proteins for the efficient generation of antibodies.  The amount of DNA required to 
produce a high titer of antibody is significantly reduced if the codon usage patterns of 
the genes are optimized (Narum et al., 2001 and Deml et al., 2001). 
Codon optimization has also been used to increase the efficiency of reporter proteins 
for expression in mammalian cells.  Zhang et al., 2002 optimized the green 
fluorescent protein (GFP) from Aequrea victoria for enhanced expression in 
mammalian cells.  This enhanced GFP gene, EGFP, was shown to make the protein 
35 times brighter than the wild type version (Zhang et al., 2002).  This same idea has 
been used to optimize the expression of Renilla luciferase proteins in mammalian 
cells (Gruber and Wood, 2000).  In both of these instances, the reporter protein 
became a stronger reporter for gene expression and reliable monitoring formats. 
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CHAPTER 2 
 
DETERMINING AN OPTIMAL EXPRESSION FORMAT FOR EXPRESSION OF 
THE BACTERIAL LUCIFERASE GENES (luxA AND luxB) 
 
 
Introduction 
Mammalian cell lines expressing reporter proteins are commonly used in both 
basic and applied research.   Current methodologies that depend on firefly luciferase 
(Luc) and green fluorescent protein (GFP) reporter constructs in mammalian cells are 
limited due to the required cell lysis, substrate addition and/or exogenous excitation to 
evoke a measurable response.  Consequently, these reporter constructs cannot be 
implemented into continuous, real-time, on-line monitoring devices or strategies.  
Bacterial luciferase is unique in that it is the only bioreporter system available that 
generates its own substrate, thus allowing for autonomous signal generation. 
Unfortunately, the bacterial luciferase system’s potential has not been realized in 
mammalian cells because of difficulties encountered with efficient expression of this 
multi-enzyme system. 
Unlike polycistronic expression of multiple genes often found in bacterial 
systems, eukaryotic gene expression generally requires that each individual gene be 
preceded by its own promoter.  This has limited the expression of the lux genes in 
eukaryotes to this point.  In an attempt to overcome this, several researchers have 
generated a monocistronic version of the V. harveyi luciferase protein by creating a 
translational fusion of the individual subunits.  Unfortunately, these efforts have been 
met with only modest successes.  The loss of bioluminescence activity has been 
attributed to improper folding and low thermostability of the fusion protein (Kirchner et 
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al., 1989; Olsson et al., 1989; Almashanu et al., 1990; Esther et al., 1989; Costa, 1991; 
Pazzagli et al., 1992; Gelmini et al., 1993).   None of the fusion proteins reported to date 
have shown the ability to remain stable at the optimal mammalian growth temperature, 
37°C. 
Koncz et al. (1987) reported the successful expression of the heterodimeric 
bacterial luciferase protein from V. harveyi as individual proteins expressed in a dual 
promoter vector format.  The expression levels, although difficult to compare were said 
to be adequate for monitoring chimeric genes in plant extracts (Koncz et al., 1987).  
These data also showed for the first time that individual subunits of the protein could be 
transcribed and translated separately and subsequently assemble to form a functional 
luciferase enzyme in a eukaryotic cell.  Gupta et al. (2003) showed that by linking the 
lux genes transcriptionally with IRES elements, the complete lux operon could be 
efficiently expressed in the yeast, S. cerevisiae.   However, no one expression format 
has been shown to be the optimal choice for expression of the bacterial luciferase genes 
in mammalian cells and therefore no mammalian reporter systems are currently 
available that utilize this uniquely powerful reporter system.  Therefore, further research 
is needed to identify the optimal expression format for the heterodimeric luciferase 
protein in mammalian cells.  In this research effort the specific objectives are: 
• To construct and evaluate the overall bioluminescence potential from a 
constitutively expressed luxAB fusion protein, a dual promoter vector 
harboring both the luxA and luxB genes, expression from co-transfected 
plasmids harboring the luxA and luxB genes independently and 
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expression from a transcriptionally fused luxA and luxB that are 
independently translated via an IRES element.  
• To establish if episomal expression of the lux genes provides a higher 
bioluminescent signal than constructs integrated into the host’s 
chromosome. 
• To determine the stability of an episomal plasmid in mammalian cell 
lines without selective pressure. 
• To evaluate if FMNH2 is a limiting substrate for efficient 
bioluminescence in mammalian cells. 
 
 
Materials and Methods 
Cell Culture and Plasmid Maintenance  
All relevant constructs and strains, bacterial and mammalian, used in this study 
are outlined in Table 3.  E. coli cells were routinely grown in Luria Bertani (LB) (Fisher 
Scientific, Pittsburgh, PA) broth containing the appropriate antibiotic selection with 
continuous shaking (200rpm) at 37°C.  Kanamycin and Ampicillin were used at a final 
concentration of 50µg/ml and 100 µg/ml, respectively. 
 All cell culture reagents and media were obtained from Sigma Aldrich, (St. 
Louis, MO) unless otherwise stated.  Mammalian cells were grown in the appropriate 
complete growth media containing 10% heat-inactivated horse or fetal bovine serum, 
0.01mM non-essential amino acids and 0.1mM sodium pyruvate in a Dubelco’s 
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Table 3.  Strains and plasmids used in the determination of the optimal expression 
format for bacterial luciferase in mammalian cells.  
 
Plasmid/Strain 
Designation 
 
Relevant Genotype/ Characteristics 
 
Source 
Strains   
E. coli   
 
DH5α 
Φ80dlacZ∆M15, recA1, endA1, gyrA96, thi-1, 
hsdR17 (rK-, mK+), supE44, relA1, deoR, 
∆(lacZYA-argF)U169 
 
Gibco, BRL 
 
 
TOP 10 
 
F-, mcrA ∆(mrr-hsdRMS-mcrBC) Φ80/lacZ 
∆lacX74 deoR recA1 araD139 ∆(ara-leu) 7697 
ga/K rpsL endA1 nupG 
 
 
Invitrogen 
 
Mammalian Cell Lines 
  
 
HEK293 
Permanent line of primary human embryonal 
kidney transformed by sheared human 
adenovirus type 5 (Ad 5) DNA. ATCC# CRL-
1573 
 
ATCC 
 
 
COS-7 
 
Monkey Kidney cells transformed with an origin 
defective mutant of SV40 which codes for wild-
type T antigen. ATCC# CRL-1651 
 
 
ATCC 
 
HeLa 
 
Human cervical cancer cell line ATCC# CCL-2  
 
ATCC 
 
Plasmids 
  
 
 
pCR2.1-TOPO 
 
TOPO TA cloning vector for easy cloning of 
PCR products generated with 3′ A overhangs 
Kmr, Ampr 
 
 
Invitrogen 
 
 
pCR4-TOPO 
 
TOPO TA cloning vector for easy cloning of 
PCR products generated with 3′ A overhangs 
designed for sequencing Kmr, Ampr 
 
 
Invitrogen 
 
 
pcDNA3.1 
 
Mammalian expression vector, constitutive 
CMV promoter, contains a Neomycin G418 
antibiotic selection  and a ColEI and Ampr for 
replication in E. coli 
 
 
Invitrogen 
 
 
pCEP4 
 
Mammalian episomally maintained expression 
vector, constitutive CMV promoter, Hygromycin 
antibiotic selection marker and a ColEI and 
Ampr for replication in E. coli 
 
 
Invitrogen 
 
 
pREP9 
 
Mammalian episomally maintained expression 
vector, constitutive RSV promoter, Neomycin 
G418 antibiotic selection marker and a ColEI 
and Ampr for replication in E. coli 
 
 
Invitrogen 
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Plasmid/Strain 
Designation 
 
 
 
 
Relevant Genotype/ Characteristics 
 
 
 
 
Source 
 
 
 
 
pIRES2-DsRed2 
 
 
Mammalian expression vector containing the 
internal ribosomal entry site (IRES) of the 
encephalomyocarditis virus between the multi-
cloning site and a DsRed reporter protein, a 
constitutive CMV promoter, Neomycin G418 
antibiotic selection marker and a pUC ori and 
Kmr for replication in E.coli 
 
 
 
 
Clontech 
 
 
 
pIRES 
 
Mammalian expression vector containing the 
internal ribosomal entry site (IRES) of the 
encephalomyocarditis virus between two multi-
cloning sites which allows for the expression of 
two genes under the control of a single 
constitutive CMV promoter, Neomycin G418 
antibiotic selection marker and a pUC ori and 
Kmr for replication in E.coli 
 
 
 
Clontech 
 
pCR4PLluxCDABE 
 
pCR4 harboring a 6.1 kb luxCDABE cassette 
from Photorhabdus luminescens 
 
This Study 
 
pCR4luxA 
 
pCR4 TA cloning vector harboring the luxA 
from Photorhabdus luminescens 
 
This Study 
 
pCR4luxB 
 
pCR4 TA cloning vector harboring the luxB 
from Photorhabdus luminescens 
 
This Study 
 
pCR2luxA 
 
pCR2.1 TA cloning vector harboring the luxA 
from Photorhabdus luminescens 
 
This Study 
 
pCR2luxB 
 
pCR2.1 TA cloning vector harboring the luxB 
from Photorhabdus luminescens 
 
This Study 
 
 
pCRluxAf 
 
pCR2.1 TA cloning vector harboring the luxA 
from Photorhabdus luminescens amplified with 
the reverse fusion primer 
 
 
This Study 
 
 
pCRluxBf 
 
pCR2.1 TA cloning vector harboring the luxB 
from Photorhabdus luminescens amplified with 
the luxB forward fusion primer 
 
 
This Study 
 
pCRluxABf 
 
pCR2.1 TA cloning vector harboring the luxAB 
generated by ligating the luxAf and luxBf 
together 
 
This Study 
 
pcDNABf 
 
pcDNA3.1 harboring the luxABf  
 
This Study 
   
Table 3. Continued 
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Plasmid/Strain 
Designation 
 
 
 
 
 
Relevant Genotype/ Characteristics 
 
 
 
 
 
Source 
 
 
 
pcDNABfKoz 
 
 
 
pcDNA3.1 harboring the luxABf with the Kozac 
sequence modification 
 
 
 
This Study 
 
pcDNluxA 
 
pcDNA3.1 harboring the luxA  from                   
P. luminescens 
 
This Study 
 
pCEPluxA 
 
pCEP4 harboring luxA from P.luminescens 
 
This Study 
 
pREPluxB 
 
pREP9 harboring luxB from P.luminescens 
 
This Study 
 
 
pCRSVluxBpA 
 
pCR4 harboring the RSV promoter, luxB and the 
SV40 pA with introduced ClaI and BglII sites on 
both the 5′ and 3′ ends of the gene 
 
 
This Study 
 
pREPABf 
 
pREP9 harboring luxAB fusion from 
P.luminescens 
 
This Study 
 
 
pCEPluxARluxB 
 
pCEP4 harboring the luxA cloned into the MCS 
and the RSV-luxB-SV40pA into a unique ClaI 
restriction site within the vector 
 
 
This Study 
 
pcDNARB 
 
pcDNA3.1 harboring luxA cloned into the MCS 
and the RSV-luxB-SV40pA into a unique BglII 
restriction site within the vector 
 
 
This Study 
 
pluxAIEGFP 
 
pIRES-EGFP harboring the luxA from P. 
luminescens  
 
This Study 
 
pluxBIDsRed 
 
pIRES-DsRed harboring the luxB from P. 
luminescens 
 
This Study 
 
pCR4NotIluxA 
 
pCR4 harboring the luxA from P. luminescens 
with introduced NotI sites on both the 5′ and 3′ 
ends of the gene 
 
This Study 
 
pluxAIRES3 
 
pIRES harboring the luxA from P. luminescens 
cloned into the MCS(A) 
 
This Study 
 
pluxAIRESluxB 
 
pIRES harboring the luxA cloned into the 
MCS(A) and luxB cloned into MCS(B) from P. 
luminescens 
 
This Study 
Table 3. Continued 
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minimal essential media base (DMEM) (M4655).  Cells were routinely grown at 37°C 
in a 5% CO2 atmosphere to confluency and split every three to four days by 
trypsinization at a 1:4 ratio into fresh complete growth media.  Appropriate 
concentrations of antibiotic were used to maintain constructs after transfection  
according to susceptibility kill curve analysis. Kill curves were completed for each cell 
line and lot of antibiotic.  A range of typical concentrations used for each antibiotic is 
found in Table 4.   
 
Antibiotic Kill Curves 
 Kill curve experiments were performed to determine the antibiotic susceptibility 
for each cell line to each lot of antibiotic.  Cells were plated into six well tissue culture 
plates and grown to 50-60% confluency.  Varying concentrations of antibiotic were 
mixed into each well along with one control well (no antibiotic).  The plates were 
incubated at 37°C in a 5% CO2 atmosphere for seven to ten days with the media being 
refreshed every three days.  Cells were checked daily by microscopic analysis and 
changes in cell morphology and viability were recorded.  The minimum concentration 
of antibiotic that was toxic to the cells within eight days was used for selection of stable 
cell lines (Table 4). 
 
Construction of a luxA- luxB Fusion Protein 
 To create a monocistronic version of the heterodimeric luciferase protein 
encoded by the luxA and luxB genes, a translational fusion of the two polypeptides was 
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Table 4.  Concentrations of antibiotics used for each cell line based on results of kill 
curves.  
 
Antibiotic HEK293 COS-7 HeLa 
Neomycin G418 450-650µg/ml 400-700µg/ml 500-750µg/ml 
Zeocin 250-400µg/ml Not Tested Not Tested 
Hygromycin 400-600µg/ml Not Tested Not Tested 
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constructed.  Synthetic oligonucleotides were designed to fuse the 3′ end of the luxA to 
the 5′ end of the luxB.  Both oligonucleotide sequences were complementary to 
sequences at the 3′ end of the luxA, the intergenic region between the luxA and luxB, 
and the start codon of luxB.  These oligos were synthesized with the following 
modifications:  luxA Reverse Primer:  the luxA stop codon (TAG) was removed by  
substituting a Cytosine nucleotide for the Guanine resulting in a tyrosine codon, a single 
base addition of Guanine was also added to place the luxB in the same reading frame to 
create a fusion protein, further, a Guanine was substituted to generate an AvrII 
restriction site at the 3′ end of the luxA.  luxB Forward Primer: the primer was the 
exact complement of the luxA reverse primer.   The luxA and luxB genes were 
individually amplified using Taq polymerase (to generate 3′ A overhangs) and TA 
cloned into the pCR2.1 TOPO cloning vector (Invitrogen Corporation, Carlsbad, CA) to 
construct pCRluxAf and pCRluxBf.   These plasmids were then digested with EcoRI 
and AvrII and the products were gel purified by electroelution (Sambrook et al., 1999).  
The fragments were then ligated in equal molar concentrations for 2 h. The ligation 
product (1 µl) was then used as template for a PCR reaction using the outermost luxA 
forward and luxB reverse primer pair to generate a luxAB fusion.  The resultant PCR 
products of the correct size were TA TOPO cloned into the pCR2.1 TOPO cloning 
vector to generate pCRluxABf.  The construct was then digested with AvrII and EcoRI 
restriction enzymes and sequenced to ensure its integrity.  The sequence of the wild 
type and modified intergenic region of the fusion are shown in Figure 5.    
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luxA stop                            luxB start
tat tag cta agg aga aag a*a atg aaa ttt luxAB unfused
Tyr Stop                                                        Met Lys    Phe
AvrII
Base substitution          base addition           luxB start     
tat tac cta ggg aga aag aga atg aaa ttt luxAB fused
Tyr     Tyr    Leu     Gly      Arg     Lys      Arg Met Lys     Phe
Figure 5.  Sequence of the wild type luxAB and luxABf.  Introduced AvrII site is in 
the shaded area.  Base substitutions and base additions are noted and * 
represents the absence of the base in the wild type luxAB. 
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Episomal Expression 
For the expression fusion protein as an episome, the luxABf was cloned into the 
pREP9 mammalian expression vector (Clontech Corporation, Palo Alto, CA).  To create 
this clone, the luxABf insert was cleaved from pCRABf with KpnI and XhoI restriction 
sites located within the vector and then ligated into the pREP9 vector that had been 
digested with the same enzymes.  The ligation of these two fragments generated 
pREPABf (Figure 6A).   
Chromosomal Expression 
The luxAB fusion was cleaved from pCRABf via 3′ and 5′ EcoRI sites and non-
directionally cloned into pcDNA3.1 to generate pcDNABf (Figure 6B) for 
chromosomal insertion and expression in mammalian cells.   
To facilitate high levels of expression in eukaryotes, Kozac sequences are often 
inserted at the 5′ ends of genes.  To accomplish this addition to the luxAB fusion a luxA 
forward primer was modified to insert a Kozac sequence by substituting an Adenine at 
the –3 position and a Guanine at the +4 position around the start site of the luxA.  The 
luxAB fusion was then amplified from the pCRABf plasmid construct and the resultant 
PCR product was subsequently TA cloned into pCR2.1 to generate pCRABfKoz.  This 
insert was then cleaved by EcoRI and cloned into the pcDNA3.1 mammalian expression 
vector to create pcDNABfKoz. 
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CMV
luxABf
SV40 pA
Neo G418
pcDNABf
A 
Figure 6. Diagram of vector plasmids for the expression of the luxAB fusion in 
mammalian cells. pcDNABf construct provides chromosomal expression and 
neomycin G418 selection.  B. pREPABf construct allows for episomal 
expression and neomycin G418 selection.  
B PCMV
luxABf
SV40pA
Neo G418
EBNA-1
OriP
pREPABf
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Construction of a Dual Promoter Vector for Expression of luxA and luxB 
Episomal Expression 
 
Pasting pieces from pCEP4 and pREP9 episomal mammalian expression vectors 
together generated a dual promoter vector that allowed for the expression of both genes 
(luxA and luxB) from their own promoters.  First, luxA was cleaved from pCRluxA with 
introduced 5′ NheI and a 3′ XhoI sites and cloned into pCEP4 to generate pCEPluxA.  
The luxB gene was then cloned into pREP9 to generate pREPluxB using the same clone 
strategy described above for cloning luxA into pCEP4.  Oligonucleotide primers were 
designed and synthesized to amplify the RSV promoter region of pREP9, luxB gene, 
and the SV40 ployA region from pREPluxB with the introduction of 5′ and 3′ ClaI-
BglII restriction sites.  The resultant PCR product was then TA TOPO cloned into pCR4 
TOPO (Invitrogen Corporation, Carlsbad, CA) to generate pCRSVluxBpA.  This 
construct was then cleaved via ClaI and the insert cloned into a complementary site on 
pCEPluxA to generate pCEPluxARluxB (Figure 7A). 
Chromosomal Expression 
 
To chromosomally express both the luxA and luxB from individual promoters 
with only one selection marker required, a dual promoter vector was constructed. This 
expression vector was generated on the plasmid backbone of the pcDNA3.1 mammalian 
expression vector (Invitrogen Corporation, Carlsbad, CA).  First, the luxA gene was 
cleaved from pCRluxA with EcoRI and nondirectionally ligated into pcDNA3.1.  The 
clones were then checked for insert presence and orientation by restriction digestion and 
sequencing to generate pcDNluxA. Once verified the RSV, luxB and SV40 polyA  
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CMV
luxA
SV40 pA
Neo G418
PRSV
luxB SV40 pA
pcDNARB
PCMV
luxA
SV40 pA
EBNA-1
OriP
Hygromycin
SV40 pA
luxB
PRSV
pCEPluxARluxB
A 
B 
Figure 7. Diagram of vector plasmids for the expression of luxA and luxB from 
individual promoters within the same vector in mammalian cells.  A.  
pcDNARB construct allows for chromosomal expression and hygromycin 
selection.  B. pCEPluxARluxB construct provides  episomal expression 
and neomycin G418 selection.  
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region were cleaved from pCRSVluxBpA via a unique 5′ and 3′ BglII sites and cloned 
into pcDNluxA to generate pcDNARB (Figure 7B). 
 
Construction of GFP vectors for co-transfection Experiments 
Episomal Expression 
  
Co-transfection of each gene (luxA and luxB) on separate plasmids would allow 
the proteins to be expressed independently.  For episomal expression, the pREP9 and 
pCEP4 (both from Clontech Corporation, Palo Alto, CA) expression vectors were used.  
The luxA and luxB genes were cloned into these vectors as previously described to 
generate pCEPluxA (Figure 8A) and pREPluxB (Figure 8B). 
Chromosomal Expression  
 
Separate EGFP and DsRed reporter vectors were constructed to allow for co-
transfection of luxA and luxB genes on separate plasmids and integration within the 
host’s chromosome.  luxA was cloned into pIRES-EGFP and luxB was cloned into 
pIRES2-DsRed2 (both from Clontech Corporation, Palo Alto, CA).  These reporter 
vectors were chosen to allow for the monitoring of co-transfection efficiency and 
plasmid maintenance.  Each plasmid contains a GFP variant reporter gene under the 
translational control of an encephalomyocarditis virus (EMCV) internal ribosomal entry 
site (IRES) that immediately follows the multi-cloning site within the vector.  To 
generate these constructs, each vector was digested with EcoRI and the luxA or luxB 
was cleaved from pCRluxA or pCRluxB using the same enzyme.  The vector and 
inserts were then ligated via the complementary ends to generate pluxAIEGFP (Figure 
9A) and pluxBIDsRed (Figure 9B).    
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PCMV
Kan/Neo
luxB
IRES
DsRed
pluxB-DsRed
PCMV
Kan/Neo
luxA
IRES
EGFP
pluxA-EGFP
A 
B 
Figure 8. Diagram of vector plasmids for the expression of luxA and luxB from 
individual plasmids along with a GFP reporter protein in mammalian 
cells.  A.  pluxA-EGFP expresses the luxA gene and an EGFP reporter 
protein from a single bi-cistronic transcript.  B. pluxB-DsRed construct 
expresses the luxB gene and a DsRed reporter protein from a single bi-
cistronic transcript. 
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PRSV
Neo G418
luxB
SV40 pAEBNA-1
OriP
pREPluxB
PCMV
luxA
SV40 pA
EBNA-1
OriP
Hygromycin
pCEPluxA
A 
B 
  Figure 9. Diagram of vector plasmids for the expression of luxA and 
luxB from individual plasmids in mammalian cells.  A. 
pCEPluxA allows for expression of the luxA gene as an 
episome with hygromycin selection.  B. pREPluxB construct 
allows fro the expression of the luxB gene as an episome with 
neomycin G418 selection.
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Construction of a Bi-cistronic Vector to Express luxA and luxB 
 To co-express both luxA and luxB genes from a single promoter, the pIRES 
mammalian expression vector was chosen (Clontech Corporation, Palo Alto, CA).  This 
expression vector contains two multi-cloning sites separated by an internal ribosomal 
entry site (IRES) from encephalomyocarditis virus (EMCV).  The IRES element allows 
for the expression of two genes (one cloned into each multi-cloning site) from a single 
constitutive CMV promoter.  To create this construct, the luxA gene from P. 
luminescens was amplified from pCR4PLluxCDABE plasmid that harbors the complete 
luxCDABE cassette (Table 3) with the introduction of unique NotI restriction sites on 
both the 5′ and 3′ ends of the luxA gene.  The resultant PCR product was TA TOPO 
cloned into pCR4 TOPO to generate pCR4NotIluxA.  The luxA gene was then cloned 
into the MCS(A) of pIRES via the unique NotI restriction sites to generate pluxAIRES3.  
Once this construct was confirmed by sequencing, the plasmid was purified using the 
Wizard midi-prep plasmid purification kit according to the manufacturer’s instructions 
(Promega Corporation, Madison, WI).  The luxB gene was cleaved via a 5′ XbaI and 3′ 
SpeI site from pCRluxB and cloned into the XbaI site within the MCS(B) of 
pluxAIRES3 to generate pluxAIRESB (Figure 10). 
 
Ligation Reactions 
Plasmid vectors and inserts were digested (2-6 h) with the appropriate enzymes 
(Promega Corporation, Madison, WI).  Linearized vectors were dephosphorylated using 
a calf intestine alkaline phosphatase enzyme according to the manufacturer’s 
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PCMV
Kan/Neo
luxA
IRES
luxB
pAIRESB
Figure 10. Diagram of vector construct for the expression of luxA and luxB 
as a single bi-cistronic transcript, pAIRESB.  
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instructions (Promega Corporation, Madison, WI).  Both vector and insert DNA were 
gel purified from 1% agarose gels using the Geneclean gel extraction kit (Bio101, 
Carlsbad, CA).  The recovered DNA was then quantified using a Dyna Quant 200 
fluorometer (Hoefer Pharmacia Biotech Incorporated, San Francisco, CA) and ligations 
were set up as 20µl reactions using a 3:1 molar ratio of insert to vector DNA.  The 
ligation reactions were then incubated at 17°C overnight. 
 
Electroporation 
Electrocompetent cells were prepared as outlined by the manufacturer (BTX, 
San Diego, CA).  Electroporations were performed using the BTX Electroporator 600 
with the following conditions: 40µl cells, 1-2µl ligation mixture (above), a 2.5kV pulse 
for 4.7ms using a 2mm gap cuvette.  After the pulse, cells were immediately 
resuspended in 1ml of sterile LB and allowed to recover for 1 h at 37°C (200 rpm).  
Cells were then plated on selective media containing the appropriate antibiotic. 
 
Selection of Bacterial Clones 
Resistant colonies were picked after 24 h and expanded to patches on grid 
plates.  To test for proper insert presence and orientation, rapid boil plasmid mini-preps 
(Promega Corporation, Madison, WI) were done followed by the digestion of the 
plasmid with the appropriate restriction enzyme mixture according to the 
manufacturer’s instructions (Promega Corporation, Madison, WI).  Products were run 
on 1% agarose gels to determine if the banding pattern indicated the insert presence and 
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proper orientation.  Upon identifying correct clones, the plasmids were further purified 
using the Wizard midiprep plasmid purification system according to the manufacture’s 
protocol (Promega Corporation, Madison, WI) and sequenced. 
 
Sequencing 
All constructs were sequenced to ensure their integrity.  Sequencing was done in 
the University of Tennessee Molecular Biology Service Facility using an Applied 
Biosystems 3100 Genetic Analyzer sequencer (Foster City, CA).   
 
 
Determination of Thermostability of the luxAB Fusion Protein  
 To determine the thermostability of the luxAB fusion protein, E. coli cells 
harboring the pCRABf construct were grown at 23°C, 30°C and 37°C overnight with    
50 µg Kanomycin/ml in LB.  The bioluminescence levels for each temperature 
condition were taken in triplicate.  Bioluminescence measurements were done using the 
FB14 luminometer (Zylux Corporation, Pforzheim, Germany) at a 1 s integration and 
reported as relative light units (RLU).  To normalize the data each bioluminescence 
reading was divided by absorbance O.D.600 for the culture and reported as relative 
bioluminescence.     
 
Transfection of Mammalian Cells  
Transfection of all cell lines was done in six well poly-D-lysine coated tissue 
culture plates (Fisher Scientific, Pittsburgh, PA).  Cells were split from stock cultures 
and inoculated into each well at approximately 1X105 cells per well in complete growth 
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media.  The plate was then placed at 37°C in a 5% CO2 atmosphere for 1-2 days until 
the cells became 80-90% confluent.  The day of transfection, the medium was refreshed.  
DNA for transfections was purified from 100ml overnight E. coli cultures using the 
Wizard Purefection plasmid purification kit to remove endotoxins according to the 
manufacturer’s instructions (Promega Corporation, Madison, WI).  For chromosomal 
integration, the plasmid DNA was linearized before transfection to increase proper 
integration.  For episomal expression, plasmids were transfected as circular DNA. 
HEK293 Cells 
  
Purified plasmid DNA (3.2 µg) was mixed into 200 µl of serum free DMEM in 
a 1.5 ml tube.  In a second tube, 8 µl of Lipofectamine 2000 reagent (Invitrogen 
Corporation, Carlsbad, CA) was added to 200 µl of serum free DMEM.  The 
lipofectamine mixture was added to the DNA mixture within 5 min and incubated at 
room temperature for 20 min.  The entire mixture (400 µl total) was added directly to 
the appropriate well on the plate and rocked back and forth to ensure adequate mixing.  
Twenty-four hours post transfection, the complexes were removed and the media was 
replaced with fresh complete growth media supplemented with the appropriate 
antibiotic for selection.   
COS-7 Cells 
  
Purified plasmid (1.5 µg) was mixed with 100 µl of serum free DMEM in a 1.5 
ml tube.  In a second tube, 5 µl of lipofectin (Invitrogen Corporation, Carlsbad, CA) 
was mixed with 100 µl of serum free DMEM.  The two mixtures were then mixed 
together and incubated at room temperature for 45 min.  After incubation, 0.8 ml of 
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serum free DMEM was added to the mixture and then directly placed on the cells in the 
plate that had been previously rinsed two times with serum free DMEM to remove any 
residual serum.  The complexes were incubated on the cells for 5 h at 37°C in a 5% CO2 
atmosphere.  After incubation DMEM supplemented with 20% fetal calf serum was 
added.  Forty-eight hours after transfection, complete DMEM plus antibiotic was 
applied to the cells for selection. 
HeLa Cells 
  
Purified plasmid DNA (1.6 µg) was added to 200 µl of serum free DMEM along 
with 10 µl of the PLUS Reagent (Invitrogen Corporation, Carlsbad, CA) and incubated 
at room temperature for 15 min.  In a second tube 1 µl of Lipofectin (Invitrogen 
Corporation, Carlsbad, CA) reagent was added to 50 µl of serum free DMEM and 
incubated at room temperature for 30 min.  The two tubes were then mixed gently and 
incubated further for 15 min.  The growth media was removed from the cells and 
replaced with serum free DMEM and the DNA-Lipofectin complexes were added 
directly to the wells and gently mixed.  The plates were then incubated at 37°C in a 5% 
CO2 atmosphere for 3 to 5 h.  After incubation, 15% fetal bovine serum was added to 
each well. Twenty-four hours post transfection, growth media supplemented with the 
appropriate antibiotic was applied to the cells for selection. 
 
 
Selection of Mammalian Cell Clones 
Twenty-four to forty-eight hours post transfection, selective medium was added 
to all wells and refreshed every three to four days.  Within two weeks all control cells 
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were dead and the transected cells were forming small colonies on the plate surface.  
Colonies were separated from the rest of the well by placing a sterile chamber around 
the cell mass and sealing it with silicon (Fisher Scientific, Pittsburgh, PA).  The media 
could then be removed and each colony could be trypsinized and transferred to 
individual tissue culture flasks.  To accomplish this, after washing with a PBS solution, 
200 µl of a 1X Trypsin-EDTA solution (Sigma Aldrich, St. Louis, MO) was added 
directly to the chamber and incubated at 37°C for 3 to 5 min.  The trypsin-EDTA 
solution was then replaced with complete growth media and the cells were transferred 
to a 25cm2 tissue culture flask for propagation.  Each clone was given a number and 
expanded to individual cell lines.  Each line was split and maintained as described 
earlier with the addition of selective media.  At between nine and twenty cell lines were 
propagated in this manner for each plasmid tested.     
  
 
Bioluminescence Assays from Mammalian Cells 
To determine bioluminescence potential from each cell line clone, total proteins 
were extracted and in vitro enzyme (bioluminescence) assays performed.  To extract the 
proteins, the cells were trypsinized from the plate or flask surface using standard 
protocols and resuspended into 2.0 ml Sarstedt tubes (Fisher Scientific, Pittsburgh, PA).  
The cells were then spun down and washed two times in sterile phosphate buffered 
saline (PBS) to remove any residual medium (Sigma Aldrich, St. Louis, MO).  Cell 
pellets were then resuspended into 1 ml 0.1M potassium phosphate buffer pH 7.8 and 
disrupted by three consecutive cycles of freeze (30 s liquid N2) thaw (5 min at 37°C) 
extraction.  After disruption, the cell debris was pelleted by spinning the samples at 
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14,000Xg for 5 min and the supernatant was used in the bioluminescence assay.  To 
determine light intensity, the protein extract was mixed with 0.1 mM NAD(P)H, 4 µM 
FMN, 0.2% (w/v) BSA, 0.002% (w/v) n-decanal.  Bioluminescence was measured 
using the FB14 luminometer (Zylux Corporation, Pforzheim, Germany) at a 1 s 
integration and reported as relative light units (RLU).  To determine if FMNH2 was a 
limiting factor for the bioluminescence reaction, a flavin oxidoreductase enzyme (1U) 
isolated from V. harveyi (Roche Scientific, Indianapolis, IN) was added to the 
bioluminescence assay and the light levels were measured again for comparison (Table 
5).     
 Bioluminescence signals were normalized between samples and cell lines by 
dividing the RLU measurement by the total protein and reporting the bioluminescence 
as RLU/µg total protein.  Protein concentrations were determined using the Coomassie 
Plus protein assay according to the manufacture’s instructions (Biorad, Hercules, CA).   
 
In Vitro Transcription/Translation 
 To determine if the lux genes could be generated in vitro in rabbit reticulocyte 
lysate (mammalian translation machinery), pCR2.1 TOPO vectors harboring luxA, luxB 
and luxABf were transcribed and translated.  First, the plasmid DNA containing the 
genes was digested at a unique SpeI restriction site at the 3′ end of the gene within the 
vector.  This digestion linearized the plasmid and allowed for the generation of run-off 
transcript from the vector derived T7 promoter.  Each gene was transcribed via T7 
polymerase using the RiboMax large-scale transcription system (Promega Corporation, 
Madison, WI).  Three individual transcription reactions were set up along with 
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Plasmid Expression Cell Line Tested Selection 
Marker 
pcDNABf Chromosomal HEK293, HeLa, COS-7 G418 
pcDNABfKoz Chromosomal HEK293, HeLa, COS-7 G418 
pREPABf Episomal HEK293 G418 
pCEPluxA Episomal HEK293 Hygromycin 
pREPluxB Episomal HEK293 G418 
pluxA-EGFP Chromosomal HEK293 G418, EGFP 
pluxB-DsRed Chromosomal HEK293 G418, DsRed 
pCEPluxARluxB Episomal HEK293 Hygromycin 
pcDNARB Chromosomal HEK293 G418 
pluxAIRESluxB Chromosomal HEK293 G418 
 
Table 5.  Final constructs transfected into mammalian cell lines. 
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a positive T7 control and a negative control containing no template DNA.  Each 
reaction was set up according to the manufacturer’s protocol and then incubated at 37°C 
for 1 h.  Transcripts were quantified by absorbance (260/280) measurements (Beckman 
Coulter, Fullerton, CA).  Ten micrograms per ml of total RNA transcript was then 
added to 50 µl (total volume) rabbit reticulocyte lysate translation reactions.  Each 
reaction was gently mixed on ice according to the manufacturer’s protocol for 35S 
labeled protein generation and then incubated at 30°C for 90 min (Promega 
Corporation, Madison, WI).  Once translation was complete, 15 µl of each reaction was 
loaded onto a 12% SDS-PAGE mini-gel and run at 30mA for 1 h.  The gel was removed 
and dried at 60°C with vacuum pressure using a model 443 Slab Dryer (BioRad, 
Hercules, CA) onto 3MM filter paper (Fisher Scientific, Pittsburgh, PA).  To visualize 
the generated proteins, the gel was placed onto x-ray film overnight and specific activity 
was measured upon film development.    
 
Genomic DNA Isolation 
Genomic DNA from each cell line clone was accomplished using the Wizard 
genomic DNA extraction kit according to the manufacture’s protocols (Promega 
Corporation, Madison, WI).   
 
 
RNA Isolation and Blotting 
At passage six post transfection, selected cell line clones were expanded to 
75cm2 tissue culture flasks.  When the cells became 80-95% confluent, the cells were 
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trypsinized to remove the cells from the surface and transferred to 2.0 ml Sarstedt tubes 
(Fisher Scientific, Pittsburgh, PA).  Cells were spun down and washed two times in 
PBS (Sigma Aldrich, St. Louis, MO).  Total RNA was then isolated from the cells using 
the RNeasy kit (Quiagen, Valencia, CA) according to the manufacturer’s instructions 
for isolation of total RNA from mammalian cells.  To remove any contaminating DNA, 
the RNA was digested for 30 min with DNaseI (Promega Corporation, Madison, WI).  
To remove the DNaseI enzyme, the clean-up procedure from the RNeasy kit was used 
(Quiagen, Valencia, CA).  Total RNA was then quantified using the Beckman DU-640 
spectrophotometer absorbance at 260/280 (Beckman Coulter, Fullerton, CA).   
RNA Slot Blotting 
 
Ten micrograms of total RNA were loaded onto a BiotransTM nylon membrane 
(ICN, Irvine, CA) using a Bioslot blot apparatus (Biorad, Hercules, CA) according to 
the manufacturer’s protocol.  A  32P labeled probe was generated complementary to the 
300 bp of the luxA or luxB gene from P. luminescens using standard PCR protocols with 
the incorporation of a [32P] labeled dCTP nucleotide.  The free nucleotides were 
removed and the probe purified by column purification according to the manufacture’s 
instructions (Stratagene, La Jolla, CA). The specific activity of each probe was 
measured by scintillation counting (Beckman Coulter, Fullerton, CA).  Before use, the 
dsDNA probe was boiled for 10 minutes to denature the DNA and directly added to the 
pre-hybridization solution (SLIME).  The blot was incubated with the probe at 48°C 
overnight.  After probe hybridization, the blot was washed 4 times in 20X SSC to 
remove any unbound activity.  The wash temperatures were determined experimentally 
to achieve optimal probe binding without excess background activity.  The blot was air 
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dried and then placed on a phosphorescence intensifier screen (Molecular Dynamics, 
Piscataway, NJ).  Specific activity was measured using the STORM 840 
phosphoanalyzer and the data analyzed using the ImageQuant data analysis software 
(Molecular Dynamics, Piscataway, NJ).     
 
Protein Isolation and Western Blotting 
 To extract the proteins, cells were trypsinized from a plate or flask surface and 
resuspended into 2.0 ml Sarstedt tubes (Fisher Scientific, Pittsburgh, PA).  The cells 
were then spun down and washed two times in sterile phosphate buffered saline (PBS) 
to remove any residual media (Sigma Aldrich, St. Louis, MO).  Cell pellets were 
resuspended into 1 ml 0.1M potassium phosphate buffer pH 7.8 and disrupted by three 
consecutive cycles of freeze (30 s liquid N2) thaw (5 min at 37°C) extraction.  After 
disruption, the cell debris was pelleted by spinning the samples at 14,000Xg for 5 min 
and the supernatant was used as total soluble protein for Western blot analysis. 
 Protein concentrations were determined using the Coomassie Plus protein assay 
according to the manufacturer’s instructions (Pierce, Rockford, IL).  Equal amounts 
(100 – 250 µg) of protein were loaded onto a 12% SDS-PAGE gel.  Minigels were run 
at 30 mA for approximately 2 h and larger slab gels were run at 30 mA overnight.  The 
proteins were then electroblot transferred to a PDVF membrane (Biorad, Hercules, CA) 
using a semi-dry electroblotter according to the manufacture’s instructions (CBS 
Scientific Company, Incorporated, Del Mar, CA).  Blots were then blocked overnight in 
5% nonfat dry milk and hybridized with a polyclonal antibody raised against a 16 amino 
acid luxA polypeptide (′N′ - FDDSDQTRGYDFNKGC - ′C′) or a 16 amino acid luxB 
 59
polypeptide (′N′ - CMILVNYNEDSNKAKQ - ′C′) (Genemed Synthesis, Incorporated, 
San Francisco, CA).  Antibodies were diluted in T-TBS (Tris Buffered Saline + 3% 
Tween 20) at a 1:500 dilution and applied to the membrane at room temperature for 5 h 
to overnight.  The blot was then washed several times in T-TBS and incubated with a 
Goat Anti-Rabbit second antibody that has been conjugated to alkaline phosphatase.  
The blot was then developed according to the manufacture’s protocol (Biorad, Hercules, 
CA).     
 
Statistics  
 Statistical analysis of the data presented here was conducted using either the 
JMP (SAS Institute, Incorporated, Pacific Grove, CA) or Microsoft Excel (Microsoft, 
Seattle, WA ) statistical software packages.  Graphs were made using Sigma Plot 
software (SPSS, SAS Institute, Incorporated, Pacific Grove, CA) or Microsoft Excel 
(Microsoft, Seattle, WA).  All error bars on graphs indicate one standard deviation of 
the mean from triplicate samples.  Significant differences were determined using either 
t-test or 1 way ANOVA analysis at a level of α=0.05.  
 
 
Results 
LuxAB Fusion Protein 
Creation of the LuxAB Fusion 
 
A LuxAB fusion protein from P. luminescens was generated by the elimination 
of the stop codon at the 3′ end of the luxA gene and the addition of one base within the 
intergenic region to place the two genes into the same reading frame.  Although the 
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fusion protein was functional, light levels were significantly lower (p = 0.05) when 
expressed constitutively in E. coli.  As shown in Figure 10, the LuxAB fusion protein 
had bioluminescence activity levels only approximately 30% of the wild type unfused 
LuxA and LuxB.  The addition of a Kozak sequence further reduced the 
bioluminescence level to approximately 5% of the wild type protein (Figure 11).   
 
Thermostability of the LuxAB Fusion 
To determine if temperature had an effect on the folding and activity of the 
fusion protein, the fused and wild type versions of the luxAB constitutively expressed in 
E. coli were grown as 100ml liquid cultures overnight at 23˚C, 30˚C and 37˚C.  
Bioluminescence measurements were taken in triplicate and reported as specific 
bioluminescence (RLU/O.D. 600).  Results are shown in Table 6A.  In E. coli, there was 
no statistical difference (p = 0.05) between bioluminescence activities of cells grown at 
varied temperatures.  To further evaluate this in a eukaryote, the luxAB fusion construct 
was cloned into a yeast expression vector (pYES-TOPO) and transformed into S. 
cerevisiae.  Surprisingly, contradictory to the data from E. coli, light levels significantly 
decreased when the cells were grown at 37˚C (Table 6B). 
 
In Vitro Expression    
To mimic mammalian cell translation machinery, the luxA, luxB and luxAB 
fusion genes were transcribed and translated in vitro.  Although equal molar amounts of 
RNA transcript were added to each translation reaction and equal volumes of the 
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Figure 11.  Bioluminescence values from E. coli cells harboring either 
wild type luxA and luxB, the luxAB fusion protein, or the 
luxAB fusion protein with the Kozac sequence modifications 
grown at 37°C.  Bioluminescence values were taken in 
triplicate with the addition of 20 µl of a 1% n-decanal 
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Table 6.  Effect of temperature on the LuxAB fusion protein’s activity.  A.  Light 
emission from E. coli clones harboring the luxAB fusion genes when grown at 
23°C, 30°C and 37°C. B.  Specific bioluminescence of  pYES2.1-TOPO with 
luxAB fusion in S. cerevisiae grown on galactose inducing media at 30˚C and  
37˚C.   
 
 
Temperature 23°C 30°C 37°C 
Specific 
bioluminescence ± SD 
1.56*107 
±0.12*107 
1.47*107 
± 0.12*107 
1.52*107 
±0 .11*107 
 
 
 B 
 
 
 
Temperature °C 
 
(+) Aldehyde - Specific 
bioluminescence  
(light/O.D.) ± SD 
 
30°C 
 
64,534 (±1,545) 
 
37°C 
 
16,223 (±1,018) 
 
A 
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 translation reaction were loaded onto the gel, the individual LuxA and LuxB proteins 
were not detected while the LuxAB fusion protein was easily detectable (approximately 
78 kDa) (Figure 12).   
 
Expression in Mammalian Cell Lines 
 Three mammalian cell lines were chosen to evaluate the expression of the 
LuxAB fusion protein.  These cell lines included; HeLa, COS-7 and HEK293. To 
determine if the plasmid was present within each cell type after antibiotic selection of 
clones, PCR was performed on the genomic DNA from each clone with a luxA specific 
primer set.  All cell line clones that resulted in a positive PCR product were further 
investigated for luxA message (mRNA), protein and bioluminescence activity.  All 
clones tested had luxA mRNA levels higher than background vector controls, but the 
levels varied greatly between cell lines and individual clones (data not shown).  The 
bioluminescence values obtained from cell extracts also varied between cell types and 
clones. The exogenous addition of an oxidoreductase enzyme to produce FMNH2 
increased the bioluminescence levels more than ten fold.  These data suggest that 
FMNH2 is a limiting substrate for the bioluminescence in mammalian cells.  Figure 13 
shows the average bioluminescence (RLU/mg total protein) from the brightest three 
clones from each cell type harboring pcDNABf within its chromosome.  HEK293 cells 
consistently produced the highest bioluminescence levels, however these differences 
were not statistically significant (p = 0.05).  Polyclonal antibodies to peptide epitopes 
within the LuxA and LuxB proteins were obtained (Genemed Synthesis, San Francisco, 
CA).  Unfortunately, even though the bioluminescence levels were quantifiable the lux
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Figure 12.  LuxA, LuxB and LuxAB fusion proteins translated in vitro in rabbit 
reticulocyte lysate with the incorporation of  35S methionine.  The 
molecular weight marker is labeled with [14C] methylated protein.  
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Figure 13.  Relative bioluminescence (RLU/mg total protein) from 
stably integrated pcluxABf harboring the luxAB fusion 
gene.  Bioluminescence was measured from cell extracts 
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protein levels were not adequate for detection by immunoblot analysis.   
 
LuxAB Fusion with Kozac Modifications 
Although the Kozac sequence modifications on the 5′ end of the luxA gene was 
shown to drastically diminish bioluminescence levels in E. coli (Figure 11), the Kozac 
sequence is a mammalian ribosomal binding site and therefore to evaluate its true 
effectiveness the construct was tested in HEK293 cells.  Stable cell lines harboring 
pcDNABfKoz were obtained and tested for bioluminescence activity.  The light levels 
were significantly reduced (>90%) compared to HEK293 cells expressing the fusion 
protein without the Kozac modifications (Figure 14).   
 
Alternative Expression Formats 
Although detectable bioluminescence levels were obtained from mammalian cell 
lines harboring the LuxAB fusion protein, these levels were not sufficient for the 
creation of a reliable biosensor.  Therefore, other expression formats were evaluated.   
The bioluminescence activity from the LuxAB fusion protein in HEK293 cells was 
compared to the expression of the individual luxA and luxB genes on either a single 
plasmid in a dual promoter format or by co-transfecting cells with separate plasmids 
carrying the genes.  Stable cell lines expressing the lux genes in a dual promoter or co-
transfected format were obtained.   Furthermore, each vector format (fusion, dual 
promoter and co-transfection) was evaluated when the constructs were maintained as 
episomal plasmids or were integrated into the host’s chromosome.  The average 
bioluminescence levels (RLU/mg total protein) of the three brightest clones for each 
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Figure 14.  Relative bioluminescence (RLU/mg total protein) from stably 
integrated pcluxABf harboring the luxAB fusion gene or 
pcluxABfKoz harboring the luxAB fusion with the Kozac 
modification.  Bioluminescence was measured from cell 
extracts upon the addition of 0.002% n-decanal and FMNH2. 
Bioluminescence reported as an average of the top three clones 
from each cell line. 
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construct tested are shown in Figure 15.  When the constructs were expressed as 
episomes within the nucleus of the cells, the bioluminescence was on average higher for 
the LuxAB fusion protein and for co-transfected plasmids.  However, these differences 
were not statistically significant (p<0.05).  The episomally expressed dual promoter 
plasmid carrying luxA and luxB genes (pCEPARB, Figure 6B) resulted in a significantly  
lower bioluminescence level than its integrated counterpart (pcDNARB, Figure 6A).  
This reduced amount of bioluminescence from cells episomally expressing 
pCEPluxARluxB was surprising.  Further experiments were conducted in an attempt to 
identify the expression problems with this construct. 
 Since the Lux proteins were not detectable by immunoblot, mRNA levels were 
evaluated.  RNA slot blot analysis revealed that clone DE4 had significantly higher 
amounts of luxA message compared to the luxB message.  The other two clones tested 
harboring the construct (DE8 and DE9) had the exact opposite trend for message 
quantities (Figure 16).  The backbone vector for this construct had only minimal 
hybridization with either the luxA or luxB probes. 
 
Stability of Constructs in Mammalian Cells 
To evaluate the stability of each construct in the absence of antibiotic selection, each 
HEK293 cell line clone was grown in complete growth media without antibiotic for 
twenty passages.  The bioluminescence levels were obtained every fifth passage for 
comparison.  In general, all clones were stable for at least five passages after the 
antibiotic removal.  However, the constructs that were maintained as episomes began to 
decline in bioluminescence activity by passage ten.  The co-transfected cell line 
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Figure 15.  Relative bioluminescence (RLU/mg total protein) from either chromosomally integrated  or 
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separate promoters (red) or co-transfected on separate plasmids (green).  
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Figure 16.   RNA slot blot analysis of HEK293 clones harboring the 
pCEPluxARluxB construct as an episome. A.  Probed with a 
300 bp region of the luxA gene from P. luminescens.  B.  Probed 
with a 300 bp region of the luxB from P. luminescens.  A 
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harboring two plasmids both maintained episomally had the fastest bioluminescence 
decline rate.  The bioluminescence levels from this cell line declined approximately 
10% per generation.  The constructs that were integrated into the host’s chromosome 
remained relatively stable throughout the twenty passage (approximately 2.5 months) 
evaluation (Figure 17). 
 
 
Bicistronic Expression 
 To evaluate the expression of the luxA and luxB genes as a single bicistronic 
transcript, an IRES element from EMCV virus was used to transcriptionally fuse the 
two genes together (Figure 9).  From each of the nine stable cell line clones obtained 
harboring this construct, the bioluminescence (RLU/mg total protein) was at least an 
order of magnitude greater than the average levels obtained from the brightest clones 
with any of the other expression formats tested (Figure 18).  On average, there was no 
significant difference between bioluminescence levels obtained from HEK293 cells 
expressing the luxAB fusion, the luxA and luxB in a dual promoter format or as co-
transfected separate plasmids.  However, the bioluminescence levels from HEK293 
cells harboring the luxA and luxB as a single bicistronic transcript consistently produced 
significantly higher light levels (Figure 19). 
 Because the Lux proteins were not detectable from stable cell lines, mRNA from 
the three brightest clones from each construct was isolated and probed with a [32P] 
labeled probe complementary to the luxA sequence.  luxA  mRNA was detectable from 
every cell line tested above background vector control levels (Figure 20).  However, the 
amount of transcript (determined as intensity values from autoradiougraphy) varied 
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line transfected with the pIRES vector only. 
HEK293 Cell Line Clone 
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Figure 19.  Relative bioluminescence levels (RLU/mg total protein) from stable HEK293 cell line clones 
expressing luxAB fusion (black), luxA and luxB from a dual promoter vector (red), co-
transfection of the luxA and luxB on separate plasmids (green) or as a bicistronic transcript  
via an IRES element (yellow).   
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Figure 20.   RNA slot blot analysis of HEK293 clones expressing the luxA and luxB genes either as a fusion 
protein, on separate plasmids (co-transfected), within the same plasmid but with separate promoters 
(dual promoter) or a transcriptional fusion linked with an IRES element.  Negative vector controls 
(NC) were added to determine background hybridization levels. Plasmid (pcDNABf) DNA was 
added as a positive control (PC). 
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greatly between cell lines and clones and did not correlate with the bioluminescence 
levels obtained (R2=0.15) (Figure 21). 
 
Discussion 
Previous work by Escher et al. (1989) showed that the luxAB fusion, using genes 
from Vibrio harveyi, was stable at elevated temperatures if initially expressed in E. coli 
at 23°C.  However, when the fused protein was grown and expressed at 37°C there was 
a greater than 99% reduction in light.  These data suggest that the fused luxAB does not 
fold properly at elevated temperatures.  The luciferase from P. luminescens has a higher 
thermal stability (t1/2 >3 h at 45°C) than V. harveyi (t1/2 5 min. at 45°C)  (Meighen, 
1991).  Therefore, a translational fusion generated from the P. luminescens luxA and 
luxB genes was generated and evaluated.  Although the luxAB fusion was functional in 
E. coli, bioluminescence activity was significantly reduced (70%) compared to the wild 
type unfused genes (Figure 11).   In the unfused luxAB the α and β subunits are 
individually translated and are free to fold into their specific conformation (Tu and 
Mager, 1995).  Therefore, the reduction in bioluminescence may be due to steric 
hindrance involved in the way the subunits form the heterodimer when expressed as a 
protein monomer.  The addition of a Kozak sequence further reduced the 
bioluminescence level to approximately 5% of the wild type protein.  Nevertheless, the 
Kozac sequence is a mammalian ribosomal binding site and therefore to evaluate its 
true effectiveness the construct was tested in HEK293 cells.  The light levels were 
significantly reduced (>90%) compared to HEK293 cells expressing the fusion protein 
without the Kozac modifications (Figure 13). The addition of a Kozak sequence (G at 
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Figure 21.  Relative bioluminescence (RLU/mg total protein) versus average  
intensity values from RNA slot blot analysis of each clone. 
R2=0.15 
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 the +4 position) specifically changes the second amino acid of luxA from Lysine to 
Glutamic acid.  These two amino acids have opposite net charges, which could result in 
a modification of the protein's secondary structure ultimately altering the protein's 
function resulting in decreased bioluminescence.   
To determine temperature effect on the folding of the fusion protein, the fused 
and unfused versions of the luxAB were grown at 23˚C, 30˚C and 37˚C.  In E. coli, there 
was not a statistical difference (p < 0.05) associated with temperature on 
bioluminescence as seen by Escher et al. This suggested that the folding problems in the 
V. harveyi LuxAB fusion protein were not present in the P. luminescens LuxAB fusion 
protein.  However, when the fusion construct was expressed in the yeast, S. cerevisiae 
the bioluminescence levels significantly decreased as temperature increased to 37˚C 
(Table 6B).  The differences seen in these two systems may be a result of the bacterial 
system’s ability to transcribe the luxB independently due to the ribosomal binding site 
and luxB start codon still present in the fusion.  When the fusion is expressed in the 
yeast system, the luxB is no longer independently expressed resulting in a true fusion 
protein that is unable to properly fold at 37˚C.  The independent expression of the luxB 
in bacteria may have resulted in the unfused LuxB subunit forming the heterodimeric 
conformation with the LuxA within the LuxAB fusion resulting in the unaffected 
bioluminescence observed when the construct was expressed in E. coli. 
  In an attempt to mimic mammalian translation machinery, in vitro transcription 
and translation of the luxA, luxB and luxAB fusion were performed in a rabbit 
reticulocyte lysate system.  Although the 77kDa fusion protein was easily detected, the 
individual proteins, LuxA and LuxB, were not.  This result was unexpected because 
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equal amounts of RNA transcript were added to each translation reaction.  These data 
suggest that the formation of the heterodimeric (α and β subunit) complex may be 
required for not only efficient bioluminescence activity, but also for the overall stability 
of the protein.   
 Although detectable amounts of bioluminescence were obtained from 
mammalian cell lines harboring the LuxAB fusion protein, these levels were not 
sufficient for the creation of a reliable biosensor.  Therefore, other expression formats 
were evaluated in an attempt to optimize bioluminescence activity.  It was thought that 
by expressing the lux genes separately, the subunits would be able to form a more 
natural heterodimeric conformation.  Human embryonic kidney cells (HEK293) were 
used for these evaluations.  Cells were transfected with a dual promoter vector construct 
that that was developed to constitutively express each gene from a separate promoter or 
co-transfected with two plasmids each harboring either the luxA or luxB gene.  
Furthermore, to evaluate the differences in protein expression from genes integrated in 
the host’s chromosome versus those constructs maintained as episomal plasmids, each 
expression format (fusion, dual promoter and co-transfection) was constructed on a 
plasmid backbone able to replicate episomally in HEK cells.  The bioluminescence 
levels from stable cell lines harboring each expression variation were determined.  
Although there were slight variations in  activity the differences were not statistically 
significant (p=0.05).  The only exception was the reduced bioluminescence activity 
obtained from cells harboring a dual promoter vector episomally (Figure 15).  The low 
light levels from these clones were somewhat surprising considering that the average 
bioluminescence from the fusion protein and from cells co-transfected with two 
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plasmids were slightly higher when the constructs were maintained as episomes.  Upon 
further analysis, it was determined that the mRNA levels from the individual lux genes 
were not equal and therefore in this expression format, one promoter is inducing 
transcription at a higher rate than the other.  This type of promoter occlusion where the 
transcription of one of the two promoters was significantly dampened has been seen 
previously (Horlick et al., 2000).  The unequal availability of one of the lux subunits at 
a level over the other may prevent the proper formation of the heterodimeric active 
luciferase protein and may result in inactive homodimer formation.  
 In order for a bacterial lux-based mammalian bioreporter to be useful, the 
constructs need to remain stable in the absence of antibiotic selection for long periods of 
time.  Efficient maintenance and stability of foreign genes requires that the DNA 
replicate once per cell cycle and be retained (integrated or episomally) in the nucleus.  
Expression plasmids harboring the luxA and luxB genes in three individual expression 
formats were created on both the traditional integration vectors and on Epstein-Barr 
virus (ori-P) based episomal plasmid vectors.  To determine the stability of these 
constructs in HEK293 cells, the cell line clones were grown for twenty passages in 
complete growth media without antibiotic.    In general, all clones (chromosomal and 
episomal) were stable for at least five passages after the antibiotic removal.  However, 
the constructs that were maintained as episomes began to lose bioluminescence activity 
by passage ten with episomal co-transfected cells resulting in the fastest 
bioluminescence decline rate (Figure 17). Although there was a significant decline in 
bioluminescence activity from episomally based constructs over time, the light was not 
completely lost from any of the cells lines.  Therefore, this reduction in 
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bioluminescence may be the result of natural plasmid loss and generation of a plasmid 
equilibrium within the cells.  Immediately following transfection the DNA molecules 
within each cell can be very high and a natural decline in this concentration occurs to a 
steady state for plasmid maintenance (Middleton and Sugen, 1994 and Horlick et 
al.,1997).  This number can vary, but the average is between 50 and 100 copies per cell 
with the further loss of approximately 5% per generation in the absence of selection 
(Yates and Guan, 1991).  The constructs that were integrated into the host’s 
chromosome remained relatively stable throughout the twenty passage (approximately 
2.5 months) evaluation.  These data indicate that integration of the lux genes within the 
host’s chromosome may be the most suitable way to express the genes in mammalian 
cells for long-term gene maintenance and stable bioluminescence activity.  
 In order to optimize the bioluminescence potential from mammalian cells the lux 
genes need to be processed and expressed much in the way they are in bacteria.  To 
establish a more natural expression format for the heterodimeric luciferase protein, the 
luxA and luxB genes were cloned into a bicistronic mammalian expression vector.  This 
vector was developed to allow for the expression of two genes of interest under the 
control of a single constitutive promoter with the use of an internal ribosomal entry site 
(IRES).  IRES elements can be defined as specific nucleotide sequences that allow for 
ribosomal entry and translation initiation directly at the start codon (AUG) rather than 
requiring scanning from the 5′ end, cap structure, of the mRNA (Pestova et al., 2001 
and Kozac, 2001).  Since the lux genes are naturally found in a polycistronic operon, it 
was thought that by expressing the genes in this format a more natural production and 
formation of the heterodimer could be obtained.    From each of the stable cell line 
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clones obtained harboring lux genes expressed as a bicistronic transcript, the 
bioluminescence (RLU/mg total protein) was at least an order of magnitude greater than 
levels obtained with any of the other expression formats tested (Figure 18).  On average, 
there was no significant difference between bioluminescence levels obtained from 
HEK293 cells expressing the luxAB fusion, the luxA and luxB in a dual promoter format 
or as co-transfected separate plasmids.  However, the bioluminescence levels from 
HEK293 cells harboring the luxA and luxB as a single bicistronic transcript 
constitutively produced significantly higher light levels (Figure 19). 
 Based on these data it was determined that of the four expression formats 
evaluated that the bicistronic expression of the luxA and luxB genes was by far the best 
choice.  Furthermore, although in general, the bioluminescence levels were slightly less, 
the stability of the construct when integrated into the host’s chromosome makes this a 
more suitable choice for the development of bacterial lux-based mammalian biosensors. 
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CHAPTER 3 
 
CODON OPTIMIZATION OF THE BACTERIAL LUCIFERASE FOR EXPRESSION 
IN MAMMALIAN CELLS 
 
Introduction 
 The standard term “universal genetic code” comes from the fact that there are 
sixty-four possible codons for only twenty amino acids.  Although the genetic code is 
degenerate, the alternate synonymous codons are not used with equal frequency (Sharp 
et al., 1988).  In fact, it has been shown that there is not only a selective difference, but 
also a preference for certain codons in highly expressed genes (Sharp et al., 1993).  This 
obvious codon bias has been shown to play a key role in the gene expression efficiency 
in all species tested to date (Amicis and Marchetti, 2000).  Furthermore, codon usage 
patterns are not conserved between organisms of different species.  This is especially 
true between genes from prokaryotes and eukaryotes.   
An obvious first step in developing a mammalian cell line that utilizes the 
potential benefits of the bacterial luciferase enzyme system is to optimize the expression 
of the heterodimeric luciferase protein.  The bioluminescence levels obtained through 
the expression of the wild type genes in various expression formats, although promising 
are not adequate for the development of reliable mammalian biosensors.  Based on these 
data, the lux genes need further optimization in order to realize their full potential as 
mammalian reporter proteins.   
Codon optimization is the term given to the synthetic creation of a gene 
sequence to possess the optimal codon usage patterns for the host organism.  Several 
examples of successful codon optimization have been recently published.  These 
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optimized proteins have been primarily designed for increased expression in 
mammalian hosts, as mammalian expression of foreign genes is often times limited 
(Narum et al., 2001). Several reporter proteins have been codon optimized in an attempt 
to increase expression in mammalian cells including the optimization of green 
fluorescent protein (GFP) (Zhang et al., 2002) and Renilla luciferase (Gruber and 
Wood, 2000) reporter genes.  In both of these instances, codon optimization resulted in 
these reporter proteins becoming stronger reporters for gene expression and reliable 
monitoring tools in mammalian cells. 
Based on this knowledge and the fact that further optimization is needed for the 
efficient expression of the bacterial luciferase in mammalian cells, it is hypothesized 
that by codon optimizing the luxA and luxB genes from P. luminescens that the 
bioluminescence activity from mammalian cell lines harboring these genes would be 
enhanced.  The specific objectives of the this research are: 
 
• To evaluate the luxA and luxB gene sequences from P. luminescens for 
codon usage pattern differences compared with optimal mammalian 
codon usage. 
• To design a codon optimized sequence for the luxA and luxB genes to 
potentially allow for enhanced expression in mammalian cells. 
• Compare the codon optimized sequences to the wild type genes using 
prediction analysis programs for mammalian expression. 
• Synthesize complete codon optimized genes from oligonucleotides. 
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• To determine if codon optimization significantly improves the 
expression of bacterial luciferase in mammalian cells. 
• To evaluate on what level of expression (transcription or translation) an 
increase in activity is derived. 
 
Materials and Methods 
 
Cell Culture and Plasmid Maintenance  
All relevant constructs and strains, bacterial and mammalian, used in this study 
are outlined in Table 7.  E. coli cells were routinely grown in Luria Bertani (LB) (Fisher 
Scientific, Pittsburgh, PA) broth containing the appropriate antibiotic selection with 
continuous shaking (200rpm) at 37°C.  Kanamycin and Ampicillin were used at a final 
concentration of 50µg/ml and 100 µg/ml, respectively. 
 All cell culture reagents and media were obtained from Sigma Aldrich, (St. 
Louis, MO) unless otherwise stated.  Mammalian cells were grown in the appropriate 
complete growth media containing 10% heat-inactivated horse serum, 0.01mM non-
essential amino acids and 0.1mM sodium pyruvate in a Dubelco’s minimal essential 
media base (DMEM) (M4655).  Cells were routinely grown at 37°C in a 5% CO2 
atmosphere to confluency and split every three to four days by trypsinization at a 1:4 
ratio and transfer into fresh complete growth media.  Appropriate concentrations of 
antibiotic were used to maintain constructs after transfection according to susceptibility 
kill curve analysis. Kill curves were completed for each lot of antibiotic.  The range of 
typical concentrations used for the selection of HEK293 cell line clones was between 
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Table 7.  Strains and plasmids used in the determination of the optimal expression 
format for bacterial luciferase in mammalian cells.  
 
Plasmid/Strain 
Designation 
 
Relevant Genotype/ Characteristics 
 
Source 
Strains   
E. coli   
 
DH5α 
Φ80dlacZ∆M15, recA1, endA1, gyrA96, thi-1, 
hsdR17 (rK-, mK+), supE44, relA1, deoR, 
∆(lacZYA-argF)U169 
 
Gibco, BRL 
 
 
TOP 10 
 
F-, mcrA ∆(mrr-hsdRMS-mcrBC) Φ80/lacZ 
∆lacX74 deoR recA1 araD139 ∆(ara-leu) 7697 
ga/K rpsL endA1 nupG 
 
 
Invitrogen 
 
Mammalian Cells  
  
 
HEK293 
Permanent line of primary human embryonal 
kidney transformed by sheared human adenovirus 
type 5 (Ad 5) DNA. ATCC# CRL-1573 
 
ATCC 
   
 
Plasmids 
  
 
 
pCR2.1-TOPO 
 
TOPO TA cloning vector for easy cloning of PCR 
products generated with 3′ A overhangs Kmr, 
Ampr 
 
 
Invitrogen 
 
 
pCR4-TOPO 
 
TOPO TA cloning vector for easy cloning of PCR 
products generated with 3′ A overhangs designed 
for sequencing Kmr, Ampr 
 
 
Invitrogen 
 
 
 
pIRES 
 
Mammalian expression vector containing the 
internal ribosomal entry site (IRES) of the 
encephalomyocarditis virus between two multi-
cloning sites which allows for the expression of 
two genes under the control of a single constitutive 
CMV promoter, Neomycin G418 antibiotic 
selection marker and a pUC ori and Kmr for 
replication in E.coli 
 
 
 
Clontech 
   
 
pCR4luxB 
 
pCR4 TA cloning vector harboring the luxB from 
Photorhabdus luminescens 
 
This Study 
 
pNotIluxA 
 
pCR4 harboring the luxA from P. luminescens with 
introduced NotI sites on both the 5′ and 3′ ends of 
the gene 
 
This Study 
 
pWTAI3 
 
pIRES harboring the luxA from P. luminescens 
cloned into the MCS(A) 
 
This Study 
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Plasmid/Strain 
Designation 
 
 
Relevant Genotype/ Characteristics 
 
 
Source 
pCOA#1 pCR4 vector harboring the codon optimized luxA 
gene with errors at base 365 and 1003. 
This Study 
pCOA#11 pCR4 vector harboring the codon optimized luxA 
gene with errors at bases 11, 28 and 365 
This Study 
pCOB#6 pCR4 vector harboring the codon optimized luxB 
gene with errors at base 321 and 829. 
This Study 
pCOB#7 pCR4 vector harboring the codon optimized luxB 
gene with errors at base 287 and 569. 
This Study 
 
pWTA-I-WTB 
 
pIRES harboring the luxA (WTA) cloned into the 
MCS(A) and luxB (WTB) cloned into MCS(B) 
from P. luminescens 
 
This Study 
 
pCOA-I-WTB  
 
pIRES harboring the codon optimized luxA (COA) 
into the MCS (A) and wild type luxB (WTB) into 
the MCS (B) from P. luminescens 
 
This Study 
 
pCOA-I-COB 
 
pIRES harboring the codon optimized luxA (COA) 
into the MCS (A) and codon optimized luxB 
(COB) into the MCS (B) from P. luminescencs 
 
This Study 
 
WTA-I-WTB(1-20)  
 
HEK293 cell lines stably transfected with the 
pWTA-I-WTB plasmid and selected by G418. 
 
This Study 
 
COA-I-WTB(1-20)  
 
HEK293 cell lines stably transfected with the 
pCOA-I-WTB plasmid and selected by G418. 
 
This Study 
 
COA-I-COB(1-20)  
 
HEK293 cell lines stably transfected with the 
pCOA-I-COB plasmid and selected by G418. 
 
This Study 
 
   
Table 7. Continued 
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 450µg and 650µg/ml.   
 
Determining Codon Optimized Sequence of Photorhabdus luminescens luxA and 
luxB Genes 
 To determine a codon optimized sequence for P. luminescens luxA and luxB 
genes, the codon ratios within the wild type genes were analyzed and compared to 
optimal codon usage patterns from highly expressed (top 10%) mammalian genes.  The 
optimal codon ratios were determined by information tabulated in Genbank.  The 
overall ratio for usage of each codon within the wild type genes was altered to more 
closely match mammalian codon usage (Table 8A and 8B).  In general, low frequency 
codons were used rarely or not at all and higher frequency codons were used more 
often.  The codons were replaced within the wild type sequences in a random fashion.  
The sequence was further analyzed for any potential splice sites or other regulatory 
regions using the NetGene2 algorithm for prediction of potential acceptor and donor 
splice sites (www.cbs.dtu.dk/cgi-bin/nph-webface?jobid=netgene2).  Any potential 
splice sites were removed.  Transcription factor binding sites were also identified, 
however, these sequences were too numerous to successfully eliminate.  After the final 
codon optimized sequence was determined, it was compared to the wild type sequence 
using the Genescan prediction algorithm (http://genes.mit.edu) to evaluate the potential 
expression of the new sequence versus the wild type. 
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Table 8.  Codon usage of wild type versus codon optimized genes.  (A) luxA (B) luxB 
     WTA= wild type luxA, WTB= wild type luxB, COA= codon optimized luxA  
     COB= codon optimized luxB. 
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Amino Acid 
 
 
Codon 
 
 
WTA 
 
 
COA 
 
 
Amino Acid 
 
 
Codon 
 
 
WTA 
 
 
COA 
 
Phe 
 
TTT 
 
14 
 
6 
 
Tyr 
 
TAT 
 
12 
 
5 
 TTC 5 13  TAC 5 12 
Leu TTA 9 - Ter TAA 0 - 
 TTG 5 2  TAG 1 1 
 CTT 9 4 His CAT 10 3 
 CTC 1 10  CAC 1 8 
 CTA 2 - Gln CAA 11 6 
 CTG 3 13  CAG 3 8 
Ile ATT 14 4 Asn AAT 14 5 
 ATC 4 20  AAC 6 15 
 ATA 6 - Lys AAA 17 4 
Met ATG 9 9  AAG 6 19 
Val GTT 3 3 Asp GAT 15 6 
 GTC 2 6  GAC 8 17 
 GTA 10 - Glu GAA 13 2 
 GTG 6 12  GAG 9 20 
Ser TCT 5 - Cys TGT 4 3 
 TCC 1 11  TGC 4 5 
 TCA 6 1 ter TGA 0 - 
 TCG 2 - Trp TGG 6 6 
Pro CCT 2 5 Arg CGT 4 - 
 CCC 4 4  CGC 5 9 
 CCA 2 2  CGA 2 - 
 CCG 3 -  CGG 2 3 
Thr ACT 6 5 Ser AGT 3 1 
 ACC 1 14  AGC 1 5 
 ACA 9 1 Arg AGA 2 3 
 ACG 4 -  AGG 0 - 
Ala GCT 13 15 Gly GGT 7 4 
 GCC 3 9  GGC 5 11 
 GCA 3 -  GGA 9 5 
 GCG 5 -  GGG 5 6 
A 
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Table 8. Continued
 92
 
 
 
 
 
 
 
Amino Acid 
 
 
Codon 
 
 
WTB 
 
 
COB 
 
 
Amino Acid 
 
 
Codon 
 
 
WTB 
 
 
COB 
 
Phe 
 
TTT 
 
13 
 
5 
 
Tyr 
 
TAT 
 
16 
 
4 
 TTC 5 13  TAC 1 13 
Leu TTA 9 - Ter TAA 1 1 
 TTG 6 -  TAG 0 - 
 CTT 3 3 His CAT 8 2 
 CTC 2 2  CAC 3 9 
 CTA 2 - Gln CAA 6 3 
 CTG 3 18  CAG 5 8 
Ile ATT 13 5 Asn AAT 18 4 
 ATC 5 21  AAC 6 20 
 ATA 8 - Lys AAA 16 4 
Met ATG 8 8  AAG 6 20 
Val GTT 13 3 Asp GAT 17 3 
 GTC 3 7  GAC 3 17 
 GTA 4 - Glu GAA 23 6 
 GTG 1 11  GAG 8 25 
Ser TCT 3 - Cys TGT 4 1 
 TCC 1 8  TGC 2 5 
 TCA 4 - ter TGA 0 - 
 TCG 0 - Trp TGG 2 2 
Pro CCT 6 7 Arg CGT 1 - 
 CCC 1 2  CGC 2 3 
 CCA 3 2  CGA 0 - 
 CCG 1 -  CGG 1 1 
Thr ACT 4 4 Ser AGT 7 2 
 ACC 2 12  AGC 2 7 
 ACA 6 - Arg AGA 3 3 
 ACG 4 -  AGG 0 - 
Ala GCT 8 14 Gly GGT 6 1 
 GCC 3 6  GGC 3 9 
 GCA 4 -  GGA 3 2 
 GCG 5 -  GGG 2 2 
B 
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Synthesizing the Codon Optimized luxA and luxB Genes  
 Once the codon optimized sequence had been determined, oligonucleotides for 
each gene were designed that covered the complete sequence (Table 9& 10).  Each 
oligo was designed with an 18 – 23 base pair overlap on the 5′ and 3′ ends with its 
adjacent oligos.  These overlapping regions were designed with Tm values of 53°C - 
56°C.  Once the oligos were designed they were synthesized by Sigma Genosys (Sigma, 
St. Louis, MO) and polyacrylamide gel (PAGE) purified to ensure full-length products.  
Each oligonucleotide was placed into a PCR reaction with the following conditions; 
internal oligos (0.25 pmol), the two outermost oligos (25 pmols), dNTP mixture (200 
nm), 1X Pfu buffer, 1X Pfu Enhancer solution, MgCl2 (concentration determined 
experimentally) and 1U of Pfu DNA polymerase (Stratagene, La Jolla, CA).   
 All PCR reactions were performed in 0.2 ml thin walled PCR tubes using a 
PTC-225 DNA Engine (MJ Research, Waltham, MA).  For gene synthesis the following 
program was used; (1) initial denaturation 95°C for 5 min, (2) 30 cycles of 94°C for 1 
min, 50°C for 1 min and 68°C for 2 min followed by (3) final extension 68°C for 10 
min.  Resultant PCR products were run on 1% agarose gels in 1X TBE.  Unfortunately, 
there were no detectable products of the correct size.  As an alternative strategy, four 
separate reactions were set up with four adjacent oligos in each reaction (Figure 22).  
The two innermost primers were added at a final concentration of 0.25 pmols and the 
two outermost oligos were used as both template and primers at a concentration of 25 
pmols.  Each piece was then amplified using the parameters outlined above with the 
exception of the extension step was reduced from 2 min to 45 sec.  The resultant PCR 
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Figure 22.  Schematic diagram of the recursive PCR method used to construct the 
synthetic luxA and luxB genes.  Outside oligonucleotides were added at 25 
pmol final concentration while the inside oligonucleotides were added at 0.25 
pmol final concentration. 
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Table 9.  Oligonucleotide primer sequences used to synthesize the codon optimized 
luxA gene. 
 
 
Primer Name 
 
Sequence 5′ to 3′ 
COA1  
(Sense) 
5′CGAAACCATGAAGTTCGGCAACTTCCTGCTCACATATCAGCC 
TCCCCAGTTTTCCCAAACCGAGGTCATGAAGCGGCTGGTTA 
AGCTCGGCCGCATCTC C 3′ 
COA2 
(Antisense) 
 
5′ AAGCAGCAGCGACATAAGGGTTACCAAGCAGGCCGAA         
CTCGGTGAAGTGGTGCTCCAGCAGCCACACGGTGTCGAAAC 
CGCACTCCTCGGAGATGCGGCCGAGCTTA 3′ 
 
COA3  
(Sense) 
 
5′ CCCTTATGTCGCTGCTGCTTATCTGCTCGGCGCCAC                  
CAAGAAACTGAACGTCGGCACTGCCGCTATCGTTCTC                          
CCCACCGCCCATCCAGTCCGCCAGCTT 3′ 
 
COA4 
(Antisense) 
 
5′ GAAGTCCTTGTTGTAAAGCCCGCGGCAGATGCCGAA       
CCGAAAGCGCCCCT TGGACATTTGATCCAGCAAGTTC                    
ACGTCCTCAAGCTGGCGGACTGGATGG 3′ 
 
COA5  
(Sense) 
 
5′ CGGGCTTTACAACAAGGACTTCCGCGTGTTCGGCA                   
CCGACATGAACAACAGCCGCGCCCTGGCCGAGTGTT          
GGTACGGGCTGATCAAGAATGGCATGA 3′ 
 
COA6 
(Antisense) 
 
5′ GAGCGCCACCTCTGCTGTAAGCGGCGGGGTTCACTT                         
TGACTTTGTGGAACTTGATGTGCTCATTGTCGGCTTCC           
ATGTATCCCTCGGTCATGCCATTCTTGATCAGCC 3′ 
 
COA7  
(Sense) 
 
5′ ACAGCAGAGGTGGCGCTCCTGTTTATGTGGTGGCTG               
AGTCAGCTAGTACCACTGAGTGGGCTGCTCAATTTGG                    
CCTCCCTATGATCCTGTCCTGGATCATCAACAC 3′ 
 
COA8 
(Antisense) 
 
5′ CAGGCAGTGGTCGATGTTATGAATGTCGTGCCCG           
TACTCTTGAGCCACTTCGTTGTAAAGCTCGAGCTGG  
GCCTTCTTCTCATTAGTG TTGATG ATCCAGGACAGG 3′ 
 
COA9  
(Sense) 
 
5′ CATAACATCGACCACTGCCTGTCCTACATCACCTC                     
CGTGGACCACGACTCCATCAAGGCCAAGGAGATTTG    
CCGGAAGTTTCTCGGGCATTGGTATGATAG 3′ 
 
COA10 
(Antisense) 
 
5′ AACACGAAATCGCGCCACTGCCCCTTGTTGAAGTC              
GTAACCTCTGGTCTGGTCGGAGTCGTCAAAGATAGTG 
GTAGCATTCACG  TAGCTAT CATACCAATGCCCGAG 3′ 
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Primer Name 
 
 
COA11 
(Sense) 
 
 
Sequence 
 
 
 
5′ AGTGGCGCGATTTCGTGTTGAAAGGACACAAGG       
ATACTAACAGACGCATCGACTACAGCTACGAGATCAA 
TCCCGTGGGCACCCCTCAG  GAGTGCATTGACATCATCC 3′ 
 
COA12 
(Antisense) 
5′ ATGGAAGCGATGATCTCGTCCACGGTTCCGTTAGCCTCA        
AATCCACAACAGATGTTGGAGATTCCGGTAGCATCAA            
TGTCCTTTTGGATGATG TCAATGCACTCCTG 3′ 
 
COA13 
(Sense) 
 
5′ GACGAGATCATCGCTTCCATGAAGCTCTTCCAGTCCG         
ATGTCA TGCCATTCCTCAAGGAGAAGCAACGCA  
GCCTCCTGTACTAGGGATCC 3′ 
COA14 
(Antisense) 
 
 
5′ GGATCCCTAGTACAGGAGGCTGC 3′ 
 
 
Table 9. Continued 
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Table 10.  Oligonucleotide primer sequences used to synthesize the codon optimized 
luxB gene. 
 
 
Primer Name 
 
Sequence 5′ to 3′ 
 
COB1  
(Sense) 
 
5 ′CGAAACCATGAAGTTCGGACTGTTCTTCCTTAACTTCATCA  
ACTCCACCACTGTGCAGGAGCAAAGCATCGTGCGCATGCAG    
GAGATCACCGAGTATGTGGAC 3′ 
 
COB2 
(Antisense) 
 
5 ′CACAGTCAGAGGAGCGCCGACAACGCCATTGTCGGAAAA    
GTGGTTCTCGTACACCAGGATCTGCTCGAAGTTCAGCTTG 
TCCACATAC TCGGTGATCTCC 3′ 
 
COB3  
(Sense) 
 
5 ′ GGCGCTCCTCTGACTGTGTCCGGCTTCCTGCTCGGCCT         
GACCGAGAAGATCAAAATTGGCTCCCTGAACCACATCAT        
CACCACTCATCATCCTGTCGCCATCGCT 3′ 
 
COB4 
(Antisense) 
 
5 ′ GTGCATCTCGTCCTTCTTCTCGCAATCGCTGAACCCC 
AGGATGAATCTCCCCTCGCTCAGCTGATCCAGCAGGCA 
AGCCTCCTCAGCGATGGCGACAGGATG 3′ 
 
COB5  
(Sense) 
 
5 ′GAGAAGAAGGACGAGATGCACTTTTTCAACCGCCCTGT 
GGAATATCAGCAG CAACTGTTTGAAGAGTGCTACGAGAT        
CATTAACGACGCTCTGACCACCGGCTACTGC 3′ 
 
COB6 
(Antisense) 
 
5 ′AGCGGTGACATACTTCCGAGGGCCGCCTGGGGTGTAA 
GCGTGGGGGTTGACGGAGATTTTAGGGAAGCTGTAG 
AAGTCATTGTCGGGGTTGCAGTAGCCGGTGGTCAG 3′ 
 
COB7 
(Sense) 
5 ′TCGGAAGTATGTCACCGCTACCAGTCATCACATCGTGG 
AGTGGGCTGCCAAG AAAGGCATCCCTCTCATCTTTAAGT         
GGGATGACTCCAACGACGTGAGATACGAGTA 3′ 
 
COB8 
(Antisense) 
 
5′ TAACCAGGATCATCAGCTGGTGGTCGATTTCGGACAG 
GTCAACGTCATATTTGTCAGCCACGGCCTTGTATCTC 
TCAGCGTACTCGTATCTCACGTCGTTGG 3′ 
 
COB9  
(Sense) 
 
5′ CCAGCTGATGATCCTGGTTAACTACAACGAAGACAGC      
AACAAGGCTAAG CAGGAGACCCGCGCCTTCATTAGCGA                 
CTACGTGCTTGAAATGCACCCTAAC 3′ 
 
COB10 
(Antisense) 
 
5′ CCAGCTTAGCAGCAGTGATACACTCGGTGTAGTTTCCG 
ACAGCGTTCTCGGCGATGATTTCCTCAAGCTTGTTCTCGA 
AGTTCTCGTTAGGGTGCATTTCAAGCAC 3′ 
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Primer Name 
 
 
COB11 
(Sense) 
 
 
Sequence 
 
 
5′ TGTATCACTGCTGCTAAGCTGGCCATCGAGAAGTGCGGT      
GCTAAGAGTGTCCTGCTGTCCTTTGAGCCAATGAATGAC          
CTGATGAGCCAAAAGAACGTCAT 3′ 
 
COB12 
(Antisense) 
5′ GGATCCTTAGGTGTACTCCATGTGGTACTTCTTAATATTG 
TCGTCCACAATGTTGATGACGTTCTTTTGGCTCATCAG 3′ 
 
  
  
 
Table 10. Continued 
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 products were then gel purified using the Geneclean gel extraction kit according to the 
manufacturer’s instructions (Bio101, Carlsbad, CA).  The extracted products were  
quantified using a Dyna Quant 200 fluorometer (Hoefer Pharmacia Biotech 
Incorporated, San Francisco, CA) and placed into a second PCR reaction at equal molar 
concentrations (0.25 pmols).  The two outermost (5′ and 3′) oligos were used as primers 
at a final concentration of 25 pmols.  After the second PCR reaction, the products of the 
correct size were again gel purified as previously described.  Because Pfu polymerase 
produces blunt end products, 3′ A overhangs were added to allow for TA TOPO cloning 
of the products.  To accomplish this, the gel-extracted product was mixed with dATP 
(200nM) 1X amplitaq buffer and 1U of Taq polymerase (Amersham Pharmacia, San 
Francisco, CA) and placed at 72°C for 20 – 30 min.  Immediately following the addition 
of the A’s, the product was TA TOPO cloned into the pCR4 TOPO cloning vector 
(Invitrogen Corporation, Carlsbad, CA).  Resultant colonies were then checked for 
insert by an EcoRI restriction digest and sequenced to ensure their integrity.   
 
Site Directed Mutagenesis 
Although the oligos were successfully joined into a double stranded synthetic 
gene, several point mutations were determined by sequencing.  A number of clones for 
each gene were completely sequenced in an attempt to identify a flawless clone without 
success.  To correct these errors, site directed mutagenesis was done.  First, for the 
codon optimized luxA gene, two separate clones pCOA#1 and pCOA#11 were used as 
template.  Site directed mutagenesis primers were designed to introduce the necessary 
changes.  The complete luxA sequence was amplified in two separate sections (365 bp 
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from pCOA#1 and 719bp from pCOA#11) that overlapped between the bases where the 
necessary changes were required.  Each segment was gel purified and then linked back 
together by a second round of PCR as described for the original gene synthesis. 
Subsequently, 3′ A overhangs were added and the product TA TOPO cloned into pCR4.  
Upon sequencing, a construct with the correct sequence was identified and termed 
pPA2.  Site directed mutagenesis was also performed on the codon optimized luxB 
sequence using overlapping primers designed to introduce the proper changes.  The 
complete luxB sequence was amplified in three segments (324 bp from pCOB#7, 340 bp 
from pCOB#6 and 319 bp pCOB#7) from two separate clones (pCOB#7 and pCOB#6) 
and subsequently linked by PCR as previously described.  A construct of the correct 
sequence was produced and termed pPB2.   
 
Construction of a Bicistronic Expression Vector 
To compare the expression of the codon optimized luxA and luxB genes to the 
wild type, the pIRES vector was used (Clontech Corporation, Palo Alto, CA). This 
expression vector contains two multi-cloning sites separated by an internal ribosomal 
entry site (IRES) from encephalomyocarditis virus (EMCV).  The IRES element allows 
for the expression of two genes (one cloned into each multi-cloning site) from a single 
constitutive CMV promoter.  For comparison purposes, a wild type luxA and luxB 
(pWTA-I-WTB) construct, a codon optimized luxA and wild type luxB (pCOA-I-WTB) 
construct and a codon optimized luxA and codon optimized luxB (pCOA-I-COB) 
construct were generated.     
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 pWTA-I-WTB 
  To create this construct, the luxA gene from P. luminescens was amplified from 
pPLluxCDABE plasmid that harbors the complete luxCDABE cassette (Table 7) and 
unique NotI restriction sites were introduced on both the 5′ and 3′ ends of the luxA gene.  
The resultant PCR product was TA TOPO cloned into pCR4 TOPO to generate 
pNotIluxA.  The luxA gene was then cloned into the MCS(A) of pIRES via the unique 
NotI restriction sites to generate pWTAI.  Once this construct was confirmed by 
sequencing, the plasmid was purified using the Wizard midi-prep plasmid purification 
kit according to the manufacturer’s instructions (Promega Corporation, Madison, WI).  
The luxB gene was cleaved via a 5′ XbaI and 3′ SpeI site from pCRluxB and cloned into 
the XbaI site within the MCS(B) of pWTAI to generate pWTA-I-WTB (Figure 23A). 
pCOA-I-WTB 
 To generate this construct, the codon optimized luxA gene (COA) was cleaved 
from pPA2 via unique NotI restriction sites and cloned into the MCS(A) of the pIRES 
vector (Clontech Corporation, Palo Alto, CA) to generate pCOAI.  Once this construct 
was confirmed by sequencing, the plasmid was purified using the Wizard midi-prep 
plasmid purification kit according to the manufacturer’s instructions (Promega 
Corporation, Madison, WI).  The wild type luxB gene was cleaved via a 5′ XbaI and 3′ 
SpeI site from pCRluxB and cloned into the XbaI site within the MCS(B) of pCOAI to 
generate pCOA-I-WTB (Figure 23B). 
pCOA-I-COB 
To generate this construct, the codon optimized luxB (COB) gene was cleaved 
from pPB2 via introduced 5′ and 3′ XbaI sites and cloned into the MCS(B) from pCOAI 
to create pCOA-I-COB (Figure 23C). 
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Figure 23.  Schematic diagram of the final constructs used to compare the wild type 
luxA and luxB to the codon optimized genes.  A. Wild type luxA and wild 
type luxB B.  Codon optimized luxA and wild type luxB C. Codon optimized 
luxA and codon optimized luxB.  
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Ligation Reactions 
Plasmid vectors and inserts were digested (2-6 h) with the appropriate enzymes 
(Promega Corporation, Madison, WI).  Linearized vectors were dephosphorylated using 
a calf intestine alkaline phosphatase enzyme according for the manufacturer’s 
instructions (Promega Corporation, Madison, WI).  Both vector and insert DNA were 
gel purified from 1% agarose gels using the Geneclean gel extraction kit (Bio101, 
Carlsbad, CA).  The recovered DNA was then quantified using a Dyna Quant 200 
fluorometer (Hoefer Pharmacia Biotech Incorporated, San Francisco, CA) and ligations 
were set up as 20µl reactions using a 3:1 molar ratio of insert to vector DNA.  The 
ligation reactions were then incubated at 17°C overnight.   
 
 
Electroporation 
Electrocompetent cells were prepared as outlined by the manufacturer (BTX, 
San Diego, CA).  Electroporations were performed using the BTX Electroporator 600 
with the following conditions: 40µl cells, 1-2µl ligation mixture, a 2.5kV pulse for 
4.7ms using a 2mm gap cuvette.  After the pulse, cells were immediately resuspended in 
1ml of sterile LB and allowed to recover for 1 h at 37°C (200 rpm).  Cells were then 
plated on selective media containing the appropriate antibiotic. 
 
Selection of Bacterial Clones 
Resistant colonies were picked after 24 h and expanded to patches on grid 
plates.  To test for proper insert presence and orientation, rapid boil plasmid mini-preps 
(Promega Corporation, Madison, WI) were done followed by the digestion of the 
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plasmid with the appropriate restriction enzyme mixture according to the 
manufacturer’s instructions (Promega Corporation, Madison, WI).  Products were run 
on 1% agarose gels to determine if the banding pattern indicated the insert presence and 
proper orientation.  Upon identifying correct clones, the plasmids were further purified 
using the Wizard midiprep plasmid purification system according to the manufacturer’s 
protocol (Promega Corporation, Madison, WI) and sequenced. 
 
Sequencing 
All constructs were sequenced to ensure their integrity.  Sequencing was done in 
the University of Tennessee Molecular Biology Service Facility using an Applied 
Biosystems 3100 Genetic Analyzer sequencer (Foster City, CA).   
 
Transfection of Mammalian Cells  
Transfection of mammalian cell lines was done in six well poly-D-lysine coated 
tissue culture plates (Fisher Scientific, Pittsburgh, PA).  Cells were split from stock 
cultures and inoculated into each well at approximately 1X105 cells per well in 
complete growth media.  The plate was then placed at 37°C in a 5% CO2 atmosphere 
for 1-2 days until the cells became 80-90% confluent.  The day of transfection, the 
media was refreshed.  DNA for transfections was purified from 100ml overnight E. coli 
cultures using the Wizard Purefection plasmid purification kit to remove endotoxins 
according to the manufacturer’s instructions (Promega Corporation, Madison, WI).  For 
chromosomal integration, the plasmid DNA was linearized before transfection to 
increase proper integration.  
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HEK293 Cells 
 Purified plasmid DNA (3.2 µg) was mixed into 200 µl of serum free DMEM in 
a 1.5 ml tube.  In a second tube, 8 µl of Lipofectamine 2000 reagent (Invitrogen 
Corporation, Carlsbad, CA) was added to 200 µl of serum free DMEM.  The 
lipofectamine mixture was added to the DNA mixture within 5 min and incubated at 
room temperature for 20 min.  The entire mixture (400 µl total) was added directly to 
the appropriate well on the plate and rocked back and forth to ensure adequate mixing.  
Twenty-four hours post transfection, the complexes were removed and the media was 
replaced with fresh complete growth media supplemented with the appropriate 
antibiotic for selection.   
 
Selection of Mammalian Cell Clones 
Twenty-four hours post transfection, selective media was added to all wells and 
refreshed every three to four days.  Within two weeks all control wells were dead and 
the transfected cells were forming small colonies on the plate surface.  Colonies were 
separated from the rest of the well by placing a sterile chamber around the cell mass and 
sealing it with silicon (Fisher Scientific, Pittsburgh, PA).  The media could then be 
removed and each colony could be trypsinized and transferred to individual tissue 
culture flasks.  To accomplish this, after washing with a PBS solution, 200 µl of a 1X 
Trypsin-EDTA solution (Sigma Aldrich, St. Louis, MO) was added directly to the 
chamber and incubated at 37°C for 3 to 5 min.  The trypsin-EDTA solution was then 
replaced with complete growth media and the cells were transferred to a 25cm2 tissue 
culture flask for propagation.  Each clone was given a number and expanded to 
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individual cell lines.  Each line was split and maintained as described earlier with the 
addition of selective media.  Twenty cell lines were propagated in this manner for each 
plasmid tested.     
  
 
Bioluminescence Assays from Mammalian Cells 
 To determine bioluminescence potential from each cell line clone, total proteins 
were extracted and in vitro enzyme (bioluminescence) assays performed.  To extract the 
proteins, the cells were trypsinized from the plate or flask surface using standard 
protocols and resuspended into 2.0 ml Sarstedt tubes (Fisher Scientific, Pittsburgh, PA).  
The cells were then spun down and washed two times in sterile phosphate buffered 
saline (PBS) to remove any residual media (Sigma Aldrich, St. Louis, MO).  Cell pellets 
were then resuspended into 1 ml 0.1M potassium phosphate buffer pH 7.8 and disrupted 
by three consecutive cycles of freeze (30 s liquid N2) thaw (5 min at 37°C) extraction.  
After disruption, the cell debris was pelleted by spinning the samples at 14,000Xg for 5 
min and the supernatant was used in the bioluminescence assay.  To determine light 
intensity, the protein extract was mixed with 0.1 mM NAD(P)H, 4 µM FMN, 0.2% 
(w/v) BSA, 0.002% (w/v) n-decanal.  Bioluminescence was measured using the FB14 
luminometer (Zylux Corporation, Pforzheim, Germany) at a 1 s integration and reported 
as relative light units (RLU).  To determine if FMNH2 was a limiting factor for the 
bioluminescence reaction, a flavin oxidoreductase enzyme (1U) isolated from V. 
harveyi (Roche Scientific, Indianapolis, IN) was added to the bioluminescence assay 
and the light levels were measured again for comparison.     
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 Bioluminescence signals were normalized between samples and cell lines by 
dividing the RLU measurement by the total protein and reporting the bioluminescence 
as RLU/µg total protein.  Protein concentrations were determined using the Coomassie 
Plus protein assay according to the manufacture’s instructions (Biorad, Hercules, CA).   
 
In Vitro Transcription/Translation 
 To determine if the lux genes could be translated in vitro in rabbit reticulocyte 
lysate (mammalian translation machinery), pIRES vector harboring the wild type luxA 
(WTA), and codon optimized luxA (COA) were transcribed and translated.  First, the 
plasmid DNA containing the genes was digested at a unique XbaI restriction site at the 
3′ end of the gene within the vector.  This digestion linearized the plasmid and allowed 
for the generation of run-off transcript from the vector derived T7 promoter.  Each gene 
was transcribed via T7 polymerase using the RiboMax large-scale transcription system 
(Promega Corporation, Madison, WI).  Three individual transcription reactions were set 
up along with a positive T7 control and a negative control containing no template DNA.  
Each reaction was set up according to the manufacturer’s protocol and then incubated at 
37°C for 1 h.  Transcripts were quantified by absorbance (260/280) measurements 
(Beckman Coulter, Fullerton, CA).  Ten micrograms per ml of total RNA transcript was 
then added to 50 µl (total volume) rabbit reticulocyte lysate translation reactions.  Each 
reaction was gently mixed on ice according to the manufacturer’s protocol for S35 
labeled protein generation and then incubated at 30°C for 90 min (Promega 
Corporation, Madison, WI).  Once translation was complete, 15 µl of each reaction was 
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loaded onto a 12% SDS-PAGE mini-gel and run at 30 mA for 1 h.  The gel was 
removed and dried at 60°C with vacuum pressure using a model 443 Slab Dryer 
(BioRad, Hercules, CA) onto 3MM filter paper (Fisher Scientific, Pittsburgh, PA).  To 
visualize the generated proteins, the gel was placed onto an intensifier screen overnight 
and specific activity was measured using the STORM 840 phosphoanalyzer (Molecular 
Dynamics, Piscataway, NJ).   
 
Genomic DNA Isolation and Southern Blotting 
Genomic DNA from each clone was accomplished using the Wizard genomic 
DNA extraction kit according to the manufacturer’s protocols (Promega Corporation, 
Madison, WI).  After isolation each preparation was quantified using a Dyna Quant 200 
fluorometer (Hoefer Pharmacia Biotech Incorporated, San Francisco, CA).  In two 
separate reaction tubes restriction digestions were set up with 2.5µg of DNA each using 
a BamHI restriction enzyme according to the manufacturer’s instructions (Promega 
Corporation, Madison, WI).  Digestions were carried out in a 37°C water bath for four 
hours.  After digestion the products were loaded and run on a 1% agarose gel at 30V for 
6 hours.  The gel was then stained with ethidium bromide and photographed before the 
transfer.  The gel was then soaked for 15 min in a depurination solution (250mM HCl) 
and 30 min in a denaturation solution (0.5M NaOH and 1M NaCL), rinsed with dH2O 
and then neutralized two times for 15 min in (0.5M Tris/ 1.5M NaCl) before a final 
equalization in 20X SSC.  The DNA was then transferred to   BiotransTM nylon 
membrane (ICN, Irvine, CA) using the Turbo blotter apparatus according to the 
manufacturer’s instructions (Schleicher and Schuell, Keene, NH).   
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Double stranded DNA probes were generated complementary to a 300 bp 
portion of the codon optimized and wild type luxA genes using standard PCR protocols 
with the incorporation of a [32P] labeled dCTP nucleotide.  The probe was purified by 
column purification according to the manufacturer’s instructions (Stratagene, La Jolla, 
CA).  The specific activity of the each probe was measured by scintillation counting 
(Beckman Coulter, Fullerton, CA). Double stranded probes were boiled for 10 min to 
denature the DNA and directly added in equal amounts of specific activity to each blot. 
The blot was incubated with the probe at 65°C overnight.  After probe hybridization, the 
blot was washed 4 times in 20X SSC to remove any unbound activity.  The wash 
temperatures were determined experimentally to achieve optimal probe binding without 
excess background activity.  The blot was air dried and then placed on a 
phosphorescence intensifier screen (Molecular Dynamics, Piscataway, NJ).  Specific 
activity was measured using the STORM 840 phosphoanalyzer and the data analyzed 
using the ImageQuant data analysis software package (Molecular Dynamics, 
Piscataway, NJ).    
 
RNA Isolation and Blotting 
At passage six, post transfection, selected cell line clones were expanded to 
75cm2 tissue culture flasks.  When the cells became 80-95% confluent, they were 
trypsinized to remove the cells from the surface and transferred to 2.0 ml Sarstedt tubes 
(Fisher Scientific, Pittsburgh, PA).  Cells were spun down and washed two times in 
sterile PBS (Sigma Aldrich, St. Louis, MO).  Total RNA was then isolated from the 
cells using the RNeasy kit (Quiagen, Valencia, CA) according to the manufacturer’s 
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instructions for isolation of total RNA from mammalian cells.  To remove any 
contaminating DNA, the RNA was digested for 30 min with DNaseI (Promega 
Corporation, Madison, WI).  To remove the DNaseI enzyme, the clean-up procedure 
from the RNeasy kit was used (Quiagen, Valencia, CA).  Total RNA was then 
quantified using the Beckman DU-640 spectrophotometer absorbance at 260/280 
(Beckman Coulter, Fullerton, CA).   
Northern Blotting 
 Ten micrograms of total RNA were loaded onto a 0.8% agarose formaldehyde 
gel and run at 100V for 2 hrs.  The gel was then stained in an ethidium bromide solution 
and visualized.  The RNA was then transferred to a BiotransTM nylon membrane (ICN, 
Irvine, CA) using a semi-dry electroblot transfer apparatus according to the 
manufacturer’s instructions (CBS Scientific, San Francisco, CA).   
A 26 base pair oligonucleotide was designed to specifically hybridize to the 
codon optimized and wild type luxA sequences.  This oligonucleotide was then 3′ end 
labeled with a γ [32P] dATP by T4 polynucleotide kinase according to the 
manufacturer’s protocol (Promega Corporation, Madison, WI).  The oligonucleotide 
probe was then purified by column purification as outlined by the manufacturer 
(Stratagene, La Jolla, CA).  The specific activity of the probe was measured by 
scintillation counting (Beckman Coulter, Fullerton, CA) and added directly to the blot.   
 Double stranded DNA probes were generated complementary to a 300 bp 
portion of the codon optimized and wild type luxA genes using standard PCR protocols 
with the incorporation of a [32P] labeled dCTP nucleotide.  The probe was purified by 
column purification according to the manufacturer’s instructions (Stratagene, La Jolla, 
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CA).  The specific activity of the each probe was measured by scintillation counting 
(Beckman Coulter, Fullerton, CA). Double stranded probes were boiled for 10 min to 
denature the DNA and directly added in equal amounts of specific activity to each blot. 
The blot was incubated with the probe at 50°C overnight.  After probe 
hybridization, the blot was washed 4 times in 20X SSC to remove any unbound activity.  
The wash temperatures were determined experimentally to achieve optimal probe 
binding without excess background activity.  The blot was air dried and then placed on 
a phosphorescence intensifier screen (Molecular Dynamics, Piscataway, NJ).  Specific 
activity was measured using the STORM 840 phosphoanalyzer and the data analyzed 
using the ImageQuant data analysis software (Molecular Dynamics, Piscataway, NJ).     
 
Protein Isolation and Western Blotting 
 To extract the proteins, cells were trypsinized from a plate or flask surface and 
resuspended into 2.0 ml Sarstedt tubes (Fisher Scientific, Pittsburgh, PA).  The cells 
were then spun down and washed two times in sterile phosphate buffered saline (PBS) 
to remove any residual media (Sigma Aldrich, St. Louis, MO).  Cell pellets were 
resuspended into 1 ml 0.1M potassium phosphate buffer pH 7.8 and disrupted by three 
consecutive cycles of freeze (30 s liquid N2) thaw (5 min at 37°C) extraction.  After 
disruption, the cell debris was pelleted by spinning the samples at 14,000Xg for 5 min 
and the supernatant was used as total soluble protein for Western blot analysis. 
 Protein concentrations were determined using the Coomassie Plus protein assay 
according to the manufacturer’s instructions (Pierce, Rockford, IL).  Equal amounts 
(100 – 250 µg) of protein were loaded onto a 12% SDS-PAGE gel.  Minigels were run 
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at 30 mA for approximately 2 h and larger slab gels were run at 30 mA overnight.  The 
proteins were then electroblot transferred to PDVF membrane (Biorad, Hercules, CA) 
using a semi-dry electroblotter according to the manufacturer’s instructions (CBS 
Scientific Company, Incorporated, Del Mar, CA).  Blots were then blocked overnight in 
5% nonfat dry milk and hybridized with a polyclonal antibody raised against a 16 amino 
acid luxA polypeptide (′N′ - FDDSDQTRGYDFNKGC - ′C′) or a 16 amino acid luxB 
polypeptide (′N′ - CMILVNYNEDSNKAKQ - ′C′) (Genemed Synthesis, Incorporated, 
San Francisco, CA).  Antibodies were diluted in T-TBS (Tris Buffered Saline + 3% 
Tween 20) at a 1:500 dilution and applied to the membrane at room temperature for 5 h 
to overnight.  The blot was then washed several times in T-TBS and incubated with a 
Goat Anti-Rabbit second antibody that has been conjugated to alkaline phosphatase.  
The blot was then developed according to the manufacturer’s protocol (Biorad, 
Hercules, CA).     
 
Statistics  
 Statistical analysis of the data presented here was conducted using either the 
JMP (SAS Institute, Incorporated, Pacific Grove, CA) or Microsoft Excel (Microsoft, 
Seattle, WA) statistical software packages.  Graphs were made using Sigma Plot 
software (SPSS, SAS Institute, Incorporated, Pacific Grove, CA) or Microsoft Excel 
(Microsoft, Seattle, WA).  All error bars on graphs indicate one standard deviation of 
the mean.  Significant differences were determined using either t-test or 1 way ANOVA 
analysis at a level of α=0.05.  
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Results 
 
Determining a Codon Optimized Sequence of P. luminescens luxA and luxB for 
Expression in Mammalian Cells  
 The ratio of codons in the wild type luxA and luxB nucleotide sequences was 
compared to codon usage patterns of highly expressed (top 10%) mammalian genes 
according to the Genbank sequence database.   It was determined that the codon usage 
patterns between P. luminescens and human genes were extremely different.  Therefore, 
to create an optimized version of the lux genes, the codon ratios were altered to more 
closely follow codon usage patterns within the human genome. Higher frequency 
codons were used more often while rare codons were eliminated from the sequence 
entirely.  Changes were made within the nucleotide sequence in a random fashion. This 
codon optimized sequence was further analyzed for potential regions that may act as 
target splice sites or other regulatory signals.  The sequence was then modified until all 
potential splice sites and the more obvious regulatory sequences were removed.  A 
comparison of the final codon optimized and wild type lux sequences was made.  Once 
the codon optimized sequence was finalized it was tested using the GENSCAN online 
algorithm that predicts protein expression levels of gene sequences in human cells by 
comparing the sequence to known highly expressed genes within the matrix specified 
(http://genes.mit.edu).  The results of this analysis were encouraging and a predicted a 
significant increase in expression on both transcriptional and translational levels.  
Further, although verification was not possible, GENSCAN predicted a cleavage of the 
first twenty amino acids of the wild type LuxA protein when expressed in mammalian 
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cells (Table 11).   This cleavage was eliminated in the codon optimized sequence and a 
full length product was predicted to form.  A seqence alignment of the wild type and 
codon optimized genes is shown in Figures 24 and 25.  The wild type and codon 
optimized luxA and luxB ratios for codon usage is shown in Table 8A and 8B. 
 
Construction of the Codon Optimized luxA and luxB Genes 
 To evaluate the potential impact of codon optimization on the expression of the 
bacterial luciferase genes in mammalian cells, codon optimized versions of each gene 
were synthesized in vitro.  To generate functional genes, single stranded 
oligonucleotides (80-106 bp) were designed that spanned the entire gene sequence with 
overlapping (18-23 bp) regions. Four oligonucleotides were placed into a single PCR 
reaction to amplify segments of the genes individually (Figure 22).  The two outside 
oligonucleotides were used as both template and primers for the amplification reaction 
and the internal oligos as template.  Resultant PCR products of the appropriate size 
were placed into a second PCR reaction and the fragments were then amplified to link 
the pieces together using the two outermost oligonucleotides as primers (Figure 22).  
Products of the correct size were again purified and TA TOPO cloned to generate pPA2 
and pPB2.  Complete sequence analysis was performed and revealed several introduced 
errors that were subsequently corrected by site directed mutagenesis.   
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Table 11.  GENSCAN transcription and translation prediction scores for expression   
       of the luxA and luxB in a human host.  (http://genes.mit.edu) 
   
 
 
I = initiation signal T = termination signal   CodRg = Coding Region score 
P = probability of an exon    Trans. = exon score 
*Score interpretation: 0-50 = weak       50-100 = moderate       >100 = strong 
 
Gene  Type  Begin  End    Length    I     T     CodRg      P          Trans.
luxA(wt)   1       61   1083        1023     45   42      791         0.7          67.01
luxA(op)   1         1       1083        1083     66   42     1910       0.88       181.78
luxB(wt)   1         1    984          984      51   38      585      0.97          46.37
luxB(op)   1         1        984          984      66   41     1952     0.99        185.60
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  WTA  1 atgaaatttggaaactttttgcttacataccaacctccccaattttctcaaacagaggta               
||||| || || |||||  |||| ||||| || |||||||| ||||| ||||| |||||  
  COA  1 atgaagttcggcaacttcctgctcacatatcagcctccccagttttcccaaaccgaggtc  
 
  WTA 61 atgaaacgtttggttaaattaggtcgcatctctgaggagtgtggttttgataccgtatgg  
         ||||| ||  |||||||  | || |||||||| |||||||| ||||| || ||||| ||| 
  COA 61 atgaagcggctggttaagctcggccgcatctccgaggagtgcggtttcgacaccgtgtgg  
 
  WTA121 ttactggagcatcatttcacggagtttggtttgcttggtaacccttatgtcgctgctgca  
          | |||||||| || ||||| ||||| ||  ||||||||||||||||||||||||||||  
  COA121 ctgctggagcaccacttcaccgagttcggcctgcttggtaacccttatgtcgctgctgct  
 
  WTA181 tatttacttggcgcgactaaaaaattgaatgtaggaactgccgctattgttcttcccaca  
         ||| | || ||||| || || ||| |||| || || ||||||||||| ||||| |||||  
  COA181 tatctgctcggcgccaccaagaaactgaacgtcggcactgccgctatcgttctccccacc  
 
  WTA241 ggcccatccagtacgccaacttgaagatgtgaatttattggatcaaatgtcaaaaggacga  
         ||||||||||| ||||| |||||| || ||||| ||  ||||||||||||| || || ||  
  COA241 ggcccatccagtccgccagcttgaggacgtgaacttgctggatcaaatgtccaaggggcgc 
 
  WTA301 tttcggtttggtatttgccgagggctttacaacaaggactttcgcgtattcggcacagat  
         |||||||| || || ||||| |||||||||||||||||||| ||||| |||||||| ||  
  COA301 tttcggttcggcatctgccgcgggctttacaacaaggacttccgcgtgttcggcaccgac 
 
  WTA361 atgaataacagtcgcgccttagcggaatgctggtacgggctgataaagaatggcatgaca  
         ||||| ||||| |||||| | || || || |||||||||||||| ||||||||||||||  
  COA361 atgaacaacagccgcgccctggccgagtgttggtacgggctgatcaagaatggcatgacc 
 
  WTA421 gagggatatatggaagctgataatgaacatatcaagttccataaggtaaaagtaaacccc  
         |||||||| |||||||| || ||||| || ||||||||||| || || ||||| |||||| 
  COA421 gagggatacatggaagccgacaatgagcacatcaagttccacaaagtcaaagtgaacccc 
 
  WTA481 gcggcgtatagcagaggtggcgcaccggtttatgtggtggctgaatcagcttcgacgact  
         || || || |||||||||||||| || ||||||||||||||||| ||||||   || ||| 
  COA481 gccgcttacagcagaggtggcgctcctgtttatgtggtggctgagtcagctagtaccact 
 
  WTA541 gagtgggctgctcaatttggcctaccgatgatattaagttggattataaatactaacgaa  
         ||||||||||||||||||||||| || |||||  |    ||||| || || ||||| ||  
  COA541 gagtgggctgctcaatttggcctccctatgatcctgtcctggatcatcaacactaatgag 
 
  WTA601 aagaaagcacaacttgagctttataatgaagtggctcaagaatatgggcacgatattcat  
         ||||| || || || |||||||| || |||||||||||||| || |||||||| |||||| 
  COA601 aagaaggcccagctcgagctttacaacgaagtggctcaagagtacgggcacgacattcat  
 
  WTA661 aatatcgaccattgcttatcatatataacatctgtagatcatgactcaattaaagcgaaa  
         || |||||||| ||| | || || || || || || || || ||||| || || || ||  
  COA661 aacatcgaccactgcctgtcctacatcacctccgtggaccacgactccatcaaggccaag 
 
 
  Figure 24.  Wild type and codon optimized luxA sequence alignment. 
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  WTA721 gagatttgccggaaatttctggggcattggtatgattcttatgtgaatgctacgactatt  
         |||||||||||||| ||||| |||||||||||||||   || ||||||||||| |||||  
  COA721 gagatttgccggaagtttctcgggcattggtatgatagctacgtgaatgctaccactatc 
 
  WTA781 tttgatgattcagaccaaacaagaggttatgatttcaataaagggcagtggcgtgacttt  
         ||||| || || ||||| || |||||||| || ||||| || ||||||||||| || ||  
  COA781 tttgacgactccgaccagaccagaggttacgacttcaacaaggggcagtggcgcgatttc 
 
  WTA841 gtattaaaaggacataaagatactaatcgccgtattgattacagttacgaaatcaatccc  
         || || |||||||| || ||||||||  | || || || ||||| ||||| ||||||||| 
  COA841 gtgttgaaaggacacaaggatactaacagacgcatcgactacagctacgagatcaatccc 
 
  WTA901 gtgggaacgccgcaggaatgtattgacataattcaaaaagacattgatgctacaggaata  
         ||||| || || ||||| || |||||||| || ||||| |||||||||||||| |||||  
  COA901 gtgggcacccctcaggagtgcattgacatcatccaaaaggacattgatgctaccggaatc 
 
  WTA961 tcaaatatttgttgtggatttgaagctaatggaacagtagacgaaattattgcttccatg  
         || || || |||||||||||||| ||||| ||||| || ||||| || || ||||||||| 
  COA961 tccaacatctgttgtggatttgaggctaacggaaccgtggacgagatcatcgcttccatg 
 
 WTA1021 aagctcttccagtctgatgtcatgccatttcttaaagaaaaacaacgttcgctattatat  
         |||||||||||||| |||||||||||||| || || || || |||||    ||  | || 
 COA1021 aagctcttccagtccgatgtcatgccattcctcaaggagaagcaacgcagcctcctgtac  
 
 WTA1081 tag 
         ||| 
 COA1081 tag 
 
Figure 24. Continued
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WTB  1 atgaaatttggattgttcttccttaacttcatcaattcaacaactgttcaagaacaaagt  
       ||||| || ||| |||||||||||||||||||||| || || ||||| || || |||||  
COB  1 atgaagttcggactgttcttccttaacttcatcaactccaccactgtgcaggagcaaagc 
 
WTB 61 atagttcgcatgcaggaaataacggagtatgttgataagttgaattttgaacagatttta  
       || || ||||||||||| || || |||||||| || ||| |||| || || |||||  |  
COB 61 atcgtgcgcatgcaggagatcaccgagtatgtggacaagctgaacttcgagcagatcctg 
 
WTB121 gtgtatgaaaatcatttttcagataatggtgttgtcggcgctcctctgactgtttctggt  
       ||||| || || || ||||| || ||||| ||||||||||||||||||||||| || ||  
COB121 gtgtacgagaaccacttttccgacaatggcgttgtcggcgctcctctgactgtgtccggc 
 
WTB181 tttctgctcggtttaacagagaaaattaaaattggttcattaaatcacatcattacaact  
       || ||||||||  | || ||||| || |||||||| ||  | || |||||||| || ||| 
COB181 ttcctgctcggcctgaccgagaagatcaaaattggctccctgaaccacatcatcaccact 
 
WTB241 catcatcctgtcgccatagcggaggaagcttgcttattggatcagttaagtgaagggaga  
       ||||||||||||||||| || ||||| |||||| |  |||||||| | || || |||||| 
COB241 catcatcctgtcgccatcgctgaggaggcttgcctgctggatcagctgagcgaggggaga 
 
WTB301 tttattttagggtttagtgattgcgaaaaaaaagatgaaatgcatttttttaatcgcccg  
       || ||  | ||||| || |||||||| || || || || ||||| ||||| || |||||  
COB301 ttcatcctggggttcagcgattgcgagaagaaggacgagatgcactttttcaaccgccct 
 
WTB361 gttgaatatcaacagcaactatttgaagagtgttatgaaatcattaacgatgctttaaca  
       || |||||||| |||||||| ||||||||||| || || ||||||||||| ||| | ||  
COB361 gtggaatatcagcagcaactgtttgaagagtgctacgagatcattaacgacgctctgacc 
 
WTB421 acaggctattgtaatccagataacgatttttatagcttccctaaaatatctgtaaatccc  
       || ||||| || || || || || || || || |||||||||||||| || || || ||| 
COB421 accggctactgcaaccccgacaatgacttctacagcttccctaaaatctccgtcaacccc 
 
WTB481 catgcttatacgccaggcggacctcggaaatatgtaacagcaaccagtcatcatattgtt  
       || ||||| || |||||||| |||||||| ||||| || || ||||||||||| || ||  
COB481 cacgcttacaccccaggcggccctcggaagtatgtcaccgctaccagtcatcacatcgtg 
 
WTB541 gagtgggcggccaaaaaaggtattcctctcatctttaagtgggatgattctaatgatgtt  
       |||||||| ||||| ||||| || ||||||||||||||||||||||| || || || ||  
COB541 gagtgggctgccaagaaaggcatccctctcatctttaagtgggatgactccaacgacgtg 
 
WTB601 agatatgaatatgctgaaagatataaagccgttgcggataaatatgacgttgacctatca  
       ||||| || || ||||| ||||| || ||||| || || ||||||||||||||||| ||  
COB601 agatacgagtacgctgagagatacaaggccgtggctgacaaatatgacgttgacctgtcc 
 
WTB661 gagatagaccatcagttaatgatattagttaactataacgaagatagtaataaagctaaa  
       || || ||||| ||| | |||||  | |||||||| |||||||| || || || |||||  
COB661 gaaatcgaccaccagctgatgatcctggttaactacaacgaagacagcaacaaggctaag 
 
 
Figure 25.  Wild type and codon optimized luxB sequence alignment. 
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WTB721 caagagacgcgtgcatttattagtgattatgttcttgaaatgcaccctaatgaaaatttc  
       || ||||| || || || ||||| || || || ||||||||||||||||| || || ||| 
COB721 caggagacccgcgccttcattagcgactacgtgcttgaaatgcaccctaacgagaacttc 
 
WTB781 gaaaataaacttgaagaaataattgcagaaaacgctgtcggaaattatacggagtgtata  
       || || || ||||| ||||| || || || |||||||||||||| || || ||||||||  
COB781 gagaacaagcttgaggaaatcatcgccgagaacgctgtcggaaactacaccgagtgtatc 
 
WTB841 actgcggctaagttggcaattgaaaagtgtggtgcgaaaagtgtattgctgtcctttgaa  
       ||||| |||||| |||| || || ||||| ||||| || |||||  |||||||||||||  
COB841 actgctgctaagctggccatcgagaagtgcggtgctaagagtgtcctgctgtcctttgag 
 
WTB901 ccaatgaatgatttgatgagccaaaaaaatgtaatcaatattgttgatgataatattaag  
       |||||||||||  ||||||||||||| || || ||||| ||||| || || ||||||||| 
COB901 ccaatgaatgacctgatgagccaaaagaacgtcatcaacattgtggacgacaatattaag 
 
WTB961 aagtaccacatggaatatacctaa  
       |||||||||||||| || |||||| 
COB961 aagtaccacatggagtacacctaa 
 
Figure 25.  Continued 
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In Vitro Transcription and Translation of the Wild Type and Codon Optimized 
luxA 
 To quickly evaluate the translation efficiency in a mammalian cell system of the 
codon optimized and wild type luxA genes, in vitro transcription and translation analysis 
was performed.  The pIRES expression vector contains a bacteriophage T7 promoter 
region upstream of the MCS (A). This promoter was used to generate runoff transcripts 
of the wild type and codon optimized luxA sequences.  The transcript was then 
translated in vitro using rabbit a reticulocyte lysate system that incorporates a 35S 
methoinine into the polypeptide sequence and allows for easy detection. The codon 
optimized LuxA protein (COA) was determined to be produced by this system 
approximately twenty fold over the wild type LuxA protein (Figure 26). 
 
In Vivo Expression of the Wild Type Versus Codon Optimized luxA and luxB 
Genes  
 To evaluate the optimized genes in vivo, wild type and codon optimized versions 
of the luxA and luxB were cloned into the pIRES mammalian expression vector to allow 
for bicistronic expression of both genes with only one selection marker.  Twenty 
 stable clones (HEK293 cells) were selected for each construct along with one negative 
vector control.  At passage three post transfection, each clone was tested in vitro for 
bioluminescence upon the addition of n-decanal and FMNH2.  These data revealed that 
each clonal cell line varied in its bioluminescence levels (Figure 27).  The average 
bioluminescence from each gene combination is shown in Figure 28.  Based on these 
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Figure 26.  In vitro translation products of the wild type luxA and codon optimized luxA 
genes.  Products were labeled by the incorporation of [35S] methionine.   
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Figure 27.  Bioluminescence measurements taken at passage three post transfection for 
the twenty clones for each construct.  A.  WTA/WTB clones                       
B.  COA/WTB clones  C. COA/COB Clones. 
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Figure 27. Continued 
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Figure 28.  Average bioluminescence from stably transfected HEK293 cell 
lines. (20 clones tested for each clone type in triplicate). 
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data, the two or three clones producing the highest bioluminescence levels were chosen 
for further study.   At passage six, each clone selected was expanded into triplicate 
75cm2 tissue culture flasks.  From these cells, total genomic DNA, total RNA and 
soluble proteins were extracted for further analysis.   
 
Determining Insertion Number in HEK293 Clones 
  To determine gene insertion number in each clone, a southern blot was 
performed using luxA probes generated to both the wild type and codon optimized luxA 
sequences.  As shown in Figure 29, all of the cell lines tested had either one or two 
copies of the gene inserted with the exception of the COA/COB3 clone.  To simplify 
further measurements, this clone was then disregarded for further bioluminescence 
comparisons. 
 
Determination of luxA Message Levels in HEK293 Clones 
 To determine transcript levels, total RNA was extracted and northern blot analysis 
was performed.  The same probes that were used for Southern blot analysis were used in 
these experiments as well.   Transcript levels were determined to be approximately 
equal with the exception of the WTA/WTB1 clone that had a lower amount of luxA 
transcript (Figure 30).  The vector (NC) control had little to no background 
hybridization (Figure 30).  The ethidium bromide stained 28S was included as an RNA 
loading reference.   
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Figure 29.  Southern blot analysis on the stable HEK293 clones harboring either wild 
type luxA and luxB, codon optimized luxA and wild type luxB or codon 
optimized luxA and luxB.  The blot was probed with a 300 bp [32P] labeled 
probe of both the wild type and codon optimized luxA sequence.   
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Figure 30.  Northern blot analysis of the stable HEK293 clones harboring either wild 
type luxA and luxB, codon optimized luxA and wild type luxB or codon 
optimized luxA and luxB.  Ethidium bromide stained 28S rRNA was used to 
ensure RNA quality and loading controls.  
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Determination of LuxA Protein Levels in HEK293 Clones 
 
Total soluble proteins from each clone were isolated by a series of freeze (liquid 
N2) thaw (37°C) cycles. Two hundred fifty micrograms of total protein were run on an  
SDS-PAGE gel and Western blot analysis was performed using a polyclonal luxA 
antibody (Figure 31).  LuxA protein was not detected in any of the wild type luxA and 
luxB clones, only detected at very low levels in codon optimized luxA with wild type 
luxB clones, but readily detectable when both genes were codon optimized (Figure 31).  
This increase in LuxA protein concentration was observed despite the fact that the 
levels of luxA mRNA transcript were relatively equivalent for all of the clones tested 
(Figure 32).   
 
Bioluminescence Levels from Wild Type Versus Codon Optimized Luciferase 
Genes 
Bioluminescence levels were evaluated on whole cell extracts upon the addition 
of n-decanal and FMNH2.  Each clone was tested in triplicate from individual 35cm2   
wells.  Bioluminescence values were found to be greater than two orders of magnitude 
higher in cell lines harboring both a codon optimized luxA and luxB (COA/ COB) over 
that of the cell lines harboring the wild type genes (WTA/WTB) (Figure 33).  The 
bioluminescence levels obtained increased in the order WTA/WTB < COA/WTB < 
COA/COB.   Based on these data it was determined that codon optimization had a 
significant effect (p<0.05) on the bioluminescence potential from HEK293 cells.
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Figure 31.  Western blot analysis of HEK293 clones harboring either wild type luxA 
and luxB, codon optimized luxA and wild type luxB or codon optimized luxA 
and luxB.  The β-actin protein was used as a loading control. 
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Figure 32.  Comparison of mRNA levels and protein levels in each of the stable 
HEK293 cell line clones.  A.  Northern blot of total RNA (20µg) from stably 
transfected HEK293 cells probed with 32P labeled complimentary luxA 
probes.  B.  Western blot of total soluble protein (250 µg) from stably 
transfected HEK293 cells immunoblotted with a polyclonal luxA antibody.   
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Figure 33.  Average bioluminescence from individual HEK293 clones stably 
transfected with WTA/IRES/WTB, COA/IRES/WTB or COA/IRES/COB.   
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Discussion  
 Codon usage regulates gene expression at the level of translation and the usage 
patterns between species are not conserved (Kurland, 1991).  This is especially true 
between genes derived from eukaryotes versus those from prokaryotes.  Therefore, to 
efficiently express the bacterial lux genes in mammalian cells, the nucleotide sequence 
was altered in such a way as to create a “humanized” form of the gene without altering 
the amino  acid sequence.  This approach has been used previously to optimize the 
expression of both GFP and Renilla luciferase proteins for expression in mammalian 
cells (Zhang et al., 2002 and Gruber and Wood, 2000).  The design of this new 
sequence was carefully determined, removing all potential splice sites and most 
regulatory regions. After the final codon optimized sequence was determined, it was 
evaluated using the GENSCAN prediction algorithm to determine the potential 
 expression efficiency in a human cell.  According to the output from this program the 
overall expression of the codon optimized lux genes would be significantly improved 
versus the wild type.  The increase in expression was predicted to be caused by an 
increase in both transcription and translation efficiency.  Furthermore, it was predicted 
that the first sixty bases (20 amino acids) of the wild type luxA gene would be 
completely eliminated when expressed in mammalian cells.  Considering that this 
region of the LuxA protein holds most of the catalytic properties (active site) for the 
bacterial luciferase enzyme, this would be devastating for its expression.  If this were 
the case, the low expression levels observed for the LuxAB fusion protein, shown 
earlier, may be better explained in part by a nonfunctional protein being formed rather 
than inefficient folding or heat liability.    
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 To test the expression of the codon optimized genes, modified versions were 
required.  However, because the necessary changes were to numerous to achieve by site 
directed mutagenesis, a complete in vitro gene synthesis protocol was pursued. Large 
oligonucleotides (80-106 bp) were designed with overlapping (18-22 bp) regions.  The 
original plan was to amplify all of the oligonucleotides together in one PCR reaction 
according to methods set by Prodromou and Pearl (1992).  However, because of the 
larger size of the lux genes (approximately 1000 bp each), this was not possible.  As an 
alternative, the gene was synthesized in parts and the subsequently linked by a second 
round of PCR.  The two outside oligonucleotides were used as both template and 
primers for each reaction.  After some experimental effort, it was determined that for 
optimal amplification the internal oligonucleotides (template) should be added at a 
concentration that equaled 100 fold less than the outside oligos. Amplification products 
of the correct size were cloned and sequenced.  Unfortunately, sequence analysis 
revealed several base substitution mutations within all clones tested.  These mutations 
were present despite the fact that care was taken by using a Pfu polymerase that has 
proof reading abilities. This finding was disappointing while not surprising given that 
two consecutive PCR reactions were required to obtain the final gene product resulting 
in > 60 cycles of amplification.  To eliminate these errors and produce the proper 
sequence, site directed mutagenesis was performed. 
   It was determined  previously through work accomplished in S. cerevisiae and 
mammalian cells for the expression of the bacterial luciferase genes that IRES elements 
may be an efficient way to express independent proteins as single bicistronic transcripts. 
This expression format provides the most natural expression of the genes, most closely 
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mimicking the polycistronic form found in the bacterial operon.  Therefore, experiments 
were set up to compare the codon optimized and wild type luxA and luxB genes in 
mammalian cells using an IRES based expression vector.  The expression vector used 
was designed to highly express two independent genes under the control of a single 
constitutive encephalomyocarditis virus (ECMV) promoter region by linking two 
multicloning sites fused to either side of an internal ribosomal entry site (IRES).  The 
IRES element allows for the translation of two consecutive open reading frames from 
one messenger RNA (Jang et al., 1990; Jackson et al., 1990; Rees et al., 1996).  By 
constructing plasmids with different combinations of the codon optimized luxA and 
luxB with their wild type counterparts, a direct comparison of the genes was made.   
To quickly determine if a difference in translation efficiency could be detected 
between the optimized and wild type luxA genes, in vitro transcription and translation 
analysis was performed.  The codon optimized luxA gene (COA) was detected 
approximately twenty fold over wild type (Figure 26).  This finding supported the 
results that shown earlier with the in vitro generation of the wild type LuxA protein.  
Since the rabbit reticulocyte lysate translation system is used to mimic mammalian 
translation machinery in vitro, these results indicated that the codon optimization would 
indeed make a significant impact on the translation efficiency of the lux proteins in 
mammalian systems.   
 HEK293 cells were transfected with the WTA/ WTB, WTA/ COB or COA/COB 
constructs and stable cell line clones were selected by antibiotic resistance. Twenty 
stable clones for each luxA and luxB combination were selected and bioluminescence 
levels were determined upon the exogenous addition of n-decanal and FMNH2.  The 
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bioluminescence significantly increased in the order WTA/WTB < COA/WTB < 
COA/COB.  These data indicated that codon optimization had made a significant 
impact on the potential bioluminescence levels obtained from mammalian cells.  To 
analyze this data further, the two or three brightest clones were chosen for further study.  
From these cells, total genomic DNA, total RNA and total soluble proteins were 
extracted.      
 Foreign gene integration in mammalian cells is a random event, therefore it is 
possible to have more than one insertion of the construct occur during each transfection.  
Since integration is fairly inefficient, the copy number per cell is generally very low.  
However, because of this possibility, it was important to determine the copy number of 
the inserted genes for at true comparison.  To accomplish this, Southern blot analysis 
was performed on each of the seven clones that produced the highest bioluminescence 
levels.  All of the cell lines tested had either one or two copies of the gene inserted with 
the exception of the COA/COB3 clone which had three.  To simplify further 
measurements, this clone was then disregarded for further bioluminescence 
comparisons.  Nevertheless, it should be noted that increased copy number does not 
correlate with increased expression levels.  Numerous other factors have been shown to 
impact from gene expression at a greater level. 
 The overall amount of luxA mRNA transcript was determined by Northern blot 
analysis.  Transcript levels were relatively equal with the exception of the WTA/WTB1 
clone that produced significantly lower amounts of luxA mRNA.  Since each construct 
contained the same promoter (ECMV) element and initiation signals, it would be 
expected that each clone would have approximately equal amounts of transcript for the 
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introduced genes.  However, cis acting regulatory elements could potentially interfere 
with transcription initiation and overall transcript levels in vivo.  These types of 
interferences would vary based on where within the chromosome the genes were 
integrated.  Therefore, the position effect of various clones could explain the lower 
amount of transcript detected with the WTA/WTB1 clone.  Other factors that can 
potentially impact the amount of RNA transcript would be a direct result of increased 
RNA degradation of certain mRNA sequences that can occur.  This type of RNA 
instability would be less likely after codon optimization because of the removal of 
several AU rich target degradation regions.  However, because the lower amount of 
transcript was not seen in both the WTA/WTB clones, this scenario is unlikely. 
To evaluate the overall protein concentrations and determine translation 
efficiency of each construct, Western blot analysis was performed.  Total soluble 
proteins from each clone were isolated and quantified.  Western blot analysis was 
performed using a polyclonal luxA antibody (Figure 31). The LuxA protein was not 
detectable from WTA/WTB clones and faintly visible in the COA/WTB clones.  
However, large amounts of LuxA protein were detected from the COA/COB clones 
which harbored a construct carrying codon optimized versions of both genes.  This 
finding was intriguing and unexpected.  Since the only available antibody was raised 
against a polypeptide of LuxA, it was expected that the constructs harboring the 
COA/WTB and COA/COB would produce equal amounts of LuxA protein.  Since this 
was not the case, these data indicated that the codon optimization of both genes might 
infer stability on the heterodimeric complex that makes up the luciferase enzyme.  This 
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increased stability of the complex may have allowed the proteins to be detected in the 
Western blot while the other construct was not detected.   
Perhaps the most valuable measurement to determine if codon optimization was 
a success is the amount of enzyme activity that could be obtained from each construct.  
Bioluminescence levels were evaluated on whole cell extracts upon the addition of n-
decanal and FMNH2.  Average bioluminescence values were found to be greater than 
two orders of magnitude higher in cell lines harboring both a codon optimized luxA and 
luxB (COA/COB) over that of the cell lines harboring the wild type genes (WTA/WTB) 
(Figure 33).  While bioluminescence levels were significantly higher in clones 
expressing COA and WTB versus WTA and WTB, the optimal bioluminescence was 
obtained from clones harboring optimized versions of both genes (Figure 33).  These 
data further support the stabilization conclusion of the heterodimeric protein. Based on 
these data it was determined that codon optimization had a significant effect on the 
protein expression in HEK293 cells. 
  In conclusion, the codon optimization of the luxA and luxB genes was 
successful in increasing the overall expression levels of the individual proteins.  This 
increase in protein quantities resulted in a significant increase in bioluminescence from 
cell lines harboring these constructs.  Furthermore, the bioluminescence levels from 
codon optimized luxA and luxB provide adequate bioluminescence for the proof in 
principle data needed for the future development of reliable reporter constructs for 
analyte sensing in mammalian cells. 
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CHAPTER 4 
 
EVALUATION OF MAMMALIAN CELLS FOR FMNH2 AVAILABILITY AND 
STABILITY OF BACTERIAL LUCIFERASE IN STABLE MAMMALIAN CELL 
LINES 
 
 
Introduction 
 The bacterial luciferase enzyme system has several advantages over other 
bioreporter systems available.  Of these advantages, the ability to directly measure in 
vivo gene expression without the disruption of the reporter cell or loss of cell viability is 
perhaps the most obvious benefit.  This property has made the lux system sought out by 
many for various research applications using prokaryotic cells.  As a result, numerous 
biosensor systems utilizing the bacterial luciferase system have been developed and are 
currently in use. However, as discussed earlier, the bacterial luciferase system has not 
yet been efficiently expressed in mammalian cell lines and therefore the full potential of 
this technology is not yet realized.  The obstacles encountered by researchers trying to 
employ the bacterial lux system in eukaryotes have included low expression levels of 
the Lux proteins and limited amounts of substrates and cofactors required for the 
reaction within the cells.   
 The bacterial luciferase enzyme system consists of a multi-enzyme complex 
encoded by five genes that provide the luciferase enzyme as well as the luciferin 
(aldehyde) substrate for the reaction.  However, this reaction additionally requires the 
host cell metabolism to provide adequate amounts of molecular O2, the reducing power 
of FMNH2 and the energy of ATP as co-factors and substrates.  To produce 
bioluminescence, the reaction goes through several intermediate steps.  With a 
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stoichiometry of 1:1:1, the α and β subunits bind with a reduced flavin molecule 
(FMNH2) to form a C4a hydroxyflavin.  As this hydroxyflavin becomes dehydrated to 
FMN, a blue-green light is emitted (Baldwin et al., 1979).  Because of the stoichiometry 
of the reaction and its absolute requirement, the FMNH2 molecule is considered to be an 
additional substrate for the bioluminescence reaction rather than a co-factor.  On the 
other hand, the luciferase reaction itself can proceed in the absence of the decal-
aldehyde substrate, but its presence significantly increases the light output kinetics and 
therefore is required for bioreporter applications (Volkova et al., 1999).   
 In bacteria, the availability of FMNH2 is not a limiting factor for the 
bioluminescence reaction.  Nevertheless, in several bioluminescent strains of bacteria, a 
flavin oxidoreductase gene (frp) has been identified in close proximity to the lux 
operon.  This enzyme has the ability to reduce pools of FMN within the cell to FMNH2 
and then recycle itself to catalyze further reductions.  Although the availability of 
FMNH2 in yeast was shown to be a limiting substrate for the bioluminescence reaction 
in these cells, it was subsequently shown that yeast could be further engineered to 
express the flavin oxidoreductase gene (frp) from Vibrio harveyi to overcome this 
limitation (Gupta et al., 2003).  This was the first illustration of the use of a flavin 
reductase enzyme to improve the bioluminescence output from an engineered lux 
bioreporter cell. Although the availability of the FMNH2 substrate has not been 
completely evaluated in mammalian cells, it has been hypothesized to be one of the 
major problems leading to inefficient expression of the bacterial luciferase system in 
eukaryotes.  Furthermore, to this point, all mammalian cell line experiments have been 
conducted with the exogenous addition of FMNH2 or the enzymes required to produce 
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this substrate.  In order to efficiently express the bacterial luciferase system in 
mammalian cells, the availability of FMNH2 needs to be fully evaluated and the 
possibilities available to overcome this limitation need to be explored.   
 For the future generation of a useful mammalian bioreporter cell line for gene 
expression analysis or target analyte monitoring, the engineered cell line not only needs 
to  be able to efficiently express the lux genes but, it must also remain stable for long 
periods of time in the absence of antibiotic selection.  Some of the proposed 
applications for this technology may require that the cells remain stable for extended 
periods with very little to no intervention.  Therefore, the overall stability of engineered 
mammalian cell lines harboring the lux genes needs to be evaluated to completely 
understand the limitations of this technology.  Therefore, in this research effort, the 
following objectives will be met: 
 
• Determine to what extent FMNH2 limits the bioluminescence reaction in 
mammalian cell lines expressing the bacterial luciferase enzyme. 
• Obtain a bioluminescent cell line that can overexpress the flavin oxidoreductase 
enzyme from Vibrio harveyi. 
• Evaluate the ability of this engineered cell line to produce adequate levels of 
FMNH2 for the bioluminescence reaction. 
• Evaluate the overall stability of the constructs within stably integrated 
mammalian cell lines engineered with the bacterial luciferase genes for long 
term maintenance without antibiotic pressure. 
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Materials and Methods 
Cell Culture and Plasmid Maintenance 
 All relevant constructs and strains, bacterial and mammalian, used in this study 
are outlined in Table 12.  E. coli cells were routinely grown in Luria Bertani (LB) 
(Fisher Scientific, Pittsburgh, PA) broth containing the appropriate antibiotic selection 
with continuous shaking (200 rpm) at 37°C.  Kanamycin and Ampicillin were used at a 
final concentration of 50µg/ml and 100µg/ml, respectively.   
 All cell culture reagents and media were obtained from Sigma Aldrich (St. 
Louis, MO) unless otherwise stated.  Mammalian cells were grown in the appropriate 
complete growth media containing 10% heat-inactivated horse serum, 0.01mM non-
essential amino acids and a Dubelco’s minimal media base (DMEM) (M4655).  Cells 
were routinely grown at 37° C in a 5% CO2 atmosphere to confluency and split every 
three to four days by trypsinization at 1:4 ratio and transferred into fresh complete 
growth media.  Appropriate concentrations of antibiotic were used to maintain 
constructs after transfection according to susceptibility kill curve analysis.  Kill curves 
were completed for each lot of antibiotic.  The range of typical concentrations used for 
the selection of HEK293 cell line clones was between 450µg/ml and 650µg/ml of 
Neomycin G418 and 250µg/ml and 400µg /ml of Zeocin (Invitrogen Corporation, 
Carlsbad, CA). 
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Table 12.  Constructs and Strains used in this study. 
Plasmid/Strain 
Designation 
 
Relevant Genotype/ Characteristics 
 
Source 
Strains   
E. coli   
 
DH5α 
Φ80dlacZ∆M15, recA1, endA1, gyrA96, thi-1, 
hsdR17 (rK-, mK+), supE44, relA1, deoR, 
∆(lacZYA-argF)U169 
 
Gibco, BRL 
 
 
TOP 10 
 
F-, mcrA ∆(mrr-hsdRMS-mcrBC) Φ80/lacZ 
∆lacX74 deoR recA1 araD139 ∆(ara-leu) 7697 
ga/K rpsL endA1 nupG 
 
 
Invitrogen 
 
Mammalian Cells  
  
 
HEK293 
Permanent line of primary human embryonal 
kidney transformed by sheared human adenovirus 
type 5 (Ad 5) DNA. ATCC# CRL-1573 
 
ATCC 
   
 
Plasmids 
  
   
 
 
pCR4-TOPO 
 
TOPO TA cloning vector for easy cloning of 
PCR products generated with 3′ A overhangs 
designed for sequencing Kmr, Ampr 
 
 
Invitrogen 
 
 
 
pIRES 
 
Mammalian expression vector containing the 
internal ribosomal entry site (IRES) of the 
encephalomyocarditis virus between two multi-
cloning sites which allows for the expression of 
two genes under the control of a single 
constitutive CMV promoter, Neomycin G418 
antibiotic selection marker and a pUC ori and 
Kmr for replication in E.coli 
 
 
 
Clontech 
 
 
pcDNAHISMAX 
 
Mammalian expression vector allows for 
constitutive expression under the control of a 
constitutive CMV promoter contains a SPC163 
translational enhancer, Zeocin antibiotic selection 
marker and pUC ori and Ampr for replication in 
E. coli. 
 
 
 
Invitrogen 
 
 
pcDNA3.1Zeo 
 
Mammalian expression vector allows for 
constitutive expression under the control of a 
constitutive CMV promoter, Zeocin antibiotic 
selection marker and pUC ori and Ampr for 
replication in E. coli. 
 
 
Invitrogen 
 
pCR4frp 
 
pCR4 TA cloning vector harboring the frp from 
Vibrio harveyi. 
 
This Study 
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Plasmid/Strain 
Designation 
 
 
Relevant Genotype/ Characteristics 
 
 
Source 
 
 
pMaxfrp 
 
 
pcDNAHISMAX vector harboring the frp gene 
from V. harveyi.  
 
 
This Study 
 
 
pcfrpZeo 
 
 
pcDNA vector harboring the frp gene from V. 
harveyi. 
 
 
This Study 
 
Mammalian Cell Line 
Constructs 
 
 
COA/COB(2)  
 
 
 
 
 
HEK293 cell lines stably transfected with the 
pCOA-I-COB plasmid and selected by G418. 
 
 
 
 
 
Chapter 3 
 
frp (1-9)       
 
COA/COB2 cell line stably transfected with the 
pcDNAfrp plasmid and selected by G418 and 
Zeocin. 
 
 
This Study 
 
Table 12. Continued 
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Construction of a Mammalian Expression System for frp 
 To generate a strain to overexpress the flavin oxidoreductase enzyme in 
mammalian cells, the frp gene was amplified from V. harveyi strain VHU08996 DNA.  
The gene was then TA TOPO cloned into the pCR4-TOPO cloning vector according to 
the manufacturer’s instructions  to generate pCR4frp (Invitrogen Corporation, Carlsbad, 
CA) and subsequently cut and ligated into the pcDNAHISMAX mammalian expression 
vector using introduced unique 5`BamHI and 3` NotI restriction sites to generate 
pMaxfrp (Figure 34A) (Invitrogen Corporation, Carlsbad, CA).  This expression vector 
possesses an SPC163 untranslated sequence upstream of the gene insert.  This sequence 
has been shown to enhance translation between four and five fold over expression 
without the enhancer. 
 A second plasmid was generated to express the frp gene from V. harveyi by 
cloning the gene via the introduced unique 5`BamHI and 3`NotI restriction sites into the 
pcDNA3.1Zeo mammalian expression vector to generate pcfrpZeo (Figure 34B).    
 
Ligation Reactions 
 Plasmid vectors and inserts were digested (2-6 h) with the appropriate enzymes 
(Promega Corporation, Madison, WI).  Linearized vectors were dephosphorylated using 
a calf alkaline phosphatase enzyme according to the manufacturer’s instructions 
(Promega Corporation, Madison, WI).  Both vector and insert DNA were gel purified 
from 1% agarose gels using the Geneclean gel extraction kit (Bio101, Carlsbad, CA).  
The recovered DNA was then quantified using the Dyna Quant 200 fluorometer (Hoefer 
Pharmacia Biotech Incorporated, San Francisco, CA) and ligations were set  
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Figure 34.  Schematic diagram of the expression vectors used to express the flavin 
oxidoreductase enzyme (frp) from V. harveyi in mammalian cells.  A.  
Expression in the pcDNAHISMAX that provides an SPC163 translational 
enhancer region for enhanced translation and protein expression driven from 
a constitutive CMV promoter region.  B.  Expression in the pcDNA3.1Zeo 
provides high constitutive expression from a CMV promoter.   
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up as 20µl reactions using a 3:1 molar ratio of insert to vector DNA.  The ligation 
reactions were then incubated at 17ºC overnight.   
 
Electroporation 
 Electrocompetent cells were prepared as outlined by the manufacturer (BTX, 
San Diego, CA).  Electroporations were performed using the BTX Electroporator 600 
with the following conditions: 40µl cells, 1-2µl ligation mixture, a 2.5kV pulse for  4.7 
ms using a 2 mm gap cuvette.  After the pulse, cells were immediately resuspended in 1 
ml of sterile LB and allowed to recover for 1 h at 37ºC (200 rpm).  Cells were then 
plated on selective media containing the appropriate antibiotic. 
 
Selection of Bacterial Clones 
 Resistant colonies were picked after 24 h and expanded to patches on grid 
plates.  To test for proper insert presence and orientation, rapid boil mini-preps were 
done followed by the digestion of the plasmid with the appropriate restriction enzymes 
according to the manufacturer’s instructions (Promega Corporation, Madison, WI).  
Digestions products were run on 1% agarose gels to determine if the banding pattern 
indicated the insert presence and proper orientation.  Upon identification of correct 
clones, the plasmids were further purified using the Wizard midiprep plasmid 
purification system according to the manufacturer’s protocol (Promega Corporation, 
Madison, WI) and sequenced. 
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Sequencing 
 All constructs were sequenced to ensure their integrity.  Sequencing was done in 
the University of Tennessee Molecular Biology Service Facility using an Applied 
Biosystems 3100 Genetic Analyzer sequencer (Foster City, CA). 
 
Transfection of Mammalian Cells 
 Transfection of mammalian cell lines was done in six well poly-D-lysine coated 
tissue culture plates (Fisher Scientific, Pittsburgh, PA).  Cells were split from stock 
cultures and inoculated into each well at approximately 1 X 105 cells per well in 
complete growth media.  The plate was then placed at 37ºC in a 5% CO2 atmosphere for 
1-2 days until the cells became 80-90% confluent.  The day of transfection, the media 
was refreshed.  DNA for transfections was purified from 100ml overnight E. coli 
cultures using the Wizard Purefection plasmid purification kit to remove endotoxins 
according to the manufacturer’s instructions (Promega Corporation, Madison, WI).  For 
chromosomal integration, the plasmid DNA was linearized before transfection to 
increase proper integration. 
HEK293 Cells 
 Purified plasmid DNA (3.2µg) was mixed into 200µl of serum free DMEM in a 
1.5 ml tube.  In a second tube, 8µl of Lipofectamine 2000 reagent (Invitrogen 
Corporation, Carlsbad, CA) was added to a 200µl of serum free DMEM.  The 
lipofectamine mixture was added to the DNA mixture within 5 min and incubated at 
room temperature for 20 min.  The entire mixture (400µl total) was added directly to the 
appropriate well on the plate and rocked back and forth to ensure adequate mixing.  
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Twenty-four hours post transfection, the complexes were removed and the media was 
replaced with fresh complete growth media supplemented with the appropriate 
antibiotic for selection of the two co-transfected plasmids. 
 
Selection of Mammalian Cell Clones 
 Twenty-four hours post transfection, selective media was added to all wells and 
refreshed every three to four days.  Because these transfections were conducted on a 
cell line that already harbored a Neomycin G418 resistance plasmid, the G418 was 
added at a concentration to maintain the plasmid and Zeocin was added to select for the 
second plasmid.  When the COA/COB2 clone was co-transfected with the pMaxfrp, 
resistant clones never appeared within the transfected wells.  Therefore, the pcfrp clone 
was generated to determine if the overexpression of the gene was causing a lethal 
product for the cells.  Within two weeks after co-transfection with this plasmid 
construct, all control wells were dead and the transfected cells were forming small 
colonies on the plate surface.  Colonies were separated from the rest of the well by 
placing a sterile chamber around the cell mass and sealing it with silicon (Fisher 
Scientific, Pittsburgh, PA).  The media could then be removed and each colony could be 
trypsinized and transferred to individual tissue culture flasks.  To accomplish this, after 
washing with a PBS solution, 200µl of a 1X Trypsin-EDTA solution (Sigma Aldrich, 
St. Louis, MO) was added directly to the chamber and incubated at 37°C for 3 to 5 min.  
The trypsin-EDTA solution was then replaced with complete growth media and the 
cells were transferred to a 25cm2 tissue culture flask for propagation.  Each clone was 
given a number and expanded to individual cell lines.  Each line was split and 
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maintained as described earlier with the addition of selective media.  Nine cell lines 
were propagated in this manner. 
 
In Vitro Bioluminescence Assays 
 To evaluate the bioluminescence potential from each cell line clone, total 
proteins were extracted and in vitro enzyme (bioluminescence) assays were performed.  
To extract the proteins, the cells were first trypsinized from the plate or flask surface 
and resuspended into 2.0 ml Sarstedt tubes (Fisher Scientific, Pittsburgh, PA).  The cells 
were then spun down and washed two times in sterile phosphate buffered saline (PBS) 
to remove any residual media (Sigma Aldrich, St. Louis, MO).  Cell pellets were then 
resuspended into 1 ml 0.1M potassium phosphate buffered pH 7.8 and disrupted by 
three consecutive cycles of freeze (30 s liquid N2) thaw (5 min at 37ºC) extraction.  
After disruption, the cell debris was pelleted by spinning the samples at 14,000 X g for 
5 min and the supernatant was used in the bioluminescence assay.  To determine light 
intensity, the protein extract was mixed with 0.1mM NAD(P)H, 4µM FMN, 0.2% (w/v) 
BSA, 0.002% (w/v) n-decanal.  Bioluminescence was measured using the FB14 
luminometer (Zylux Corporation, Pforzheim, Germany) at a 1 s integration and reported 
as relative light units (RLU).  To evaluate the limitation of FMNH2 for the 
bioluminescence reaction, a flavin oxidoreductase enzyme (1U) isolated and purified 
from V. harveyi (Roche Scientific, Indianapolis, IN) was added to the mixture and light 
levels were measured again for comparison. 
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 Bioluminescence levels were determined by taking measurements from triplicate 
35 cm2 wells and recording the values as relative light units (RLU) using a 1 s 
integration time. 
 
Whole Cell Bioluminescence Assays 
 To evaluate the bioluminescence levels from intact cells, the adherent cell lines 
were first trypsinized from the flask or plate surface and resuspended in 2.0 ml 
Sardstedt tubes (Fisher Scientific, Pittsburgh, PA).  The cells were then spun down and 
washed two times in sterile phosphate buffered saline (PBS) to remove any residual 
media (Sigma Aldrich, St. Louis, MO).  Cell pellets were resuspended into 1 ml 0.1M 
potassium phosphate (pH 7.8).  The cells were then mixed 1:1 volume of the enzyme 
mix that consisted of:  0.2% BSA and 0.002% (w/v) n-decanal.  Bioluminescence was 
measured immediately using the FB14 luminometer (Zylux Corporation, Pforzheim, 
Germany) at a 1 s integration and reported as relative light units (RLU).   
 Bioluminescence levels were normalized between samples and cell lines by 
dividing the RLU measurement by the number of cells in the assay and reporting the 
bioluminescence as relative light units (RLU) per 1 X 105 cells.  The total cell count 
was determined by direct counting the samples by standard methods.  The cells were 
first mixed with a Trypan Blue stain (Sigma Aldrich, St. Louis, MO) and individual 
cells were counted under light microscopy with a hemocytometer. 
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Stability of the Bacterial Luciferase Constructs 
 In order to determine the overall stability of the HEK293 cell line clones 
expressing the bacterial luciferase genes, each line was grown in culture for > 40 
passages in the presence and absence of antibiotic selection.  Cell extract 
bioluminescence measurements were taken every fifth passage to compare light levels 
over time.   
 
Statistics  
 Statistical analysis of the data presented here was conducted using either the 
JMP (SAS Institute, Incorporated, Pacific Grove, CA) or Microsoft Excel (Microsoft, 
Seattle, WA) statistical software packages.  Graphs were made using Sigma Plot 
software (SPSS, SAS Institute, Incorporated, Pacific Grove, CA) or Microsoft Excel 
(Microsoft, Seattle, WA).  All error bars on graphs indicate one standard deviation of 
the mean.  Significant differences were determined using either t-test or 1 way ANOVA 
analysis at a level of α=0.05. Statistically different groups were indicated on graphs by 
letter. 
 
Results 
Evaluation of FMNH2 Bioavailability in Mammalian Cells 
 To determine the overall bioavailability of the FMNH2 substrate in mammalian 
cells, bioluminescence assays were performed and light measurements were taken 
before and after the addition of a purified flavin oxidoreductase enzyme.  This enzyme 
in the presence of FMN and NAD(P)H reduces the FMN to the required FMNH2 for the 
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reaction.  Bioluminescence levels from each of the cell line clones increased at least an 
order of magnitude after the addition of FMNH2 (Figure 35, maroon bars).  These data 
illustrated that FMNH2 was extremely limiting for the bioluminescence reaction from 
these engineered human cell lines.  However, in every case, the clones harboring the 
luxA and luxB genes alone were able to produce bioluminescence levels above 
background without the addition of the flavin oxidoreductase enzyme indicating that 
some FMNH2 was available within the cells for the reaction (Figure 35, blue bars).  
Nevertheless, to achieve optimal bioluminescence values and generate a useful 
bioreporter, the lack of available FMNH2 within mammalian cells needs to be 
addressed. 
 
Expression of the Flavin Oxidoreductase Enzyme 
 In an attempt to overcome this limitation, the COA/COB2 clone (brightest 
clone) was co-transfected with an frp gene that was isolated from V. harveyi and cloned 
into a mammalian expression vector containing a translational enhancer region 
upstream of the multi-cloning site.  Unfortunately, when COA/COB2 clones were co-
transfected with this plasmid, the HEK293 cells were not able to survive and as a result 
no clones were obtained from this construct.  As an alternative approach, the frp gene 
was cloned into and expressed constitutively from the pcDNA3.1Zeo vector that allows 
for high constitutive expression but does not contain the SPC163 enhancer region.  Nine 
stable cell line clones were obtained by resistance to toxic concentrations of both 
Neomycin G418 and Zeocin antibiotics simultaneously.  Resultant clones were 
expanded to individual cell lines and tested for bioluminescence potential.  
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Figure 35. Bioluminescence levels (RLU) from stable HEK293 clones before (blue bars)  and after 
(maroon bars) the addition of FMNH2. 
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 Bioluminescence levels were evaluated from total cell protein extracts and in whole 
cell bioluminescence assays.   
 
In Vitro Bioluminescence Assays 
From in vitro bioluminescence assays (total protein extracts), the overall light 
levels increased with the expression of the frp gene at least an order of magnitude in 
both the absence and after the addition of exogenous flavin oxidoreductase versus the 
COA/COB2 clone without the frp gene tested under the same conditions (Figure 36).  
These data indicated that the expression of the frp gene was successful in producing an 
excess of available FMNH2 within HEK293 cells.  The further increase in 
bioluminescence after the exogenous addition of the purified oxidoreductase enzyme 
however, indicates that the system has yet to reach saturation.     
The bioluminescence levels obtained from the cell extract, in vitro, assays 
remained stable for several minutes before gradually declining to background levels.  
The light intensity could be increased back to peak levels upon exogenous addition of 
additional NAD(P)H to provide the reducing power for the flavin oxidoreductase 
enzyme and generate more FMNH2.  Thus the luciferase complex itself remained stable 
throughout the assay and bioluminescence levels were correlated to availability or 
decay of reduced FMN. 
 
Whole Cell Bioluminescence Assays 
Whole cell bioluminescence assays were performed to determine if these cell 
lines could produce adequate bioluminescence levels for use in gene expression
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Figure 36.  Bioluminescence levels from clone COA/COB2 versus the COA/COB2 clone co-expressed 
with a V. harveyi flavin oxidoreductase enzyme.  Bioluminescence measurements were taken 
before the addition of FMNH2 (blue bars) and after (maroon bars). 
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analysis, much in the same way that firefly luciferase (Luc) is currently used today in 
several reporter applications.  Average bioluminescence levels from the COA/COB2 
clone were obtained that were at least two orders of magnitude greater than background 
levels (4 X 104 RLU/s versus 380 RLU/s).  The bioluminescence was further increased 
at least another order of magnitude when the frp gene was co-expressed along with the 
luciferase genes. All clones co-transfected to express the frp gene produced 
significantly more light than without the enzyme being expressed (p<0.05).  
Furthermore, there were significant differences between the nine frp clones as well 
(Figure 37).   However, unlike the relatively stable nature of the bioluminescence signal 
from in vitro bioluminescence assays, the light levels from these whole cell clones 
resulted in a flash bioluminescent response.  The maximum light output was obtained 
within 1 s of n-decanal addition and returned to background levels within five seconds.  
These levels could not be induced with the further addition of n-decanal or FMNH2 to 
achieve a second peak in bioluminescent activity. 
 
In Vitro versus In Vivo Light Measurements 
 To better determine cytoplasmic concentrations of FMNH2, whole cell 
bioluminescence measurements were compared to levels obtained from in vitro assays.  
In the whole cell assays, the light levels were obtained immediately upon the addition of 
n-decanal and recorded as relative light units (RLU) for 1 X 106 cells.  The cells were 
then lysed and bioluminescence was remeasured upon the addition of n-decanal and 
FMNH2.  The cell number was determined by direct counting. Overall, the light levels  
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from whole cells were much lower (as much as 20 fold) than those obtained from 
protein extracts (Table 13).    
 
 
Stability of Bacterial Luciferase in Mammalian Cells Over Long Periods of Time 
The stability of mammalian cell lines engineered to stably express the bacterial 
luciferase genes was monitored by performing bioluminescence assays over time.  The 
bioluminescence levels remained relatively constant for forty passages, for every clone 
except WTA/WTB2 where the level radically deteriorated after passage thirty (Figure 
38).  Although the light levels for the other clones remained relatively stable during this 
time, other phenotypic changes occurred within the cells, including a lower binding 
affinity to the flask surface.   
 
Discussion 
The expression of the bacterial luciferase enzyme system in eukaryotic cells has 
long been desired.  Unfortunately, several obstacles have been encountered that resulted 
in only modest success when trying to employ this technology in eukaryotes.  Among 
the problems associated with the ultimate development of this technology, the lack of 
available FMNH2, the reduced flavin molecule that is required for the bioluminescence 
reaction is perhaps one of the most obvious.   The FMNH2 limitation in mammalian 
cells engineered with the luxA and luxB genes was shown to hamper potential light 
outputs significantly (Figure 35).  These data clearly showed that light levels were 
significantly enhanced upon the exogenous addition of a flavin reductase enzyme.  
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Table 13.  Bioluminescence levels from HEK293 cells engineered to express luxA and 
luxB genes with and without the co-expression of the flavin oxidoreductase 
(frp) enzyme.  Each bioluminescence measurement was made in triplicate 
from approximately 1 X 106 cells and reported as relative light units (RLU). 
 
 
Clone 
Whole Cell 
Assay 
In Vitro 
(without FMNH2) 
In Vitro        
(with FMNH2) 
 
 
COA/COB2 
 
4.3 X 104 
(±7,913) 
 
2.5 X 105  
(±31,201) 
 
6.77 X 106 
(±170,098) 
 
 
frp1 
 
2.75 X 105 
(±68,373) 
 
2.42 X 106  
(±161,278) 
 
22.8 X 106 
(±4,078,998) 
 
 
frp2 
 
3.06 X 105 
(±16,526) 
 
2.50 X 106  
(±98,006) 
 
31.0 X 106 
(±3,909,260) 
 
 
frp3 
 
3.27 X 105 
(±36,193) 
 
2.46 X 106  
(±101,456) 
 
28.0 X 106 
(±4,433,714) 
 
 
frp4 
 
2.5 X 105 
(±23,355) 
 
4.46 X 106  
(±457,293) 
 
33.4 X 106 
(±5,975,079) 
 
 
frp5 
 
1.22 X 105  
(±21,595) 
 
7.86 X 105  
(±36,862) 
 
12.74 X 106 
(±1,518,130) 
 
 
frp6 
 
1.37 X 105 
(±9,004) 
 
1.74 X 106  
(±112,367) 
 
12.96 X 106 
(±912,574) 
 
 
frp7 
 
2.66 X 105  
(±21,971) 
 
3.65 X 106  
(±346,997) 
 
28.4 X 106 
(±2,864,018) 
 
 
frp8 
 
3.62 X 105  
(±16,907) 
 
3.47 X 106  
(±440,620) 
 
18.02 X 106 
(±2,286,558) 
 
 
frp9 
 
1.54 X 105 
(±10,151) 
 
5.64 X 106  
(±381,295) 
 
28.56 X 106 
(±197,408) 
   
   
 164
1.00E+02
1.00E+03
1.00E+04
1.00E+05
1.00E+06
1.00E+07
1.00E+08
P5 P10 P15 P20 P25 P30 P35 P40
Passage Number
R
L
U
/
m
g
 
T
o
t
a
l
 
P
r
o
t
e
i
n
WTA/WTB1
WTA/WTB2
COA/WTB1
COA/WTB2
COA/COA2
COA/COB4
 
102 
103 
104 
105 
106 
107 
108 
Figure 38.  Average bioluminescence levels of HEK293 clones harboring luxA and luxB cultured without antibiotic 
versus passage number.  Bioluminescence values are the average of triplicate measurements. 
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Therefore, efforts were explored to overcome the FMNH2 limitation by 
attempting to express the reductase enzyme in vivo to provide adequate levels of this 
substrate. 
Recently, this approach was taken in yeast cells by the overexpression of an 
NAD(P)H –dependent FMN reductase enzyme from V. harveyi (Gupta et al., 2003 and 
Szittner et al., 2003).  In these studies, the bioluminescence levels from whole yeast 
cells were significantly increased by the expression of the frp gene.  These data 
illustrated that the limiting substrate in yeast was indeed a lack of the reduced FMNH2 
and that the FMN and NAD(P)H precursors were available within cytoplasm of yeast 
cells. Based on these results, it was hypothesized that the overexpression of the frp gene 
in mammalian cells may also provide adequate pools of FMNH2 to catalyze 
bioluminescence.  Therefore, HEK293 cells harboring a codon optimized luxA and luxB 
gene pair were co-transfected with the frp gene and stable cell lines obtained. 
From in vitro bioluminescence assays of clones expressing frp, the overall light 
levels increased at least an order of magnitude in both the absence and after the addition 
of exogenous flavin oxidoreductase versus the COA/COB2 clone without the frp gene, 
tested under the same conditions (Figure 36).  These data indicated that the expression 
of the frp gene was successful in producing higher concentrations of FMNH2 within 
HEK293 cells.  However, because the light levels increased further upon the addition of 
exogenous flavin oxidoreductase, it was determined that FMNH2 remains the limiting 
factor for the bioluminescence potential from these mammalian cells and has yet to 
reach saturation.    
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Furthermore, it is believed that much of the available FMNH2 within 
mammalian cells would be found at much higher concentrations within the 
mitochondria of the cell. As a result, the FMNH2 would remain sequestered from the 
bioluminescence (Lux) proteins within the cytoplasm and not available for the reaction.  
By monitoring light levels as total protein extracts, the location of available FMNH2 
within the cytoplasm is unknown.  To better determine cytoplasmic concentrations of 
FMNH2, whole cell bioluminescence assays were performed.  Overall, the light levels 
from whole cells were much lower (as much as 20 fold) than those obtained from 
protein extracts (Table 13).   These data indicate that the cytoplasmic concentrations of 
FMNH2 are limiting and that much of the cellular pool of the reduced flavin molecule is 
compartmentalized within organelles, like the mitochondria.  Therefore, future 
experiments should be conducted to allow for the expression of the Lux proteins in the 
mitochondria of the cell to allow for their interaction with other necessary substrates for 
the reaction.  Targeting of the Lux proteins can be easily accomplished with the 
addition of a signaling peptide on the N- terminus of the proteins that will shuttle the 
enzymes into the mitochondria of the cell.   
The bioluminescence levels obtained from the cell extract, in vitro, assays 
remained stable for several minutes before gradually declining to background levels.  
The light intensity could be increased back to peak levels upon exogenous addition of 
additional NAD(P)H to provide the reducing power for the flavin oxidoreductase 
enzyme and generate more FMNH2.  Thus, the luciferase complex itself remained stable 
throughout the assay and the light output was directly correlated to the available 
FMNH2.  On the other hand, the whole cell in vivo assays provided a flash 
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luminescence response that could not be induced further to give a second peak upon the 
addition of n-decanal or FMNH2.  These data indicate that the n-decanal substrate was 
toxic to the cells.  Once the cells were lysed and proteins extracted, high 
bioluminescence levels could be obtained upon the addition of n-decanal and FMNH2.  
These data further support the idea that the addition of n-decanal to whole cells resulted 
in cell mortality and not the loss of stable Lux proteins. 
The stability of mammalian cell lines engineered to express the bacterial 
luciferase genes was monitored to determine if the constructs could maintain their 
bioluminescence levels over time in the absence of antibiotics.  Although the 
bioluminescence outputs remained relatively constant for > 40 passages, one of the 
clones (WTA/WTB2) bioluminescence levels radically deteriorated after passage thirty 
(Figure 38).  Furthermore, during this culture period, other phenotypic changes occurred 
within the cells, including a lower binding affinity to the flask surface.  It was further 
determined that the loss of light from the WTA/WTB2 clone was not a result of the loss 
of the genes within the cells and perhaps a change in the cell’s physiology or some 
unknown regulatory mechanism that caused the loss of light.  Even though the 
WTA/WTB2 clone resulted in a complete loss of bioluminescence activity, PCR 
analysis revealed that the luxA and luxB genes were still present.  Nevertheless, the 
bioluminescence levels did remain stable for more than five months in culture without 
the need for antibiotic selection, indicating that these cell lines would be stable enough 
for relatively long term monitoring projects and applications as long as the proper 
control experiments were also included.  
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CHAPTER 5 
 
SUMMARY AND CONCLUSIONS 
  
          This investigation achieved optimized expression of the bacterial 
luciferase enzyme in mammalian cells.  Previous attempts to express this 
heterodimeric enzyme complex in mammalian cells have been met with only 
modest success.  In this research effort, several vector formats were evaluated and a 
novel approach to codon optimize the genes was performed.  Additionally, the 
limited availability of the FMNH2 substrate was evaluated and steps were taken to 
overcome this limitation.  The overall stability of the engineered cells was also 
assessed to determine the persistence of the reporter for long-term monitoring 
applications.  Based on the findings of this study, the following conclusions were 
drawn: 
 
• A translational fusion of the two luciferase subunits is not an efficient way to 
express this enzyme in eukaryotes likely due to thermal instability and the 
inability of the subunits to properly fold forming an active heterodimer. 
 
• Integrated expression of the luciferase provides a more stable expression 
format for long-term persistence of the luciferase genes.  
 
 
 169
• The bacterial luciferase enzyme produced optimal bioluminescence in 
mammalian cells when the individual genes were expressed as a bicistronic 
transcript fused with an internal ribosomal entry site (IRES). 
 
• Codon optimization of the luxA and luxB genes significantly increased the 
translation efficiency of the proteins in vitro and in vivo when expressed in 
HEK293 cells.  This increase in translation in turn resulted in significant 
increases in bioluminescence output from the cells. 
 
• FMNH2 is a limiting substrate for the bioluminescence reaction in 
mammalian cells. 
 
• The expression of a flavin oxidoreductase gene in HEK293 provides 
additional FMNH2 for the bioluminescence reaction.  However, this 
substrate remains limiting for the reaction. 
 
• The available FMNH2 within mammalian cells may be compartmentalized in 
organelles and not readily available to interact with the luciferase enzyme. 
 
• The expression of the bacterial luciferase genes in HEK293 cells remains 
relatively stable for more than 40 passages (5 months) in culture without the 
selective pressure of an antibiotic.   
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Determining an Optimal Expression Format for Expression of the Bacterial 
Luciferase Genes (luxA and luxB) 
As a first attempt to express the bacterial luciferase enzyme in mammalian cells, 
a LuxAB fusion protein was designed.  Previous work by Escher et al. (1989) showed 
that the luxAB fusion, using genes from Vibrio harveyi, was stable at elevated 
temperatures if initially expressed in E. coli at 23°C.  However, when the fused protein 
was grown and expressed at 37°C there was a greater than 99% reduction in light.  
These data suggest that the fused luxAB does not fold properly at elevated temperatures.  
The luciferase from P. luminescens has a higher thermal stability (t1/2 >3 h at 45°C) than 
V. harveyi (t1/2 5 min. at 45°C)  (Meighen, 1991).  Therefore, a translational fusion of 
the P. luminescens luxA and luxB genes was generated in this work and evaluated.  
Although the luxAB fusion was functional in E. coli, bioluminescence activity was 
significantly reduced (70%) compared to the wild type unfused genes.   In the unfused 
luxAB the α and β subunits are individually translated and are free to fold into their 
specific conformation (Tu and Mager, 1995).  Therefore, the reduction in 
bioluminescence may be due to steric hindrance involved in the way the subunits form 
the heterodimer when expressed as a protein monomer.   
The addition of a Kozak sequence further reduced the bioluminescence level to 
approximately 5% of the wild type protein.  Nevertheless, the Kazak sequence is a 
mammalian ribosomal binding site and therefore to evaluate its true effectiveness the 
construct was tested in HEK293 cells.  The light levels were significantly reduced 
(>90%) compared to HEK293 cells expressing the fusion protein without the Kazak 
modifications. The addition of a Kozak sequence (G at the +4 position) specifically 
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changes the second amino acid of luxA from Lysine to Glutamic acid.  These two amino 
acids have opposite net charges, which could result in a modification of the protein's 
secondary structure ultimately altering the protein's function resulting in decreased 
bioluminescence. Therefore, future studies were conducted in the absence of the Kazak 
sequence or with the addition of an external Kazak for ribosomal binding.    
To determine temperature effect on the folding of the fusion protein, the fused 
and unfused versions of the luxAB were grown at 23˚C, 30˚C and 37˚C.  In E. coli, there 
was not a statistical difference (p = 0.05) associated with temperature on 
bioluminescence as seen by Escher et al. (1989).  This suggested and led us to believe 
that the folding problems in the V. harveyi LuxAB fusion protein were not present in the 
P. luminescens LuxAB fusion protein.  However, when the fusion construct was 
expressed in the yeast, S. cerevisiae the bioluminescence levels significantly decreased 
as temperature increased to 37˚C.  The differences seen in these two systems may be a 
result of the bacterial system’s ability to transcribe the luxB independently due to the 
ribosomal binding site and luxB start codon still present in the fusion.  When the fusion 
is expressed in the yeast system, the luxB is no longer independently expressed resulting 
in a true fusion protein that is unable to properly fold at 37˚C.  The independent 
expression of the luxB in bacteria may have resulted in the unfused LuxB subunit 
forming the heterodimeric conformation with the LuxA within the LuxAB fusion 
resulting in the unaffected bioluminescence observed when the construct was expressed 
in E. coli. 
  In an attempt to mimic mammalian translation machinery, in vitro transcription 
and translation of the luxA, luxB and luxAB fusion were performed in a rabbit 
 172
reticulocyte lysate system.  Although the 77kDa fusion protein was easily detected, the 
individual proteins, LuxA and LuxB, were not.  This result was unexpected because 
equal amounts of RNA transcript were added to each translation reaction.  These data 
suggest that the formation of the heterodimeric (α and β subunit) complex may be 
required for not only efficient bioluminescence activity, but also for the overall stability 
of the protein.   
 Although detectable amounts of bioluminescence were obtained from 
mammalian cell lines harboring the LuxAB fusion protein, these levels were not 
sufficient for the creation of a reliable biosensor.  Therefore, other expression formats 
were evaluated in an attempt to optimize bioluminescence activity.  It was thought that 
by expressing the lux genes separately, the subunits would be able to form a more 
natural heterodimeric conformation.  Human embryonic kidney cells (HEK293) were 
used for these evaluations.  Cells were transfected with a dual promoter vector construct 
that that was developed to constitutively express each gene from a separate promoter or 
co-transfected with two plasmids each harboring either the luxA or luxB gene.  
Furthermore, to evaluate the differences in protein expression from genes integrated in 
the host’s chromosome versus those constructs maintained as episomal plasmids, each 
expression format (fusion, dual promoter and co-transfection) was constructed on a 
plasmid backbone able to replicate episomally in HEK cells.  The bioluminescence 
levels from stable cell lines harboring each expression variation were determined.  
Although there were slight variations in activity, the differences were not statistically 
significant (p=0.05).  The only exception was the reduced bioluminescence activity 
obtained from cells harboring a dual promoter vector episomally.  The low light levels 
 173
from these clones were somewhat surprising considering that the average 
bioluminescence from the fusion protein and from cells co-transfected with two 
plasmids were slightly higher when the constructs were maintained as episomes.  Upon 
further analysis, it was determined that the mRNA levels from the individual lux genes 
were not equal and therefore in this expression format, one promoter is inducing 
transcription at a higher rate than the other.  This type of promoter occlusion where the 
transcription of one of the two promoters was significantly dampened has been seen 
previously (Horlick et al., 2000).  The unequal availability of one of the lux subunits at 
a level higher than the other, may prevent the proper formation of the heterodimeric 
active luciferase protein and may result in inactive homodimer formation.  
 In order for bacterial lux-based mammalian bioreporter to be useful, the 
constructs need to remain stable in the absence of antibiotic selection for long periods of 
time.  Efficient maintenance and stability of foreign genes requires that the DNA 
replicate once per cell cycle and be retained (integrated or episomally) in the nucleus.  
Constructs harboring the luxA and luxB genes in three individual expression formats 
were created on both the traditional integration vectors and on Epstein-Barr virus (ori-P) 
based episomal plasmid vectors.  To determine the stability of these constructs in 
HEK293 cells, the cell line clones were grown for twenty passages in complete growth 
media without antibiotic.    In general, all clones (chromosomal and episomal) were 
stable for at least five passages after the antibiotic removal.  However, the constructs 
that were maintained as episomes began to lose bioluminescence activity by passage ten 
with episomal co-transfected cells resulting in the fastest bioluminescence decline rate. 
Although there was a significant decline in bioluminescence activity from episomally 
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based constructs over time, the light was not completely lost from any of the cells lines.  
Therefore, this reduction in bioluminescence may be the result of natural plasmid loss 
and generation of a plasmid equilibrium within the cells.  Immediately following 
transfection the DNA molecules within each cell can be very high and a natural decline 
in this concentration occurs to a steady state for plasmid maintenance (Middleton and 
Sugen, 1994 and Horlick et al.,1997).  This number can vary, but the average is between 
50 and 100 copies per cell with the further loss of approximately 5% per generation in 
the absence of selection (Yates and Guan, 1991).  The constructs that were integrated 
into the host’s chromosome remained relatively stable throughout the twenty passages 
(approximately 2.5 months) evaluation.  These data indicate that integration of the lux 
genes within the host’s chromosome may be the most suitable way to express the genes 
in mammalian cells for long-term gene maintenance and stable bioluminescence 
activity.  
 In order to optimize the bioluminescence potential from mammalian cells the lux 
genes need to be processed and expressed much in the way they are in bacteria.  To 
establish a more natural expression format for the heterodimeric luciferase protein, the 
luxA and luxB genes were cloned into a bicistronic mammalian expression vector.  This 
vector was developed to allow for the expression of two genes of interest under the 
control of a single constitutive promoter with the use of an internal ribosomal entry site 
(IRES).  IRES elements can be defined as specific nucleotide sequences that allow for 
ribosomal entry and translation initiation directly at the start codon (AUG) rather than 
requiring scanning from the 5′ end, cap structure, of the mRNA (Pestova et al., 2001 
and Kozak, 2001).  Since the lux genes are naturally found in a polycisitronic operon, it 
 175
was thought that by expressing the genes in this format a more natural production and 
formation of the heterodimer could be obtained.    From each of the stable cell line 
clones obtained harboring lux genes expressed as a bicistronic transcript, the 
bioluminescence (RLU/mg total protein) was at least an order of magnitude greater than 
levels obtained with any of the other expression formats tested.  On average, there was 
no significant difference between bioluminescence levels obtained from HEK293 cells 
expressing the luxAB fusion, the luxA and luxB in a dual promoter format or as co-
transfected separate plasmids.  However, the bioluminescence levels from HEK293 
cells harboring the luxA and luxB as a single bicistronic transcript constitutively 
produced significantly higher light levels. 
 Based on these data it was determined that of the four expression formats 
evaluated that the bicistronic expression of the luxA and luxB genes was by far the best 
choice.  Furthermore, although in general, the bioluminescence levels were slightly less, 
the stability of the construct when integrated into the host’s chromosome makes this a 
more suitable choice for the development of bacterial lux-based mammalian biosensors. 
Therefore, the first hypothesis set forth in this research can be accepted which stated 
that the expression of the bacterial luciferase (lux) subunits as individual proteins rather 
than as a monomeric translational fusion will result in more efficient folding and 
thermostability resulting in a higher bioluminescent signal in mammalian cells.  
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Codon Optimization of the Bacterial Luciferase for Expression in Mammalian 
Cells 
     Codon usage regulates gene expression at the level of translation and the usage 
patterns between species are not conserved (Kurland, 1991).  This is especially true 
between genes derived from eukaryotes versus those from prokaryotes.  Therefore, to 
efficiently express the bacterial lux genes in mammalian cells, the nucleotide sequence 
was altered in such a way as to create a “humanized” form of the gene without altering 
the amino  acid sequence.  This approach has been used previously to optimize the 
expression of both GFP and Renilla luciferase proteins for expression in mammalian 
cells (Zhang et al., 2002 and Gruber and Wood, 2000).  The design of this new 
sequence was carefully determined, removing all potential splice sites and most 
regulatory regions. After the final codon optimized sequence was determined, it was 
evaluated using the GENSCAN prediction algorithm to determine the potential 
expression efficiency in a human cell.  According to the output from this program the 
overall expression of the codon optimized lux genes would be significantly improved 
versus the wild type.  The increase in expression was predicted to be caused by an 
increase in both transcription and translation efficiency.  Furthermore, it was predicted 
that the first sixty bases (20 amino acids) of the wild type luxA gene would be 
completely eliminated when expressed in mammalian cells.  Considering that this 
region of the LuxA protein holds most of the catalytic properties (active site) for the 
bacterial luciferase enzyme, this would be devastating for its expression.  If this were 
the case, the low expression levels observed for the LuxAB fusion protein, shown 
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earlier, may be better explained in part by a nonfunctional protein being formed rather 
than inefficient folding or heat liability.    
 To test the expression of the codon optimized genes, modified versions were 
required.  However, because the necessary changes were to numerous to achieve by site 
directed mutagenesis, a complete in vitro gene synthesis protocol was pursued. Large 
oligonucleotides (80-106 bp) were designed with overlapping (18-22 bp) regions.  The 
original plan was to amplify all of the oligonucleotides together in one PCR reaction 
according to methods set by Prodromou and Pearl (1992).  However, because of the 
larger size of the lux genes (approximately 1000 bp each), this was not possible.  As an 
alternative, the gene was synthesized in parts and the subsequently linked by a second 
round of PCR.  The two outside oligonucleotides were used as both template and 
primers for each reaction.  After some experimental effort, it was determined that for 
optimal amplification the internal oligonucleotides (template) should be added at a 
concentration that equaled 100 fold less than the outside oligos. Amplification products 
of the correct size were cloned and sequenced.  Unfortunately, sequence analysis 
revealed several base substitution mutations within all clones tested.  These mutations 
were present despite the fact that care was taken by using a Pfu polymerase that has 
proof reading abilities. This finding was disappointing while not surprising given that 
two consecutive PCR reactions were required to obtain the final gene product resulting 
in > 60 cycles of amplification.  To eliminate these errors and produce the proper 
sequence, site directed mutagenesis was performed. 
   It was determined previously through work accomplished in S. cerevisiae and 
mammalian cells for the expression of the bacterial luciferase genes that IRES elements 
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may be an efficient way to express independent proteins as single bicistronic transcripts. 
This expression format provides the most natural expression of the genes, most closely 
mimicking the polycistronic form found in the bacterial operon.  Therefore, experiments 
were set up to compare the codon optimized and wild type luxA and luxB genes in 
mammalian cells using an IRES based expression vector.  The expression vector used 
was designed to highly express two independent genes under the control of a single 
constitutive encephalomyocarditis virus (ECMV) promoter region by linking two 
multicloning sites fused to either side of an internal ribosomal entry site (IRES).  The 
IRES element allows for the translation of two consecutive open reading frames from 
one messenger RNA (Jang et al., 1990; Jackson et al., 1990; Rees et al., 1996).  By 
constructing plasmids with different combinations of the codon optimized luxA and 
luxB with their wild type counterparts, a direct comparison of the genes was made.   
To quickly determine if a difference in translation efficiency could be detected 
between the optimized and wild type luxA genes, in vitro transcription and translation 
analysis was performed.  The codon optimized luxA gene (COA) was detected 
approximately twenty fold over wild type.  This finding supported the results that 
shown earlier with the in vitro generation of the wild type LuxA protein.  Since the 
rabbit reticulocyte lysate translation system is used to mimic mammalian translation 
machinery in vitro, these results indicated that the codon optimization would indeed 
make a significant impact on the translation efficiency of the lux proteins in mammalian 
systems.   
 HEK293 cells were transfected with the WTA/ WTB, WTA/ COB or COA/COB 
constructs and stable cell line clones were selected by antibiotic resistance. Twenty 
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stable clones for each luxA and luxB combination were selected and bioluminescence 
levels were determined upon the exogenous addition of n-decanal and FMNH2.  The 
bioluminescence significantly increased in the order WTA/WTB < COA/WTB < 
COA/COB.  These data indicated that codon optimization had made a significant 
impact on the potential bioluminescence levels obtained from mammalian cells.  To 
analyze this data further, the two or three brightest clones were chosen for further study.  
From these cells, total genomic DNA, total RNA and total soluble proteins were 
extracted.      
 Foreign gene integration in mammalian cells is a random event, therefore it is 
possible to have more than one insertion of the construct occur during each transfection.  
Since integration is fairly inefficient, the copy number per cell is generally very low.  
However, because of this possibility, it was important to determine the copy number of 
the inserted genes for at true comparison.  To accomplish this, Southern blot analysis 
was performed on each of the seven clones that produced the highest bioluminescence 
levels.  All of the cell lines tested had either one or two copies of the gene inserted with 
the exception of the COA/COB3 clone which had three.  To simplify further 
measurements, this clone was then disregarded for further bioluminescence 
comparisons.  Nevertheless, it should be noted that increased copy number does not 
correlate with increased expression levels.  Numerous other factors have been shown to 
impact from gene expression at a greater level. 
 The overall amount of luxA mRNA transcript was determined by Northern blot 
analysis.  Transcript levels were relatively equal with the exception of the WTA/WTB1 
clone that produced significantly lower amounts of luxA mRNA.  Since each construct 
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contained the same promoter (ECMV) element and initiation signals, it would be 
expected that each clone would have approximately equal amounts of transcript for the 
introduced genes.  However, cis acting regulatory elements could potentially interfere 
with transcription initiation and overall transcript levels in vivo.  These types of 
interferences would vary based on where within the chromosome the genes were 
integrated.  Therefore, the position effect of various clones could explain the lower 
amount of transcript detected with the WTA/WTB1 clone.  Other factors that can 
potentially impact the amount of RNA transcript would be a direct result of increased 
RNA degradation of certain mRNA sequences that can occur.  This type of RNA 
instability would be less likely after codon optimization because of the removal of 
several AU rich target degradation regions.  However, because the lower amount of 
transcript was not seen in both the WTA/WTB clones, this scenario is unlikely. 
To evaluate the overall protein concentrations and determine translation 
efficiency of each construct, Western blot analysis was performed.  Total soluble 
proteins from each clone were isolated and quantified.  Western blot analysis was 
performed using a polyclonal luxA antibody. The LuxA protein was not detectable from 
WTA/WTB clones and faintly visible in the COA/WTB clones.  However, large 
amounts of LuxA protein were detected from the COA/COB clones which harbored a 
construct carrying codon optimized versions of both genes.  This finding was intriguing 
and unexpected.  Since the only available antibody was raised against a polypeptide of 
LuxA, it was expected that the constructs harboring the COA/WTB and COA/COB 
would produce equal amounts of LuxA protein.  Since this was not the case, these data 
indicated that the codon optimization of both genes might infer stability on the 
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heterodimeric complex that makes up the luciferase enzyme.  This increased stability of 
the complex may have allowed the proteins to be detected in the Western blot while the 
other construct was not detected.   
Perhaps the most valuable measurement to determine if codon optimization was 
a success is the amount of enzyme activity that could be obtained from each construct.  
Bioluminescence levels were evaluated on whole cell extracts upon the addition of n-
decanal and FMNH2.  Average bioluminescence values were found to be greater than 
two orders of magnitude higher in cell lines harboring both a codon optimized luxA and 
luxB (COA/COB) over that of the cell lines harboring the wild type genes 
(WTA/WTB).  While bioluminescence levels were significantly higher in clones 
expressing COA and WTB versus WTA and WTB, the optimal bioluminescence was 
obtained from clones harboring optimized versions of both genes.  These data further 
support the stabilization conclusion of the heterodimeric protein. Based on these data it 
was determined that codon optimization had a significant effect on the protein 
expression in HEK293 cells. 
  In conclusion, the codon optimization of the luxA and luxB genes was 
successful in increasing the overall expression levels of the individual proteins.  This 
increase in protein quantity resulted in a significant increase in bioluminescence from 
cell lines harboring these constructs.  Furthermore, the bioluminescence levels from 
codon optimized luxA and luxB provide adequate bioluminescence for the proof in 
principle data needed for the future development of reliable reporter constructs for 
analyte sensing in mammalian cells.  Based on these data, the second hypothesis 
statement proposed in this research that stated that codon optimization of the bacterial 
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luciferase (lux) genes will significantly enhance translation of the proteins and 
ultimately result in greater bioluminescence levels from mammalian cells harboring 
these optimized genes is accepted. 
 
FMNH2 Availability 
Among the problems associated with the ultimate development of a mammalian 
lux bioreporter cell line, the lack of available FMNH2, the reduced flavin molecule that 
is required for the bioluminescence reaction is perhaps one of the most obvious.   The 
FMNH2 limitation in mammalian cells engineered with the luxA and luxB genes was 
shown to hamper potential light outputs significantly.  These data clearly showed that 
light levels were significantly enhanced upon the exogenous addition of a flavin 
reductase enzyme. Therefore, efforts were explored to overcome the FMNH2 limitation 
by attempting to express the reductase enzyme in vivo to provide adequate levels of this 
substrate. 
Recently, this approach was taken in yeast cells by the overexpression of an 
NAD(P)H –dependent FMN reductase enzyme from V. harveyi (Gupta et al., 2003 an 
Szittner et al., 2003).  In these studies, the bioluminescence levels from whole yeast 
cells were significantly increased by the expression of the frp gene.  These data 
illustrated that the limiting substrate in yeast was indeed a lack of the reduced FMNH2 
and that the FMN and NAD(P)H precursors were available within cytoplasm of yeast 
cells. Based on these results, it was hypothesized that the overexpression of the frp gene 
in mammalian cells may also provide adequate pools of FMNH2 to catalyze 
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bioluminescence.  Therefore, HEK293 cells harboring a codon optimized luxA and luxB 
gene pair were co-transfected with the frp gene and stable cell lines obtained. 
From in vitro bioluminescence assays of clones expressing frp, the overall light 
levels increased at least an order of magnitude in both the absence and after the addition 
of exogenous flavin oxidoreductase versus the COA/COB2 clone without the frp gene, 
tested under the same conditions.  These data indicated that the expression of the frp 
gene was successful in producing higher concentrations of FMNH2 within HEK293 
cells.  However, because the light levels increased further upon the addition of 
exogenous flavin oxidoreductase, it was determined that FMNH2 remains the limiting 
factor for the bioluminescence potential from these mammalian cells and has yet to 
reach saturation.   Based on these data, further experiments will be necessary to accept 
or reject the third hypothesis set forth in this work, but at this point FMNH2  remains the 
limiting substrate for bioluminescence. 
Nevertheless, it is believed that much of the available FMNH2 within 
mammalian cells would be found at much higher concentrations within the 
mitochondria of the cell. As a result, the FMNH2 would remain sequestered from the 
bioluminescence (Lux) proteins within the cytoplasm and not available for the reaction.  
By monitoring light levels as total protein extracts, the location of available FMNH2 
within the cytoplasm is unknown.  To better determine cytoplasmic concentrations of 
FMNH2, whole cell bioluminescence assays were performed.  Overall, the light levels 
from whole cells were much lower (as much as 20 fold) than those obtained from 
protein extracts.   These data indicate that the cytoplasmic concentrations of FMNH2 are 
limiting and that much of the cellular pool of the reduced flavin molecule is 
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compartmentalized within organelles, like the mitochondria.  Therefore, future 
experiments should be conducted to allow for the expression of the Lux proteins in the 
mitochondria of the cell to allow for their interaction with other necessary substrates for 
the reaction.  Targeting of the Lux proteins can be easily accomplished with the 
addition of a signaling peptide on the N- terminus of the proteins that will shuttle the 
enzymes into the mitochondria of the cell.   
The bioluminescence levels obtained from the cell extract, in vitro, assays remained 
stable for several minutes before gradually declining to background levels.  The light 
intensity could be increased back to peak levels upon exogenous addition of additional 
NAD(P)H to provide the reducing power for the flavin oxidoreductase enzyme and 
generate more FMNH2.  Thus, the luciferase complex itself remained stable throughout 
the assay and the light output was directly correlated to the available FMNH2.  On the 
other hand, the whole cell in vivo assays provided a flash luminescence response that 
could not be induced further to give a second peak upon the addition of n-decanal or 
FMNH2.  These data indicate that the n-decanal substrate was toxic to the cells.  Once 
the cells were lysed and proteins extracted, high bioluminescence levels could be 
obtained upon the addition of n-decanal and FMNH2.  These data further support the 
idea that the addition of n-decanal to whole cells resulted in cell mortality and not the 
loss of stable Lux proteins.   
 
Stability of the Luciferase Constructs in Mammalian Cells 
The stability of mammalian cell lines engineered to express the bacterial 
luciferase genes was monitored to determine if the constructs could maintain their 
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bioluminescence levels over time in the absence of antibiotics.  Although the 
bioluminescence outputs remained relatively constant for > 40 passages, one of the 
clones (WTA/WTB2) bioluminescence levels radically deteriorated after passage thirty.  
Furthermore, during this culture period, other phenotypic changes occurred within the 
cells, including a lower binding affinity to the flask surface.  It was further determined 
that the loss of light from the WTA/WTB2 clone was not a result of the loss of the 
genes within the cells and perhaps a change in the cell’s physiology or some unknown 
regulatory mechanism that caused the loss of light.  Even though the WTA/WTB2 clone 
resulted in a complete loss of bioluminescence activity, PCR analysis revealed that the 
luxA and luxB genes were still present.  Nevertheless, the bioluminescence levels did 
remain stable for the other five clones tested for more than five months in culture 
without the need for antibiotic selection, indicating that these cell lines would be stable 
enough for relatively long term monitoring projects and applications given that the 
proper control experiments were also included to ensure the integrity of the reporter 
strain.     
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